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 Nothing is more damaging to the adventurous spirit within a man than a 
secure future. The very basic core of a man's living spirit is his passion for 
adventure. The joy of life comes from our encounters with new experiences, 
and hence there is no greater joy than to have an endlessly changing 
horizon, for each day to have a new and different sun. 
 
Christopher Johnson McCandless 
“ 
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Preface 
During the three years of my Ph.D. course, I was involved in two different research 
projects, both concerning cellular components of the innate immune system: natural 
killer cells and macrophages. 
In particular, my principal project (University of Eastern Piedmont, Italy) aims to 
clarify the expression and role of a protein, galectin-3, on natural killer cells.  
The other one (University of Basel, Switzerland) deals with the use of a viral vector 
to boost the antitumor activity of macrophages. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
Chapter I 
“In vitro” studies on galectin-3 in human natural killer cells 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
5 
1. Introduction  
 
1.1 The Sugar Code 
An enormous amount of events take place among cells, either intra-, inter-, or extra-
cellularly and the whole apparatus of proteins and nucleic acids is not sufficient to 
adequately perform all of them. A third category of bio-molecules with the ability to 
transmit a multitude of different messages seems to be required for assuring fine 
cellular processes, such as cell adhesion and communication. 
Sugars, in the form of mono-, oligo-, or poly-saccharides, as well as glycoconjugates, 
are a perfect example of such type of bio-molecules. These compounds are, in fact, 
endowed with a large capacity in information-storing and a great ability to transfer 
information through protein bio-recognition. 
As reported by Gabius (2000), oligo-saccharides surpass peptides by more than 
seven orders of magnitude in the theoretical ability to build isomers, when the total 
of conceivable hexamers is calculated. Most of the carbohydrates, in fact, contain at 
least one asymmetric carbon atom with a number of possible stereoisomers that grow 
rapidly with molecular weight. In addition, each carbohydrate has approximately 
four functional groups that can be used to establish connections with other sugar 
units in a linear and/or in a nonlinear/branched fashion. All the complex information 
stored in the glycostructures decorating the surface of a cell, protein, or lipid 
molecule can be deciphered by a protein having the ability to bind sugar, such as, for 
example, the lectins (Gabius 2000).  
 
1.2 Lectins 
The name lectin derives from the latin word legere, whose meaning is to pick/choose 
or select. Lectins represent a group of structurally diverse proteins able to bind and 
recognize simple/complex sugar moieties protruding from glycolipids or 
glycoproteins (Ghazarian et al. 2011). Carbohydrate-binding proteins can be roughly 
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classified into two main groups: lectins and sulfated glycosaminoglycan-binding 
proteins. The lectin superfamily phylogenetically comprises ancient proteins, 
defined by their ability to bind either soluble carbohydrates or glycoconjugates, 
mediating a large array of biological processes, including cell to cell interactions, 
communications at both inner and outer side of the cellular membrane and 
modulation of immune responses.  
The broad range of functions carried out by this heterogeneous group of proteins are 
possible thanks to their ability to bind many different types of carbohydrates, which 
are present in the extracellular matrix, at the cell surfaces, or into secreted 
glycoproteins. Lectins can read the sugar code, recognizing even slight difference in 
the complex structure of oligosaccharides and/or in simple monosaccharides, binding 
only to specific sugars. 
Originally isolated from plants, they are widely distributed in nature, ranging from 
bacteria and virus to animals. Today, based on the structures of animal lectins at least 
15 structural families of mammalian lectins exist, where galectins and C-type lectins 
are the largest families (Gupta 2012). 
 
1.3 Galectins 
Galectins are a family of highly conserved proteins whose members are 
characterized by a highly conserved carbohydrate recognition domain (CRD), 
consisting of approximately 130 amino acids (aa) (Barondes et al. 1994) which bind 
small β-galactosides/poly-N-acetyllactosamine (LacNAc)-enriched glycoconjugates 
(Gupta 2012). These proteins were initially classified as S-type lectins, where the S 
(sulphydryl or thiol) was used to indicate the dependence on reducing conditions for 
activity, a specific property of galectin-1 (Gal-1), the first studied galectin (Gupta 
2012). 
To date, up to 15 galectins have been identified in mammals and, based on their 
molecular architecture and structural differences in CRD presentation, they can be 
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classified into 3 main groups, as proposed by Hirabayashi and Kasai in 1993 (Fig. 
1A). 
The prototype group are galectins containing one CRD, that can exist as monomer 
(galectins -5, -7, -10) or homodimers with two polypeptides containing a CRD each 
(galectins -1, -2, -11, -13, -14, -15), and a short N-terminal sequence. It should be 
mentioned that classification of galectin-11, initially identified as GRIFIN (galectin-
related interfibre protein), is still under debate, since this galectin misses two of the 
seven crucial aa conserved in the CRD, and it displays no binding activity trough 
sugar molecules (Rabinovich et al. 2007). 
Tandem repeat galectins are monomers with two non-identical CRDs joined by a 
short peptide linker region (galectins -4, -6, -8, -9, -12). 
By contrast, galectin-3 (Gal-3) is the only member discovered so far of the chimera-
type with a unique structure, characterized by one CRD connected to a long N-
terminal domain. This latter is involved in Gal-3 oligomerization which results in the 
formation of Gal-3 multimers exposing several CRDs, enabling bivalent or 
multivalent binding of carbohydrate ligands (Dumic et al. 2006; Sato et al. 2009; 
Fortuna-Costa et al. 2014). 
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Figure. 1. Schematic representation of the structure of different members of the 
galectin family. (A) prototype galectins containing one or two homodimeric CRD, tandem 
repeats containing two different CRD connected by an aminoacidic linker and the unique 
chimera-type Gal-3 composed by a CRD and a collagen-like sequence. (B) schematic 
representation of Gal-3 oligomerization into pentamers through the N-terminal domain 
allowing the multivalent binding of glycans forming a lattice structure (adapted from 
Rabinovich and Toscano 2009).  
 
1.4 Galectin-3 
Gal-3 is the currently accepted name for a protein, initially identified as Mac-2, a 
surface protein expressed on murine macrophages (Ho and Springer 1982), formerly 
also known as CBP-35, LBP, L-34, L-29, or εBP (Gupta 2012). Human Gal-3, is a 
31 kDa protein encoded by a single gene (LGALS3), which is located on chromosome 
14, locus q21–q22 and spans on a total of 17 Kb. The gene has an open reading frame 
of 750pb and consists of 6 exons and 5 introns that are translated into a protein of 
250 aa. In particular, the transition start site is found within the exon II, which 
contains also the initial methionine, the first six aa and part of the 5’ untranslated 
sequence. The exon III contain entirely the long and flexible, collagen-like N-
Introduction 
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terminal domain, while exon IV-VI codify for the C-terminal domain (Argüeso and 
Panjwani 2011; Gupta 2012; Díaz-Alvarez and Ortega 2017).  
 
1.4.1 The carbohydrate recognition domain 
Gal-3 shares whit Gal-1 and Gal-2 ~25% sequence identity and their CRD have a 
similar three-dimensional structure and identical topology (Seetharaman et al. 1998). 
This latter, is composed of two anti-parallel β-sheets with five and six β-strands (F1-
5 and S1-6) (Seetharaman et al. 1998), forming a globular structure that 
accommodates the carbohydrate-binding site, composed by the side chains of the aa 
forming the 6-stranded β-sheet (Hughes 2001). This structure is responsible for the 
lectin activity of Gal-3. In particular, the two β-sheets composing the CRD are 
arranged in a convex side (F1-5) and a concave side (S1-6) with this latter forming 
a groove able to accommodate a linear tetrasaccharide (Fig. 2) (Leffler et al. 2002). 
The CRD can be schematically divided into four sub-binding sites: A, B, C, D, where 
the C subsite is made of approximately 6 conserved aa and is responsible for the β-
galactoside binding. The other sites participate in the binding activity, either by 
increasing or decreasing the protein affinity, depending on the saccharide moiety 
linked to the galactose bound in the C subsite (Salomonsson et al. 2010). Beside 
carbohydrate recognition/binding, the CRD is also involved in the anti-apoptotic 
activity associated with Gal-3 (for further details see paragraph 1.8.1). This domain, 
in fact, presents the NWGR aa sequence, which is also highly conserved within the 
BH1 domain of the anti-apoptotic B-cell lymphoma (Bcl)-2 family, and the 
interaction with this latter is responsible for the resistance to apoptotic stimuli (Yang 
et al. 1996). The importance of this sequence for Gal-3 is demonstrated by the fact 
that it is highly conserved among different species, and that a single amino acid 
substitution of Gly to Ala in the NWGR sequence abrogates the anti-apoptotic 
properties (Akahani et al. 1997). The NWGR motif is also essential for the 
carbohydrate recognition activity since the tryptophan (W) amino acid is directly 
involved in the sugar binding (Yang et al. 1998).  
Introduction 
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Finally, despite Gal-3 oligomerization has been proposed to occur through the N-
terminal domain (type-N model), recently a new model (named type-C self-
association) has been proposed. Accordingly, oligomerization would be mediated by 
the carbohydrate recognition site: the carbohydrate-binding site of one CRD would 
bind at the other side of the next CRD, and the N-terminal domain would participate 
by enhancing this association. Both models remain equally probable, and whether 
and when each model occurs in a cellular system remain to be demonstrated (Lepur 
et al. 2012). 
 
 
Figure 2. High Resolution X-Ray Structure of Human Gal-3 in complex with LacNAc 
visualized as stick model (PDB: 1KJL). (A) secondary structure of the Gal-3 CRD; (B) 
The solvent accessible surface of Gal-3 CRD with the position of A-D binding site shown 
above the binding groove, the C binding site was shown in white (adapted from Salomonsson 
et al. 2010; Hsieh et al. 2015). 
 
1.4.2 The N-terminal domain  
The N-terminal domain is a relatively flexible structure, consisting of two distinct 
portions: a collagenase sensitive, proline, glycine, alanine, and tyrosine rich motif, 
followed by 12 aa sequence also called the small N-terminal domain, containing a 
casein kinase I serine phosphorylation site. The former, consisting of 100–150 aa 
Introduction 
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residues, has homologous repeats (8 to 13 in vertebrates) (Ippel et al. 2016) of a 
consensus sequence Pro-Gly-Ala-Tyr-Pro-Gly, followed by three additional aa with 
a number of repetitions that vary among different species and lack of charged or large 
side-chain hydrophobic residues. This part of the N-terminus domain has 35.5% 
identity with collagen α1 (II) chain of bovine cartilage, and this explains the designed 
name of this domain as collagen-like N-terminal domain (Raz et al. 1989; Gupta 
2012). In addition to collagen, this portion of the N-terminal domain has a 25% 
homology with some heterogeneous nuclear ribonucleoproteins (hnRPN) (Dumic et 
al. 2006).  
 
At least four functional properties can be ascribed to the N-terminal domain: 
i) Upon binding of specific glycoconjugates, Gal-3 changes its conformation, 
resulting in N-terminal domain self-assembly and consequent protein 
oligomerization (Sato et al. 2009). This process leads to the formation of a multimer 
(such as dimer or pentamer) (Gong et al. 1999; Ahmad et al. 2004), which possesses 
multivalent CRD (Sato and Nieminen 2002) even under non-reducing conditions or 
in the presence of sodium dodecyl sulfate (Henderson and Sethi 2009), leading to 
cross-linking of cell receptors; 
ii) The N-terminal portion of the protein (small N-terminal domain) is involved in its 
secretion. In fact, the deletion of the initial 12 aa, completely abrogates secretion of 
this protein through a new mechanism independent from the classical secretory 
pathways (ER and Golgi system) (for further details see paragraph 1.6) (Dumic et al. 
2006); 
iii) Despite the carbohydrate binding is largely N-terminal independent (Dumic et al. 
2006), molecular modeling and mutagenesis studies demonstrated that the aa present 
in the N-terminal domain can participate in sugar binding (Barboni et al. 2000). 
Particularly, the N-terminal domain would contribute to carbohydrate binding 
through the stabilization of the substrate-bound lectin complex (Barboni et al. 2000). 
These studies were performed with lipopolysaccharide (LPS) as binding partner, 
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demonstrating that Gal-3 is able to bind the side chain of the O-antigen of LPS, which 
contains polymers of LacNAc, a known ligand for the CRD of this lectin. 
Alternatively, for LPS devoid of beta-galactosides, Gal-3 can interact through the N-
terminal domain, with the lipid A core region of LPS (Mey et al. 1996). The use of 
a monoclonal antibody (mAb) that recognizes an epitope within the N-terminal 
domain of Gal-3 completely abrogates the binding of this lectin to LPS (Fowler et 
al. 2006); 
iv) Post-translational phosphorylation of a serine residue (Ser6) in the small N-
terminal domain of the protein, has been associated with several Gal-3 functions: a) 
this modification acts as an "on/off" switch for its sugar-binding capability 
controlling downstream biological effects (Mazurek et al. 2000) b) similarly to Bcl-
2, whose phosphorylation at Ser70 appears to be critical for its anti-apoptotic 
function, non-phosphorylated Gal-3 mutants result in loss of Gal-3 anti-apoptotic 
activity and fail to induce cell cycle arrest (Yoshii et al. 2002). 
 
1.4.3 Galectin-3 ligand specificity 
The minimal sugar unit recognized by galectins is represented by a galactose residue 
linked to an adjacent monosaccharide in the β configuration (β-galactoside), such as 
that found in the LacNAc residues (Galactose [Gal]β1-4N-acetylglucosamine 
[GlcNAc]). Each member of the galectin family presents slightly, yet significant, 
differences in the CRD that can tune the affinity of each galectin for its ligands (Sato 
et al. 2009). 
Gal-3 can bind both N- and O-glycans (Sundblad et al. 2011) and it was originally 
identified to bind preferentially to Galβ13(4)GlcNAc (Cardoso et al. 2016); 
specific modifications of the β-galactoside core, however, can enhance or reduce the 
affinity towards Gal-3. α-N-acetylgalactosamine modifications of the Gal residue in 
the β-galactoside core, indeed, significantly increase the affinity for Gal-3, while 
modifications with α2-6- sialic acid reduce the affinity for the same protein 
(Hirabayashi et al. 2002). Moreover, the extension of the non-reducing end of the 
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disaccharide with 2- o 3- substituents on the outer galactose, such as N‐
acetylneuraminic acid (NeuNAc)α2,3 or GalNAcα1,3 and fucose (Fuc)α1,2 
substituents greatly enhances the affinity for Gal-3 (Krześlak and Lipińska 2004).  
In addition, also galactomannans and polymannans can be bound by Gal-3 (Díaz-
Alvarez and Ortega 2017). Usually the affinity of Gal-3 toward its glycan ligands is 
lower (approximately 10-6 M) than those typically observed for protein-protein 
interactions (approximately 10-8 M); however, the affinity increases for branched 
glycans and/or polylactosamine structures over simple saccharides. In fact, as 
previously mentioned, upon ligand binding Gal-3 can oligomerize through the N- 
terminal domain resulting in multiple CRD presentation. The multivalent binding of 
carbohydrate-containing glycoproteins or glycolipids by Gal-3 increases the avidity 
of the protein for its ligand, promoting the formation of organized glycan-galectin 
clusters, termed “lattices”, and mediating cross-linking of glycosylated molecules 
(Fortuna-Costa et al. 2014) (Fig. 1B). 
Further, since Gal-3 possesses an extended binding site, when compared to Gal-1 
(Sato and Nieminen 2002), this protein displays a high affinity for glycan presenting 
repeated LacNAc residues, as found in polylactosaminoglycans (polylactosamine 
effect). Amniotic fibronectin, which contains a tetra antennary complex composed 
of four parallel lactosamine residues presented by a mannose core structure, is an 
example (Sato and Hughes 1992). Interestingly, no effect is displayed against plasma 
fibronectin, that presents only two bi-antennary chains. 
 
Mutational and structural studies of the human Gal-3 carbohydrate binding site 
(formed by β-strands S4–S6) in complex with LacNAc molecule revealed the aa 
directly implied in sugar binding. In particular, the galactose C-4 hydroxyl group 
interacts with His-158, Arg-162, Asn-160 and a water molecule (W1). The C-6 
hydroxyl group interacts directly with Glu-184, Asn-174 and W3, while Arg144 can 
interact with the monomer linked to O-3 of the terminal galactose. Other favorable 
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stacking interactions are provided by Trp-181 with the hydrophobic galactose 
surface.  
The N-acetylglucosamine moiety is more exposed to the solvent; therefore, only the 
C-3 hydroxyl group can interact with Glu-184 and Arg-162. The other interactions 
involving the GlcNAc moiety are mediated through its N-acetyl group bonded to Arg 
186 and through a water molecule (W2) to Glu-165 and this probably accounts for 
the approximately 5-fold higher binding affinity of human Gal-3 for LacNAc over 
lactose (Seetharaman et al. 1998; Krześlak and Lipińska 2004). 
Since position 4 and 6 of the galactose in the β-galactoside present key interactions 
with the protein, modifications of these positions are not tolerated. On the contrary, 
appropriate modifications of position 2 and 3 are well tolerated and can enhance the 
affinity of this protein for its ligand (Leffler et al. 2002; Salomonsson et al. 2010). 
 
This chimera-type galectin not only interacts with glycan, but also with peptide 
motifs. Despite Gal-3 carbohydrate-binding activity appears to be critical for Gal-3 
function, this lectin presents also many different molecular interactions that are 
largely carbohydrate independent, some of them involving the carbohydrate binding 
groove (Wang et al. 1995; Paron et al. 2003; Elad-Sfadia et al. 2004; Shimura et al. 
2004; Shimura et al. 2005; Gupta 2012). For example, Gal-3 is able to interact with 
Bcl-2, an anti-apoptotic protein, which is not a glycoprotein (Yang et al. 1996).  
 
1.5 Galectin-3 expression and distribution in human tissues  
Data on Gal-3 expression in tissues of human adults and during embryonic stages 
are more limited if compared to mice. However, different studies (see below) have 
provided evidences about the expression pattern and distribution of this lectin in non-
hematopoietic and hematopoietic human tissues.  
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1.5.1 Galectin-3 expression in human non-hematopoietic tissues  
Gal-3 is broadly expressed in several human tissues and cells in a spatio-temporal 
fashion (Sundblad et al. 2011). During human embryogenesis, Gal-3 expression is 
mainly confined in epithelial cells of the skin, respiratory and digestive tract, 
excretory tubes of the kidney and to the uroepithelium. In the adult, Gal-3 expression 
resembles that found in embryogenesis, with protein expression restricted to the 
epithelial cells of different organs and to myeloid cells infiltrating the tissue. In 
particular, robust expression of this lectin was found during lung analysis in 
epithelial cells of the bronchus, chondrocytes of the bronchial cartilage, and in 
alveolar macrophages (Mathieu et al. 2005). Gal-3 expression is also described in 
the gastric epithelial cells, the colon, the colonic epithelial cells, and in the intestinal 
macrophages (Lippert et al. 2008). In the gut, Gal-3 expression is restricted to the 
crypt cells and macrophages of lamina propria (Mercer et al. 2009). Interestingly, 
the expression of this protein in endometrial and decidual tissues is tightly regulated 
through the menstrual cycle. Since Gal-3 has many immunomodulatory properties 
(for further details see paragraph 1.9), this observation led to hypothesize that Gal-3 
might contribute not only to the regulation of the endometrial function, but also to 
the modulation of the endometrial immune system during the implantation process 
(von Wolff et al. 2005; Sundblad et al. 2011). Finally, Gal-3 expression has been 
detected also in prostate glands, in the cytoplasm of luminal cells, and intratubular 
fibroblasts of the breast, in the cytosolic and membrane-enriched fraction of 
chondrocytes, as well as in the coronary artery smooth muscle cells (Sundblad et al. 
2011). 
Under physiologic conditions, due to its ability to shape the immune response, Gal-
3 expression in epithelia of the digestive tract and lungs might be involved in 
mucosal defense, modulating both host-pathogen interactions and immune attacks 
(Sundblad et al. 2011). 
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1.5.2 Galectin-3 expression and cellular localization in human 
hematopoietic cells  
Gal-3 has been reported to be ubiquitously expressed in many immune cells, where 
it contributes to regulate both the innate and adaptive immune responses (Chen et al. 
2005; Liu 2005; Rabinovich et al. 2007). First identified in macrophages (Ho and 
Springer 1982), Gal-3 was found in monocytes (Liu et al. 1995), dendritic cells 
(DCs) (van Stijn et al. 2009), mast cells and basophils (Craig et al. 1995), eosinophils 
(Rao et al. 2007), neutrophils (Wu et al. 2017), T and B cells (Craig et al. 1995; Chen 
et al. 2005), with a level of relative expression which is tightly regulated by the 
cellular activation state.  
In human monocytes, this lectin is constitutively expressed at low levels, both 
intracellularly and at the cell surface; however, its expression increases dramatically 
at both mRNA and protein levels, as monocytes differentiate into macrophages 
(Nangia-Makker et al. 1993; van Stijn et al. 2009). In this latter, Gal-3 was found in 
the cytoplasm/nucleus and at the plasma membrane surface. Interestingly, alternative 
macrophage polarization (M2) is associated whit higher levels of Gal-3 when 
compared to classically (M1) polarized macrophages, with a pattern of expression 
that follows the subsequent scheme: monocyte << M1 < M2 (Novak et al. 2012). 
Despite the difference in the levels of expression, cells of the monocyte/macrophage 
lineages are able to secrete this lectin in the extracellular media when properly 
stimulated (Liu et al. 1995) 
 
In a similar manner, differentiation of human monocytes into DCs leads to an 
increment in the Gal-3 protein levels with only a moderate increase in Gal-3 mRNA. 
Moreover, during cellular differentiation, the monocyte surface expression of this 
lectin slowly disappears, with Gal-3 protein that mainly localizes intracellularly in 
immature DCs (van Stijn et al. 2009). Conversely, in activated DCs, this lectin is 
principally restricted to lipid raft domains of membrane ruffles and lamellipodia, 
where it contributes to regulate cell motility (Hsu et al. 2009). Similarly to monocytes 
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and macrophages, Gal-3 secretion was reported also for DCs. Proteomic analysis of 
DC-derived exosomes demonstrates, in fact, that these cells can release in the 
extracellular microenvironment, membrane vesicles containing Gal-3 (Théry et al. 
2001). 
 
Through light microscopy immunohistochemistry and ultrastructural immunogold 
labeling, Gal-3 expression and localization were studied in human mast cells and 
basophils. In particular, in mast cells, this lectin was detected in the nucleus (over 
heterochromatin whereas euchromatin was unlabeled) and/or the cytoplasm. Of note, 
cytoplasmic labeling was principally concentrated over secretory granules. Gal-3 
localization in basophils was similar to that found in mast cells, but with a general 
low intensity of staining (Craig et al. 1995). 
 
Finally, Gal-3 expression was also reported for two other populations of innate 
immune cells: neutrophils and eosinophils. In the former, Gal-3 localize mainly 
intracellularly, despite at a lower level compared to other innate cells (Wu et al. 
2017). In addition, it and can be secreted by these cells upon treatment with mannan 
structure derived from microbial pathogens (Linden et al. 2013). Conversely, in 
human eosinophils, this chimeric protein is confined to the cells surface, with a level 
of expression that increases in allergic subjects (Rao et al. 2007).  
 
In sharp contrast with the constitutive expression of Gal-3 in innate immune cells, 
this lectin is absent, or only scarcely expressed, in lymphocytes and lymphoid cell 
lines. Resting T and B cells, for example, do not express Gal-3, but this protein can 
be induced following interleukin (IL)-4 stimulation or CD40 cross-linking in B cells 
(Acosta-Rodríguez et al. 2004), and by TCR engagement, or mitogen exposure, in T 
cells (Joo et al. 2001; Dumic et al. 2006). Likewise, also virus and/or parasite 
infections are able to induce Gal-3 expression in these cells (Dumic et al. 2006). 
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1.5.3 Regulation of galectin-3 gene expression  
Despite the amount of data available on Gal-3 expression in hematopoietic/non-
hematopoietic tissues, the regulation of gene transcription remains poorly 
understood.  
 
The analysis of the promoter sequence of LGALS3 revealed that this region contains, 
among others, two nuclear factor kappa B (NF-kB) and three putative activator 
protein (AP)-1 sites (Kadrofske et al. 1998). Particularly, in glioblastoma cells, the 
expression of this protein is regulated by Jun (a component of AP-1 transcription 
factor) and NF-kB, where Jun seems to be important for the basal expression of Gal-
3, while NF-kB is implicated in the gene induction following cell damage (Dumic et 
al. 2000). 
The presence in the promoter of cAMP-dependent response element (CRE) implies 
that cAMP-response element-binding protein (CREB) might participate in the Gal-3 
gene regulation. 
Particularly, the implication of CREB and NF-kB in Gal-3 gene regulation was 
studied in human T lymphotropic virus-I infected T cells (Hsu et al. 1996). In the 
latter, Gal-3 is under the regulation of both the CREB/activating transcription factor 
(ATF) and, to a lesser extent, the NF-kB transcription factor. Curiously, NF-kB 
regulation of Gal-3 expression is controlled by nuclin, an apoptosis-associated 
protein, which can interfere with NF-kB in order to inhibit the expression of Gal-3 
(Liu et al. 2004). On the contrary, in macrophage cells, Gal-3 expression seems to 
be principally regulated by the rat sarcoma (Ras)/mitogen activated protein kinase 
(MAPK) signal transduction pathway (Kim et al. 2003).  
 
Further analysis revealed that the promoter contains also numerous GC box motifs, 
which can be bound by the ubiquitously expressed specificity protein (Sp)1 
transcription factor, a feature which is commonly observed in the promoters of the 
housekeeping genes (Fogel et al. 1999). Nevertheless, Gal-3 expression at both 
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mRNA and protein levels, following serum addition to serum-starved fibroblasts, 
represents a feature of early genes, and sis-inducible element (SIE) was suggested to 
be a potential candidate for the growth-induced activation of LGALS3 expression 
after serum addition (Dumic et al. 2006) 
 
Finally, epigenetic mechanisms could also be involved in Gal-3 expression. The gene 
promoter and the first exon, in fact, present a high content of GcP island and the 
methylation status seems to contribute to Gal-3 expression in pituitary tumors 
(Ruebel et al. 2005). 
 
As evidenced by the different regulatory elements found in the Gal-3 promoter and 
the different transcription factors involved in LGALS-3 transcription, Gal-3 
expression results to be a complicated process probably depending on cell type, 
environmental stimuli and malignant transformation.  
 
1.6 Cellular localization  
Gal-3 is a structurally unique protein expressed in many normal tissues and immune 
cells with a cellular localization that strongly depends on the cell type and its 
proliferation status. In addition, the cellular distribution of this protein can change 
during differentiation or neoplastic transformation (Dumic et al. 2006) (Fig. 3).  
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Figure 3. Intracellular trafficking of Gal-3 based on experimental evidence. Gal-3 can 
be either found the extracellular space, attached to cell surface, in the cytoplasm, in secretory 
vesicles or in the nucleus. Moreover, it can be secreted from cells in a manner that is 
independent from classical secretory pathway (adapted from Hughes 2001). 
 
Initially synthesized on free ribosomes in the cytoplasm (Mehul and Hughes 1997), 
Gal-3 is able to shuttle between the nucleus and the cytoplasm in a manner that is 
still unclear. Using a truncated form of Gal-3 was discovered that mutants containing 
truncations of the amino-terminal half of this protein, were dispensable for nuclear 
import (Davidson et al. 2006). On the contrary, mutants of the same construct, 
containing truncations from the carboxyl terminus, showed loss of nuclear 
localization. Then, site-directed mutagenesis of this latter portion of the polypeptide 
suggested that nuclear import was dependent on the ITLT sequence (residues 253-
256). However, this sequence, by itself, is not sufficient to guarantee a correct 
nuclear localization: its activity, in fact, is strongly regulated by a neighboring 
leucine-rich nuclear export signal. 
Conversely, another study suggested that Gal-3 could be either imported into the 
nucleus via active transport and/or passive diffusion (Nakahara et al. 2006). 
Concerning the active transport, the Authors of this study identified a nuclear 
localization signal (NLS)-like motif in its protein sequence, HRVKKL (residue 223-
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228), similar to those of p53 and c-Myc, respectively. Moreover, they suggest that 
nuclear localization of Gal-3 is, at least in part, due to the importin-α/β, with the 
Arg224 amino acid residue of human Gal-3 essential for its active nuclear 
translocation and molecular stability. 
 
In contrast with nuclear import, nuclear export of this protein seems to be mediated 
by chromosome maintenance region 1 (CRM1), a nuclear export receptor. Candidate 
nuclear export signals, recognized by CRM1, can be found between residues 240 and 
255 of murine Gal-3. Direct mutagenesis studies identified residues 240-255 of the 
Gal-3 protein, as containing fundamental aa for nuclear exportation, and partially 
overlaps with the region (residues 252-258), previously identified as important for 
nuclear localization (Li et al. 2006). 
As previously reported, Gal-3 can undergo to post-translation modifications (see 
paragraph 1.4.2). In particular, this protein can be phosphorylated at both Ser6 and 
Ser12, of the NH2-terminal, even though the majority of phosphate is present at Ser6, 
while less than 10% at position Ser12 (Dumic et al. 2006). The protein responsible 
for Gal-3 phosphorylation seems to be casein kinase I and/or II, since the major 
acidic residues on both sides of Ser6 make it a good substrate for this kinase. The 
presence of both unphosphorylated and phosphorylated Gal-3 has been reported in 
mouse 3T3 fibroblasts; where phosphorylated Gal-3 was found in both nucleus and 
cytoplasm, whereas unphosphorylated form was detected only in the cytoplasm. This 
observation suggests that the phosphorylation is a mechanism required for Gal-3 
nuclear import, however, mutagenesis studies of Ser6 show that it is not essential for 
protein localization in this cellular compartment (Dumic et al. 2006).  
 
Similarly to nuclear import/export, Gal-3 secretion mechanism is still under 
debating. Gal-3 lacks any recognizable canonical secretion signals able to direct this 
protein in the classical secretory pathways through the endoplasmic reticulum and 
Golgi system (Hughes 1999). Nevertheless, it has been extensively demonstrated that 
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this protein can be secreted by immune (Théry et al. 2001; van Stijn et al. 2009; 
Linden et al. 2013) and many other cells (Hughes 1999; Menon and Hughes 1999). 
It has been proposed that Ga-3 can be released by cells through an incompletely 
understood mechanism, called ectocytosis (Menon and Hughes 1999), in which the 
protein forms aggregates underlying the plasma membrane and the release takes 
place through membrane blebbing. 
In particular, the first step in the Gal-3 secretion consists in protein accumulation and 
capture at the cytoplasmic side of the plasma membrane. This is a rate-limiting step 
and seems to be mediated by molecular chaperones and/or heat shock proteins.  
Essential requirements for this retention appear to be the acylation by the 
lymphocyte-specific protein tyrosine kinase (LcK). In particular, Cos cells 
transfected with a fusion protein containing within the N-terminal domain a Lck 
acylation sequence were efficiently acylated, retained at the cytoplasmic level and 
released in higher amount when compared to wild type lectin. 
The following step consists in the evagination of the plasma membrane and secretion 
of the Gal-3-containing extracellular vesicles, in which the protein is protected 
against proteolysis. Under culture conditions, the Gal-3 release from these 
extracellular vesicles is quite fast, with a half-life of about 1 h. Conversely, isolated 
vesicles were more stable and this suggests that vesicles breakdown and cargo 
release requires specific factor(s) secreted by cells (Krześlak and Lipińska 2004).  
 
The N-terminal domain of the protein seems to be fundamental for secretion and 
localization into secretory vesicles (Menon and Hughes 1999). The addition of the 
N-terminal domain to a cytosolic protein, the chloramphenicol acetyltransferase, 
leads to efficient export in transfected Cos cells. The 89–96 YP(90)SAP(93)GAY 
short sequence was identified as fundamental for Gal-3 secretion; however, this short 
segment alone is insufficient to induce the secretion of fusion proteins and results 
active only when larger portions of the Gal-3 N-terminal sequence are present. 
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1.7 Function of extracellular and intracellular galectin-3 in regulating 
cellular homeostasis  
The many intra- and extra-cellular localizations of this protein, together with the 
ability to interact with numerous glycosylated or unglycosylated binding partners 
(Fig. 4 and 5), allow Gal-3 to modulate several physiological processes, such as 
cellular homeostasis, apoptosis, cell activation, cell adhesion, organogenesis, 
angiogenesis, immune response, and to act as chemoattractant for many immune 
cells (Sundblad et al. 2011). 
 
1.7.1 Function of extracellular galectin-3 
On cell surfaces, carbohydrates due to their structural and conformational diversity 
represent an incredible reservoir of biological information, even greater than DNA 
or peptides (Gabius 2000; Cardoso et al. 2016). Gal-3, as sugar binding proteins, can 
decipher this “sugar code” orchestrating a variety of biological processes (Sundblad 
et al. 2011). 
In particular, once in the extracellular spaces, this protein can flow into the 
circulation, interact with the extracellular matrix or be associated with the cell 
surfaces, exhibiting numerous autocrine and paracrine effects (Sundblad et al. 2011). 
In particular, Gal-3 can modulate biological functions by forming ordered galectin-
glycan arrays (lattices structure), cross-linking different cell surface 
glycoconjugates, or, alternatively, Gal-3 can engage specific cell surface ligands 
through the classical ligand-receptors interaction (Fig. 4) (Rabinovich and Toscano 
2009; Sundblad et al. 2011).  
 
1.7.2 Gal-3 function in endocytosis 
In breast carcinoma cells, Gal-3 can participate in cellular endocytosis, through a 
caveolae-like pathway by means of which this protein promotes the endocytosis of 
CD29 (beta-1 integrin) in a lactose/temperature-dependent manner (Furtak et al. 
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2001). Interestingly, by the same pathway tumor cells can internalize from the 
extracellular spaces Gal-3 itself and this process is completely blocked by lactose 
(Furtak et al. 2001). In a similar manner, Gal-3 is involved in advanced glycation 
end products (AGE) and modified low density lipoproteins (LDL) endocytosis (Zhu 
et al. 2001).  
 
In sharp contrast, Gal-3 can also interfere with endocytosis, extending the expression 
on cell surface of specific receptors and therefore altering cell responses during 
tumor progression. Gal-3 affinity for β-1,6-N-acetylglucosamine, in fact, mediates 
its binding to many glycoproteins expressed on cell surface, including lysosomal-
membrane-associated glycoproteins (LAMPs)-1 and -2, carcinoembryonic antigen 
(CEA), mucin-1, macrophage antigen (Mac) -1/-3, transferrin receptor protein 1 
(CD-71), protein tyrosine phosphatase receptor type C (CD45), and the glycosylated 
receptors for the vascular endothelial growth factor (VEGF), the epidermal growth 
factor (EGF), and the transforming growth factor (TGF)-β (Fortuna-Costa et al. 
2014). Carcinoma transformation is often associated with the upregulation of the 
beta-1,6 N-acetylglucosaminyltransferase a Golgi enzyme which promotes the 
substitution of N-glycan with poly LacNac, the main ligand for Gal-3. This leads to 
Gal-3 cross-linking of N-glycans and lattice formation on EGF and TGF-β receptors 
at the cell surface, delaying their removal by constitutive endocytosis and prolonging 
cell activation (Partridge et al. 2004). 
 
Of note, while extracellular Gal-3 plays a pivotal role in the balance of surface 
retention of glycosylated receptors against endocytosis, intracellular Gal-3 is equally 
important for proteins trafficking from the cytoplasm to the plasma membrane.  
In a physiologic contest, cytosolic Gal-3 controls the expression of EGF receptors in 
mouse keratinocytes. In particular, in the absence of Gal-3, EGF receptor expression 
results dramatically reduced with the protein that accumulates intracellularly. Of 
note, in these cells, Gal-3 can regulate this process through the interaction and 
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modulation of ALG-2 linked protein x (Alix), a member of the endosomal sorting 
complex required for transport (ESCRT) apparatus (Liu et al. 2012).  
 
1.7.3 Cell adhesion 
Recognition of extracellular glycoproteins and glycosylated components of the 
extracellular matrix by Gal-3 plays a central role in cell adhesion/de-adhesion. Gal-
3 was demonstrated to bind laminin, fibronectin, hensin, elastin, collagen IV, and 
tenascin-C/R (Dumic et al. 2006). Overexpression of this chimera-type protein in a 
human breast carcinoma cell line significantly enhanced adhesion to vitronectin, 
fibronectin and laminin (Materasse et al. 2000). Consistently, Gal-3 binding of 
Lamp-1/2, colon cancer mucin, the carcinoembryonic antigen, and the 
glycosylphosphatidylinositol (GPI)-anchored glycoprotein C4.4A were suggested to 
participate in cancer cell adhesion to extracellular matrix (Dumic et al. 2006). 
In addition, Gal-3 was found to interact with integrins, molecules involved in cell 
adhesion. Particularly, Gal-3 has been documented to associates with α1β1 integrin 
in a lactose-dependent manner (Ochieng et al. 1998). Moreover, through a Gal-3 
affinity column purification of binding partners it was found that Gal-3 is able to 
interact with the alpha-subunit (CD11b) of the CD11b/CD18 integrin (CR3, Mac-1 
antigen), and with the heavy chain of CD98, an integrin-associated protein (Dong 
and Hughes 1997). This latter is a cell surface heterodimeric glycoprotein that 
participates in cell-cell and cell-substratum interactions, expressed on 
monocytes/macrophages and in activated lymphocyte (T and B cells) (Cantor and 
Ginsberg 2012). Gal-3 appears to be able to induce cross-linking of CD98, leading 
to activation of integrin-mediated adhesion (Hughes 2001).  
Besides the previously reported data, also a negative effect mediated by Gal-3 on 
cell adhesion was reported. In vitro, Gal-3-enriched media were demonstrated to 
inhibit thymocyte interactions with thymic microenvironmental cells (Villa-Verde et 
al. 2002).  
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Figure 4. A cartoon schematically representing some extracellular binding partners 
identified for Gal-3. Red arrows indicate positive effects (adapted from Dumic et al. 2006). 
 
1.7.4 Function of nuclear and cytoplasmic galectin-3 
Depending on the cell type, differentiation and development status, Gal-3 can be 
predominantly nuclear, exclusively cytoplasmic, or spreads over these two 
compartments (Haudek et al. 2010). In the cytoplasmic compartment, Gal-3 interacts 
with numerous partners, implying a role for Gal-3 in the regulation of numerous 
intra-cytoplasmic events (Fig. 5).  
 
1.7.5 Regulation of cell cycle 
Cell cycle regulation is a complex process that requires intricate interactions among 
different proteins. Gal-3 expression, which is regulated by cell cycle (Moutsatsos et 
al. 1987), is also able to affect the cell cycle itself. Following expression of this lectin 
in BT549, a cell line that normally undergoes apoptosis induced by the loss of cell 
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anchorage (anoikis), Gal-3 mediates G1 phase arrest without detectable cell death. 
The acquisition of this anti-anoikis activity is accompanied by cyclin A and E 
(cyclins important for progression and maintenance of phase S) level 
downregulations, and upregulation of their inhibitory protein levels p21 and p27, as 
well as cyclin D. 
These two phenomena may help the cells to bypass the critical apoptosis-sensitive 
point in early G1, arresting cells at an anoikis-resistant point (late G1). Furthermore, 
also the retinoblastoma protein, which is hyper-phosphorylated during the S/G2 
phase and most of the M phase, in Gal-3 overexpressing cells, is kept in a 
hypophosphorylated form, showing that these cells fail to enter S phase (Kim et al. 
1999). Similarly, in the same cell line overexpressing Gal-3, genistein, a soy-derived 
isoflavonoid able to induce apoptosis without any cell cycle arrest, induces arrest in 
G2/M phase without any apoptosis induction. The different phase arrests of the cell 
cycle might be dependent on genistein-induced upregulation of P21, but not P27 
upregulation, thus leading to G2/M arrest (Lin et al. 2000).  
These studies suggest that Gal-3 can regulate critical decision points through cell 
cycle progression, phase arrest (depending on the apoptotic stimuli) and induction of 
apoptosis.  
 
1.7.6 Galectin-3 in gene regulation 
Nuclear Gal-3 is also involved in gene transcription/regulation (Lin et al. 2002; 
Paron et al. 2003; Dumic et al. 2006). In particular, in human breast epithelial cells, 
Gal-3 is able to induce cyclin D promoter activity through stabilization and 
enhancement of the transcription factor binding to Sp1 and CRE sites. Moreover, in 
the same cells, Gal-3 overexpression is associated with changes in the expression 
levels of other proteins, such as cyclin A/E and p21/27. Since these cycle regulators 
contain in their promoter CRE and SP1 sites, they also represent possible candidates 
whose expression is regulated by Gal-3 (Lin et al. 2002). 
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The involvement of gene transcription was further demonstrated in papillary thyroid 
cancer cells, where Gal-3 directly interacts with the thyroid-specific transcription 
factor (TTF)-1 causing stimulation of TTF-1 binding activity (Paron et al. 2003; 
Dumic et al. 2006). 
 
Further evidence came from a study demonstrating that, in the nucleus, Gal-3 co-
localizes and binds to β-catenin/ T cell factor (Tcf) complex in a lactose-depended 
manner (even if β-catenin is not a glycoprotein). This interaction induces the 
transcriptional activity of Tcf-4 regulating c-Myc expression and promoting cell 
growth and proliferation (Shimura et al. 2004). Moreover, analysis of the Gal-3 and 
β-catenin sequences revealed that these two protein share structural similarity. In 
particular, both proteins contain the S92XXXS96 consensus sequence for glycogen 
synthase kinase GSK-3β phosphorylation. Axin, a regulatory protein of the Wnt 
signaling pathway, can complex with both proteins promoting their GSK-3β 
phosphorylation. The Authors of this study, therefore, suggest that Gal-3 is a key 
regulator of the Wnt/ β-catenin signaling pathway and of its target gene expression 
(Shimura et al. 2005). 
 
1.7.7 Galectin-3 as a factor in pre-mRNA splicing 
Nuclear Gal-3 can directly participate to the splicing machinery. It was found that 
Gal-3 can associate, in the nucleus, with ribonucleoprotein complexes and be 
involved in spliceosome assembly, acting as a pre-mRNA splicing factor (Wang et 
al. 1995). Despite in the previous study was showed that Gal-3 can interact directly 
with single-stranded DNA (ssDNA) and with RNA, more recently it has been 
demonstrated that Gal-3 might interact, in a weak protein-protein manner, with 
another splicing component, identified in Gemin-4, rather than through the direct 
binding to the splicing substrate (Wang et al. 2006). 
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1.8 Galectin-3 at the edge between life and death 
An increasing number of literature data have provided evidence about a role of Gal-
3 in the regulation of apoptosis (Hsu and Liu 2002). Despite it remains largely 
unclear how this protein is able to modulate this process, the mechanism seems to 
involve both the extracellular and the intracellular side of the membrane. In 
particular, Gal-3 can act in a dual manner either protecting or inducing cell apoptosis, 
depending on whether this protein is localized intracellularly (generally anti-
apoptotic) or extracellularly (mainly pro-apoptotic) (Dumic et al. 2006).  
 
1.8.1 The pro/anti-apoptotic effect of galectin-3 
Yang and colleagues (1996) demonstrated that transfection of the T-cell line, Jurkat, 
with the Gal-3 gene promotes the growth of the cell line in suboptimal culture 
conditions (culture medium containing only 1% bovine serum), when compared to 
untransfected cells. Further, intracellular expression of the protein was able to confer 
protection to apoptosis induced by CD95 (apoptosis antigen [Apo]-1/Fas) receptor 
ligation or by staurosporine. The intracellular anti-apoptotic role of Gal-3 was also 
demonstrated in large B-cell lymphomas, where transfection with a Gal-3 expressing 
plasmids resulted in a markedly increased resistance to anti-Fas-induced cell death 
(Hoyer et al. 2004). Similarly, targeted disruption of Gal-3 gene in peritoneal 
macrophages resulted in cells more prone to undergo apoptosis than those from Gal-
3(+/+) mice when treated with apoptotic stimuli, suggesting that expression of Gal-3 
in these cells may lead to longer cell survival (Hsu et al. 2000). 
Gal-3 expression in the breast carcinoma cell line BT-549 and Evsa-T, which do not 
or slightly express Gal-3 respectively, protects cells from apoptotic insults 
(UV/anticancer drugs/tumor necrosis factor [TNF]-α). Interestingly, in BT-549 cells 
this latter phenomenon is also associated with phosphorylated Gal-3 transport from 
the nucleus to the cytoplasm (Matarrese et al. 2000; Takenaka et al. 2004). 
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The underlying mechanisms regulating the intracellular anti-apoptotic effect of Gal-
3 are still under debate; many Authors identified several cytoplasmic binding 
partners and suggested that regulatory pathways are involved (Dumic et al. 2006). A 
possible mechanism seems to be the translocation of Gal-3, upon different apoptotic 
stimuli, from the cytoplasm/nucleus to the mitochondria, where it can interact with 
other apoptosis regulators and block the changes in mitochondrial membrane 
potential, the release of cytochrome C and therefore preventing apoptosis (Nangia-
Makker et al. 2007).  
In fact, Gal-3 can interact with Bcl-2 (Yang et al. 1996), a death suppressor, probably 
through the NWGR sequence, designated as the anti-death domain, present in both 
proteins, which it is fundamental for Bcl-2/Bax heterodimerization, Bcl-2/Bcl-2 
homodimerization (Hanada et al. 1995) and Gal-3 anti-apoptotic effect (Akahani et 
al. 1997). 
Besides Bcl-2, Gal-3 prevents the mitochondrial damage following cytochrome C 
release through the interaction with synexin, a Ca2+/phospilipid binding protein. 
Synexin can bind and mediate Gal-3 translocation to the perinuclear membrane of 
mitochondria. Downregulation of this protein impairs the ability of Gal-3 to exert its 
anti-apoptotic effect (Yu et al. 2002). 
In response to cellular stress, P53, a master regulator of apoptosis, can induce cell 
death through Gal-3 repression. In particular, Gal-3 is downregulated by the specific 
cooperation of the homeodomain-interacting protein kinase (HIPK)2 and P53, and 
the expression of a non-repressible Gal-3 prevents HIPK2 and p53-induced apoptosis 
(Cecchinelli et al. 2006). Similarly, it was demonstrated that Nuclin, an apoptosis-
associated protein, can interact with Gal-3 (Dumic et al. 2006) in the cytoplasm and 
interfere with NF-kB in order to inhibit expression of Gal-3 at both mRNA and 
protein levels (Liu et al. 2004).  
Another important partner for Gal-3 is the activated form of K-Ras, a small GTPase 
protein able to respond to different extracellular stimuli, modulating different 
biological consequences, such as senescence/proliferation, death/survival. Gal-3 acts 
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as a specific binding partner of activated K-Ras and depending on cellular contest 
can stimulate anchorage independent cell growth, cellular proliferation, and 
inhibition of apoptosis via K-Ras-mediated Raf/mitogen-activated protein (MEK)/ 
extracellular signal-regulated kinase (ERK) activation (Shalom-Feuerstein et al. 
2005; Levy et al. 2011), as well as phosphoinositide 3-kinase (PI3K) (Elad-Sfadia et 
al. 2004). 
Finally, Alix and ALG-2 interacting protein (AIP)-1 might be implied in the anti-
apoptotic effect of Gal-3. These proteins are able to interact with ALG-2, a protein 
inhibiting paraptosis, a form of programmed cell death. Similarly, Alix and AIP-1, 
are also able to interact with Gal-3, as demonstrated in Jurkat cells, probably through 
the N-terminal of these proteins, containing a proline glycine alanine and tyrosine-
rich sequence, homologous to the N-terminal part of Gal-3 (Nangia-Makker et al. 
2007). 
 
In sharp contrast, exogenously added Gal-3 has been shown to induce apoptosis in 
human T cells, neutrophils, peripheral blood mononuclear cells (PBMC) (Fukumori 
et al. 2003; Fernández et al. 2005; Stillman et al. 2006) and mouse activated T cells 
(Fukumori et al. 2003), while at the moment there is no evidence for an anti-apoptotic 
activity of exogenously added Gal-3 (Dumic et al. 2006). Concerning the 
mechanisms involved in Gal-3-induced apoptosis, at least in T cells, cell death seems 
to pass through the interaction with CD95, a member of the TNF superfamily. 
Activation of CD95 by apoptotic stimuli, can determine two different apoptotic 
signal pathways, one requires a large amount of activated caspase 8 at the cell death-
inducing signaling complex (DISC) (mitochondria independent, type I cells), the 
other (mitochondria dependent, type II cells) depends on the apoptogenic activity at 
the mitochondria. It was demonstrated that the major difference among cells which 
respond to the apoptotic insult with the type I (such as SKW6.4 or H9) or type II 
(such as Jurkat or CEM) pathway is the intracellular level of Gal-3. Transfection of 
Gal-3 in Gal-3 null cells results in binding of this lectin to CD95, converting their 
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phenotype from type II in type I apoptotic cells (Fukumori et al. 2004). This suggests 
that Gal-3 can modulate the signaling through CD95 determining which apoptotic 
signaling pathway a cell will follow.  
 
The differences in the intracellular levels between type I/II cells also reflect how 
these cells will react after extracellular Gal-3 exposure. In particular, exogenous Gal-
3 can induce apoptosis in type II cells with activation of intracellular signaling 
leading to cytochrome C release and caspase 3 activation, while type I are more 
resistant. This is probably due to the high level of endogenous Gal-3 in type I cells 
that can balance the pro-apoptotic effect of extracellular Gal-3 with an anti-apoptotic 
effect of endogenous Gal-3. Interestingly, the pro-apoptotic effect of Gal-3 passes 
through the carbohydrate-dependent interaction with surface glycosylated receptors, 
since lactose is able to reduce this effect in a dose-dependent manner. The receptors 
responsible for this effect were identified in C29 and CD7 (Fukumori et al. 2003). In 
particular, these two receptors may work as oligomers while delivering the Gal-3 
death signal, through the clustering ability of Gal-3 (already observed for T cell; Hsu 
et al. 2009). This would be in line with the observation that oligomerization of Gal-
3 is important for the pro-apoptotic effect, since the NH2 terminus removal abrogates 
this effect (Fukumori et al. 2003). 
 
The behavior of Gal-3 in response to the tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) is still elusive. This protein is a member of the TNF family 
of cytokines that promotes apoptosis, in a wide variety of tumor cells, but not in 
normal cells. Transfection of the TRAIL insensitive breast carcinoma cell line, BT-
549, with Gal-3 gene, renders these cells sensitive to apoptosis suppressing the 
activity of Akt, a serine/threonine kinase, involved in resistance to TRAIL (Lee et 
al. 2003). Surprisingly, in J8 cells, a line of human bladder carcinoma, the levels of 
Gal-3 are elevated, and consistently the levels of constitutively activated Akt, 
rendering the cells resistant to apoptosis. This opposite result might be due to the use 
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of two different cell lines, containing different Gal-3 associated proteins (Oka et al. 
2005).  
 
 
Figure 5., A cartoon schematically representing some intracellular binding partners 
identified for Gal-3. Blue lines indicate negative effects, red arrows indicate positive effects 
(adapted from Dumic et al. 2006). 
 
1.8.2 Regulation of cell growth and differentiation by endogenous and 
exogenous galectin-3 
Besides the previously reported implications of Gal-3 in life/death regulation, this 
protein can be a crucial mediator for cell growth and proliferation. In particular, 
incubation of human lung fibroblasts with recombinant Gal-3 leads to cell 
proliferation and DNA synthesis, in a dose-dependent manner (Inohara et al. 1998). 
Similarly, the addition of exogenous Gal-3 to mesangial cells cultured without serum 
is able to prolong cell survival, protect the cells from the negative effect of TGF-β, 
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and to induce the synthesis and secretion of collagen type IV (Sasaki et al. 1999). In 
neural mouse cells, extracellular Gal-3 can serve as adhesion molecule, while it is 
also able to induce the outgrowth of neurites from dorsal ganglia explants (Pesheva 
et al. 1998). Still, Gal-3 stimulates not only the capillary tube formation of umbilical 
vein endothelial cells in vitro, but also angiogenesis in vivo (Nangia-Makker et al. 
2000). 
 
A role of endogenous Gal-3 in cell growth was also demonstrated for different cancer 
and normal cells with the use of antisense oligonucleotide or cDNA strategy (Hsu 
and Liu 2002). The blockage of Gal-3 expression in human breast cancer cells leads 
to a reversion of the transformed phenotype and a suppression of tumor growth 
(Vandenbrule et al. 1997; Honjo et al. 2001), while in T cells significantly decreases 
their proliferation (Joo et al. 2001). Similarly, the overexpression of Gal-3 in thyroid 
papillary carcinoma cells is necessary for the maintenance of anchorage independent 
growth (Yoshii et al. 2001). 
 
Interestingly, opposite Gal-3 effects were observed for proliferation. In a cancer 
prostate cell line (LNCaP) transfection of Gal-3 gene reduces the proliferation rate 
in vitro compared to the vector control-transfected cell lines or to the parental LNCaP 
(Ellerhorst et al. 2002).  
Finally, Gal-3 is able to inhibit the positive effect on proliferation of bone marrow 
cells given by recombinant granulocyte-macrophage colony-stimulating factor (GM-
CSF) (Krugluger et al. 1997). 
 
1.9. Function in immune system   
During the last decades, compelling evidence has been accumulated regarding the 
ability of Gal-3 to affect both innate and adaptive immune system, modulating the 
course of immune responses, inflammation, cell growth, signaling and chemotaxis 
(Rabinovich et al. 2002; Dumic et al. 2006; Sundblad et al. 2011). This effect can be 
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mediated by either direct binding of extracellular Gal-3 to surface membrane 
receptors or by intracellular Gal-3 modulation of signaling pathways (Fig. 6) (Díaz-
Alvarez and Ortega 2017).  
 
1.9.1 T cells and B cells 
As previously mentioned, Gal-3 expression in T lymphocyte is generally absent until 
induced by strong activating agents; in particular, a combination of receptor cross-
linking and proliferative stimuli are required for high levels of Gal-3 expression. In 
these cells, the intracellular presence of this lectin is associated with an increase in 
cell proliferation, while cell growth is interrupted when Gal-3 expression is 
suppressed (Hsu et al. 2009 [A]).  
Moreover, in activated T cells, Gal-3 is recruited along with Alix, one of its 
intracellular binding partner, to the cytoplasmic side of the immunological synapse 
(IS) (Chen et al. 2009). Alix is a protein involved in protein transport and regulation 
of cell surface expression of certain receptors, and, as demonstrated by Chen et al. 
(2009), Gal-3 and Alix recruitment to the IS is associated with low levels of early 
signaling events, attenuated signal transduction, and TCR downregulation in T cells. 
Therefore Gal-3, through the modulating of Alix's function at the IS can dampen T-
cell activation and function.  
 
The pivotal role of Gal-3 in T cells regulation is not only confined to the intracellular 
side of the membrane. Extracellularly delivered Gal-3 was reported to play a 
fundamental role in the regulation TCR signaling, modulating the required number 
of receptors at the site of antigen presentation. This process is dependent on the 
formation of multivalent complexes with the N-glycans exposed by TCR, that reduce 
the lateral mobility and recruitment to the site of antigen presentation, raising the 
threshold for T cell activation and preventing uncontrolled activation of these cells 
(Demetriou et al. 2001). The formation of this lattice structure seems to be important 
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for T cell homeostasis, since disruption of this Gal-3-N-glycan interaction leads to 
hyperactive T cells and autoimmunity (Sundblad et al. 2011).  
Finally, in T cells Gal-3 plays an important role in cell life and death; either inducing 
(when extracellularly added) or preventing (when endogenously expressed) 
apoptosis of T cells (for further details see paragraph 1.8.1). 
 
Interestingly, it has been suggested that in the intestinal mucosa, Gal-3 might play 
an immunomodulatory activity on these lymphocytes. In particular, the basal 
expression of Gal-3 and its release by epithelial cells of the intestinal mucosa may 
help to prevent inappropriate immune responses against luminal antigens of food or 
commensal bacteria. On the contrary, Gal-3 downregulation during tissue 
inflammation may reflect a desired event, in order to promote an adequate immune 
response by supporting activated T cell proliferation and reducing activation-induced 
T cell death (Müller et al 2006). 
 
The function of Gal-3 in the regulation of B cell physiology is far from being 
completely understood and only a few literature reports explore the role of this 
chimeric protein in B cell activation and differentiation. Similarly to T cells, also B 
cells express Gal-3 only after a strong stimulation, such as IL-4 and CD40 cross-
linking. In these cells Gal-3 was demonstrated to be a critical mediator of cell 
differentiation and survival. In particular, endogenous expression of this protein 
promotes B cells survival and blocks their final differentiation into plasma cells, 
allowing the rising of a memory B cell phenotype (Acosta-Rodríguez et al. 2004).  
In addition, Gal-3, can be secreted by diffuse large B-cell lymphoma and binds back, 
in a carbohydrate-dependent manner, to the transmembrane tyrosine phosphatase 
CD45, promoting apoptosis resistance. Removal of cell-surface Gal-3 from CD45 
renders these cells susceptible to chemotherapeutic agents (Clark et al. 2012). 
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1.9.2 Monocytes/macrophages 
Macrophages are a heterogeneous population of highly plastic cells that can adapt 
their functional phenotypes in response to stimuli present in the environment (Díaz-
Alvarez and Ortega 2017). 
In particular, macrophages can differentiate into M1 macrophages in response to toll 
like receptor (TLR) and interferon (IFN)-γ stimulation. These cells produce high 
levels of pro-inflammatory cytokines and reactive nitrogen/oxygen intermediates 
and promote a Th1-type response. In addition, they have strong microbicidal and 
tumoricidal activities. Alternatively, under the influence of IL-4/IL-13 or IL-10, they 
can differentiate into M2/M2-like macrophage, which in turn are more involved in 
tissue remodeling, parasite containment, tumor progression, and immunoregulatory 
functions (MacKinnon et al. 2008; Díaz-Alvarez and Ortega 2017). 
Increased Gal-3 expression and secretion is a feature of M2 macrophage activation, 
while in M1 macrophage activation, Gal-3 expression and release are lower 
(MacKinnon et al. 2008). With the use of a specific inhibitor, it has been 
demonstrated that Gal-3, released by alternative activate M2 macrophages in 
response to IL-4, is able to sustain this alternative activation, and that Gal-3 deficient 
mice display an impaired M2, IL-4-mediated, polarization (MacKinnon et al. 2008).  
 
Gal-3 plays a critical role also in macrophage phagocytosis, as demonstrated by Sano 
et al. (2003). In particular, Gal-3-deficient cells exhibited reduced phagocytosis of 
IgG-opsonized erythrocytes and apoptotic thymocytes in vitro, while Gal-3 deficient 
mice showed attenuated phagocytic clearance of apoptotic thymocytes by peritoneal 
macrophages in vivo. Interestingly, extracellular Gal-3 does not contribute 
appreciably to phagocytosis, while the intracellular accumulation of Gal-3 around 
the phagosome seems to be responsible for this process.  
In addition, Gal-3 has an important anti-apoptotic role in these cells since gene 
disruption leads to a lower number of macrophages, with altered 
morphology/phenotype and more prone to undergo apoptosis (Hsu et al. 2000).  
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In human monocytes, Gal-3, can binding to cell surface glycoconjugates inducing 
superoxide release and potentiating their IL-1 production, in a lactose-sensitive 
manner (Jeng et al. 1994; Liu et al. 1995). Finally, Gal-3 recognizes and binds the 
highly glycosylated CD13 molecule, expressed on monocyte surfaces, inducing 
homotypic aggregation of inflammatory monocytic cells (Mina-Osorio et al. 2007). 
 
1.9.3 Neutrophils 
Neutrophils are abundant specialized effector leukocytes, possessing high 
phagocytosis and microbicidal activities. They represent one of the first lines of 
defense to arrive at the site of tissue injury (Díaz-Alvarez and Ortega 2017) 
In neutrophils, similarly to T cells, exogenously added and endogenous Gal-3 have 
distinct effects. Extracellular Gal-3 enhances the ability of neutrophils to migrate, 
phagocytize, produce IL-8 and reactive oxygen species (ROS), bind and induce IgE-
dependent cellular activation, as well as NADPH-oxidase activation and oxidative 
burst. In particular, candidate receptors able to induce neutrophil activation, 
oxidative burst, and NADPH-oxidase activation are the CD66a and CD66b protein 
(Feuk-Lagerstedt et al. 1999). On the contrary, endogenous Gal-3 dampens their 
activation and their pro-inflammatory activity (Truong et al. 1993; Nieminen et al. 
2005; Wu et al. 2017; [A]). 
 
1.9.4 Mast cells and eosinophils 
Gal-3 induces the cross-linking of cell surface glycoproteins, possibly high-affinity 
IgE receptors (FcεRI), that in turn trigger a signal transduction cascade, that activates 
and initiates degranulation in mast cells (Frigeri et al. 1993). Gal-3 function in these 
cells was studied by the use of transgenic mice. Gal-3 deficient mice showed reduced 
secretion of histamine, as well as IL-4, upon cell activation, and a general defect in 
mast cell responses (Chen et al. 2006).  
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Addition of Gal-3 induces a selective downregulation of IL-5 expression in human 
eosinophils, PBMC and in an Ag-specific T cell line (CD4+), in a lactose-dependent 
manner (Cortegano et al. 1998). These authors proposed that inhibition of IL-5 
passes through IgG receptor (FcγRII or CD32), since incubation of PBMC from a 
FcγRII deficient mouse with Gal-3 leads to no changes in the expression of the IL-5 
gene (Cortegano et al. 2000). 
 
 
Figure 6. A cartoon summarizing the effect of Gal-3 on immune cells. Red arrows 
indicate a positive effect, blue arrows indicate a negative effect. Light red boxes indicate 
pro-inflammatory effects; light blue boxes indicate anti-inflammatory effects (adapted from 
Dumic et al. 2006). 
 
1.9.5 Adhesion and migration of immune cells 
Gal-3 is a fundamental protein in cell adhesion (by bridging cell to cell or cell to 
extracellular matrix) and migration of immune cells. 
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In neutrophils, this lectin is involved in neutrophil recruitment and extravasation to 
the infection site, adhesion to laminin in a carbohydrate- and amino terminal-
dependent manner, and to endothelial cells through oligomerization of Gal-3 and 
cross-linking of neutrophils to the endothelium (Kuwabara and Liu 1996; Sato et al. 
2002). 
In a model of sepsis, Gal-3 deficient mice display a better survival rate and lower 
level of lung tissue damage compare to wild type animals, which display a high 
leucocyte infiltration (principally neutrophils), release of inflammatory 
cytokines/mediators, and vascular injury (Mishra et al. 2013; Díaz-Alvarez and 
Ortega 2017).   
Interestingly, despite Gal-3 is not a chemoattractant for neutrophils in vitro (Baseras 
et al. 2012), and Gal-3 deficient mice present a decrease in the number of infiltrating 
neutrophils (Bhaumik et al. 2013), suggesting that Gal-3 can indirectly induce 
neutrophil migration (Díaz-Alvarez and Ortega 2017). Similarly, once in the 
extracellular media, Gal-3 can act as chemoattractant for monocytes and 
macrophages, in a dose- and lactose-dependent manner (Sano et al. 2000). 
 
The expression of Gal-3 on the surface of human eosinophils favors the recruitment 
of these cells to the site of inflammation, mediated by rolling and adhesion to the 
vascular cell adhesion molecule (VCAM)-1 molecule (Rao et al. 2007), while it is 
also responsible for the IgE-dependent activation of these cells (Truong et al. 1993). 
These findings support a function for Gal-3 during inflammatory and infectious 
diseases.   
 
Endogenous Gal-3 has been demonstrated to be important for T cell adhesion to DCs 
or macrophage cells. During naive lymphocyte recruitment from blood to secondary 
lymphoid organs, the expressed of L-selectin on these cells, plays an important role 
in the initial attachment of T cells to high endothelial venules in lymph nodes, and 
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in cell activation. Gal-3 can enhance and optimize the initial interaction between L-
selectin activated lymphocytes and DCs (Swarte et al. 1998; Sundblad et al. 2011). 
 
1.9.6 Galectin-3 at the interface between innate and adaptive immunity  
DCs play a central role in the regulation of adaptive and innate immune responses. 
These cells patrol the peripheral tissues, capturing and processing pathogens, 
migrating to draining lymph nodes where they determine the polarization of the 
adaptive immune response, which in turn is reflected on innate immunity (Díaz-
Alvarez and Ortega 2017).  
Infection with Trypanosoma cruzi induces the upregulation of Gal-3 and Gal-3 
ligands in splenic DCs. Since DCs migration is reduced on Gal-3 coated surfaces, 
the secretion of this lectin during Trypanosoma cruzi can impair the migration of 
these antigen presenting cells to lymphoid organs and therefore reduce T cell 
activation (Vray et al. 2004). In another study of infection, investigating the role of 
Gal-3 during Toxoplasma gondii infection in a model Gal-3 deficient mice, it was 
found that Gal-3 deficient mice develop a general reduced inflammatory response of 
leucocyte infiltrating the intestines, liver, and brain but not the lungs, when compare 
to wild type animals (Bernardes et al. in 2006). Brain from Gal-3 deficient mice 
showed a significantly reduced number of infiltrating monocytes/macrophages and 
CD8+ cells, therefore suffering a higher parasite burden. DCs from Gal-3 null mice 
produce higher amounts of IL-12, which reflects in a higher Th1 response. Similarly, 
DCs from Gal-3 deficient mice infected with histoplasmosis produce higher IL-
23/IL-17 and lower IL-12/IFN-γ cytokines. This leads to an increase in Th17 and in 
a reduction in Th1 cells with a lower fungal burden (Wu et al. 2013). Finally, studies 
with the use of siRNA evidenced how Gal-3 can modulate cytokine secretion by 
human DCs. In particular, the use of Gal-3 siRNA in TLR stimulated (LPS) DCs, is 
able to downregulate the expression of IL-1β, IL-6 and IL-23, while it upregulates 
IL-12p35 and IL-10 (Chen et al. 2015; Díaz-Alvarez and Ortega 2017). Since the use 
of exogenous Gal-3 or neutralizing antibody are not able to revert this effect, the 
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Authors conclude that the change in DCs cytokine profile is due to the intracellular 
and not to the extracellular version of the protein (Chen et al. 2015). These studies 
underline, once again, the importance of Gal-3 expression in the regulation of the 
immune response, since changes in DC cytokine secretion deeply influence CD4+ T 
cells, which in turn affects the innate immune response. 
 
1.9.7 Recognition of foreign pathogens 
Unlike adaptive immunity, that can tailor the specificity of receptors for foreign 
antigens, innate immunity is programmed to recognize pathogen-associated 
molecular patterns (PAMPs) or host intracellular damage-associated molecular 
patterns (DAMPs), that are released from dying cells upon damage induced by 
microorganisms (such as heat shock protein, interleukin-1α and annexin) (Sato et al. 
2009). 
Cells of the immune system can be induced to release this DAMPs without dying, 
using a leaderless secretory pathway, in order to recruit and activate other innate 
immune cells and restore tissue homeostasis. As previously mentioned, Gal-3 can be 
passively released by dying cells, or actively secreted from cells upon specific 
stimuli, such as IFN-γ and LPS, though a leaderless pathway. The intriguing 
emerging idea is that Gal-3 can work as DAMP recognizing PAMP, recruiting in the 
site of infection immune and phagocytic cells (Sano et al. 2000; Bhaumik et al. 
2013), potentiating their activities and thereby modulating the innate/adaptive 
immune responses (Jeng et al. 1994; Yamaoka et al. 1995; Sano et al. 2003; 
Fernández et al. 2005; Sato et al. 2009; Díaz-Alvarez and Ortega 2017). 
 
During Helicobacter pylori colonization of gastric tissues, Gal-3 mRNA is 
upregulated and the protein is released by bacteria infected cells (Fowler et al. 2006). 
As previously reported (for further details see paragraph 1.4.2), Gal-3 has been 
demonstrated to recognize and bind two independent sites of LPS. This interaction, 
either through the CRD or the N-terminal domain, was demonstrated for Neisseria 
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gonorrhoea (John et al. 2002), Helicobacter pylori (Fowler et al. 2006), 
Pseudomonas aeruginosa (Gupta et al. 1997), E.coli (Fermino et al. 2011) and 
Klebsiella pneumoniae (Mey et al. 1996). Gal-3 binding to LPS results in oligomer 
formation, greatly enhancing neutrophil activation (Fermino et al. 2011). 
Interestingly, macrophages from Gal-3 deficient mice show an elevated production 
of pro-inflammatory cytokines upon LPS stimulation, when compared to wild type 
animal, and this prevents LPS-induced endotoxic shock, increasing both resistance 
to infection and Th1 response (Díaz-Alvarez and Ortega 2017). Further, evidences 
show the Gal-3 ability to recognize mycobacterial mycolic acids, the major 
constituents of Mycobacterium tuberculosis cell envelope. Despite this interaction 
inhibits the lectin self-association Gal-3 could be involved in the recognition of 
trafficking mycolic acids (Barboni et al. 2005). 
 
In macrophages, Gal-3 and Dectin-1 (a receptor for β-glucans) strictly collaborate 
for the recognition of pathogen microorganisms. In particular, Gal-3 recognizes 
oligomannans, carbohydrates composing the wall of fungi such as Candida albicans, 
and both, Dectin-1 and Gal-3 must be presented in order to have a specific TNF-α 
secretion by these cells. Direct binding of Gal-3 to β-1,2-linked oligomannans can 
induce the death of Candida albicans, and this structure is important for 
discrimination of pathogenic (Candida albican) and non pathogenic (Saccharomyces 
cerevisiae) yeast (Díaz-Alvarez and Ortega 2017).  
In addition, Gal-3 was shown to accumulate at the cytosolic face of the phagosome 
membrane in Mycobacterium-containing phagosomes during the course of 
Mycobacterium tuberculosis infection. Conversely, Gal-3 null mice revealed a 
reduced capacity to clear late Mycobacterium infection (Beatty et al. 2002) 
This lectin plays also an important role in parasite recognition. Gal-3 was reported 
to bind to GalNAc1-4GlcNAc (LacdiNAc) units present on soluble egg of 
Schistosoma mansoni, a human helminth parasite. In particular, since Gal-3 was 
found accumulated in granuloma tissue around egg shells and due its ability to 
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mediate macrophage LacdiNAc-coated particle phagocytosis; van den Berg et al. 
(2004) proposed that Gal-3 can act as an opsonin to facilitate the uptake of 
LacdiNAc-containing glycoconjugates by leukocytes, contributing to the 
development of host immunity. 
 
Finally, Gal-3 recognizes molecules associated with protozoan parasites 
Trypanosoma cruzi (Moody et al. 2000) and Leishmania major. Despite in the latter 
case Gal-3 recognition leads to the cleavage of Gal-3 (Pelletier and Sato 2002), it 
was proposed (Sato et al. 2014) that Gal-3, once released during Leishmania major 
infection, can facilitate the infiltration of neutrophils to the infected sites, reducing 
the initial parasite burden. 
 
All these observations raise the possibility that Gal-3 is involved in the complex 
molecular mechanisms underlying the immune system recognition of infection 
agents to develop adequate immune responses. 
 
1.9.8 Role in immune system regulation 
As shown in the previous paragraphs, Gal-3 is a highly promiscuous protein, with 
different cellular localization within the tissue microenvironment. It can either 
control immune cells through the intracellular compartment or it can be released and 
directly interacts with foreign molecules/immune cells, either as monomer or 
oligomer. This great flexibility of Gal-3, in turn, reflects the different processes 
modulated by this protein. 
An interesting hypothesis is that Gal-3, during homeostatic conditions, can bind to 
self-molecules expressed on cell surface of leukocyte, including macrophages, DCs, 
and T lymphocytes, lattices. Until Gal-3 keeps recognizing self-molecules the master 
switch of our innate immune system remains settled on ‘OFF’ (Sato and Nieminen 
2002). If the protein is either cleaved or sequestrated by foreign pathogens, the 
immune system can be switched to ‘ON’, starting a proper immune response. As 
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previously reported, in fact, Gal-3 has the ability to form a lattice structure on T cell 
surface that raises their activation threshold, while following its absence the cells 
become hypersensitive for activation. Further, truncation of Gal-3 and therefore 
depletion of this protein, during Leishmania major infection, leads to an increment 
of immune responses, as observed during this parasite infestation (Sato and 
Nieminen 2002). 
 
Importantly, Gal-3 would be implied not only in the beginning of immune responses, 
but also in the promotion of the inflammatory responses, through cell activation, cell 
migration, or inhibition of apoptosis, thus prolonging the survival of inflammatory 
cells (Hsu et al. 2000; Zuberi et al. 2004; Chen et al. 2005; Henderson and Sethi 
2009) 
 
Finally, Gal-3 can participate also in the resolution of inflammatory responses. In 
fact, Gal-3 plays an important role also in the removal of immune cells, an important 
mechanism to restore homeostasis after an inflammatory period. In particular, 
extracellular Gal-3 can lead to exposure of phosphatidylserine on activated 
leukocyte, a signal for macrophage phagocytosis (Stowell et al. 2008; van Stijn et al. 
2009). Absence of Gal-3 shows reduced neutrophils apoptosis, and impaired 
clearance of these cells (Wright et al. 2017) 
 
1.10 Natural killer cells 
Natural killer cells (NK) are white blood, bone marrow-derived granular 
lymphocytes cells, which can exert direct cytotoxic activities against pathogen-
infected or tumor cells with an activity similar to that of CD8+ cytotoxic T 
lymphocytes (Sun and Lanier 2011). These cells belong to the innate arm of the 
immune system and play a pivotal role in host defense against infections and 
malignancies, as demonstrated in the murine model and in cases of NK cells 
deficiencies (Smyth et al. 2005; Orange 2006).  
Introduction 
46 
Characterized as lymphocytes for their morphology, the expression of lymphoid 
markers and their origin from the common lymphoid progenitor, human NK cells are 
phenotypically identified by the absence of CD3 co-receptor and the expression of 
the neural cell adhesion molecule CD56. 
In 2007, it was proposed by the Vivier’s group that another marker able to 
specifically identified NK cells is the NKp46 receptor; however, this glycoprotein 
can also be found on T cells, while some subpopulations of NK do not express this 
surface marker (Walzer et al. 2007). Therefore, since there is still controversy on the 
use of this surface molecule for NK cells identification, the current phenotypic 
definition remain the CD56+CD3- combination (Caligiuri 2008). 
 
Human NK cells represent about the 10% of PBMC with a range that can vary 
between 5 to 20 % and about 2 billion of cell circuiting in the body of an adult at any 
given time, with an average turnover of two weeks (Caligiuri 2008; Vivier et al. 
2008; Pampena and Levy 2015). These innate lymphoid cells are not a homogeneous 
population; on the contrary, they can be generally dived in two categories with very 
distinct phenotypic and functional characteristics: the CD56bright and CD56dim 
subsets. The CD56brigh population is generally found in lymph nodes, tonsils and 
secondary lymphoid organs while only a little fraction of these cells is found in the 
peripheral blood (PB) (10%). These cells do not, or only partly, express the CD16, 
the natural cytotoxicity receptors (NCRs) and lack killer cell Ig-like receptors (KIRs) 
expression (see next paragraph for further details on NK cells receptors) (Ferlazzo et 
al. 2004). Moreover, they display low amount of perforin and only little ability to 
kill target cells, while they can produce high amount of cytokines within minutes 
after activation (Ferlazzo et al. 2004; Caligiuri 2008; Vivier et al. 2008). In particular, 
CD56brigh represent the most vigorous producer of IFN-γ within the NK population. 
IFN-γ is a pro-inflammatory cytokine secreted during the early phase of the innate 
immune response, able to shape both, adaptive and innate immune response. This 
cytokine, in fact, induces CD8+ T cells to become cytotoxic lymphocytes and help 
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CD4+ T cells to differentiate toward a Th1 phenotype (Mocikat et al. 2003; Martín-
Fontecha et al. 2004). In addition, IFN-γ regulates B cell functions, such as 
immunoglobulin production and class switching, macrophage 
antimicrobial/antitumor activities and upregulation of major histocompatibility 
complex (MHC) class I molecules, DC maturation, leukocyte attraction, growth, and 
maturation (Wallach et al. 1982; Schroder et al. 2004; Vivier et al. 2008). Moreover, 
IFN-γ impairs proliferation of transformed and virally infected cells (Maher et al. 
2007).  
 
In sharp contrast, CD56dim population presents an inverted ratio between secondary 
lymphoid tissue and bloodstream being relatively dominant in PB. These cells are 
characterized by a CD56dimCD16+ phenotype and express both KIRs and NCRs. 
The CD56dim subset is composed of cytotoxic effector cells able to efficiently lyse 
target cells upon activation and to secrete, although to a lower extent, chemokines 
and cytokines (most notably IFN-γ, TNF-α, C-C motif chemokine ligand (CCL)3 
and CCL5) (Moretta et al. 2014). 
 
In addition, another important characteristic that distinguishes these two subsets 
consist in the IL-2 receptor composition. CD56brigh cells express the hetero-trimeric, 
high affinity IL-2 receptor (IL-2Rα[CD25]/IL-2Rβ[CD122]/IL-2Rγ[CD132]) which 
can sense picomolar concentration of this cytokine released from activated T cells 
(Caligiuri et al. 1990; Nagler et al. 1990). On the contrary, CD56dim cells only express 
the hetero-dimeric form of the receptor (IL-2Rβ[CD122]/IL-2Rγ[CD132]) which 
can bind both IL-2/IL-15 and display only intermediate affinity for IL-2. These 
variations in the IL-2 receptor composition are reflected in a higher capacity of the 
CD56brigh subset to proliferate when compared to the CD56dim subset (Caligiuri 2008; 
Vivier et al. 2008). Finally, CD56brigh and CD56dim cells differ also for their homing 
capacity. 
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The CD56brigh subset, in fact, expresses the C-C motif chemokine receptor (CCR)7 
and C-X-C motif chemokine receptor (CXCR)4, which are likely to coordinate these 
cells into lymph nodes (Campbell et al. 2001; Fehniger et al. 2003; Hanna et al. 
2003). On the contrary, the CD56dim expresses the CXCR1 and CX3CR1, which can 
recruit the cells into peripheral inflamed tissue (Campbell et al. 2001; Hanna et al. 
2003).  
 
Despite it remain largely unclear the different stages of maturation of NK cells, it 
was proposed that CD56bright population could represent a more immature 
stage/precursor in NK cells development, while the CD56dim represents the mature 
form of these innate lymphoid cells (Chan et al. 2007; Romagnani et al. 2007; 
Takahashi et al. 2007).  
This was further supported by in vitro studies, demonstrating that cytokine 
stimulation is able to induce the expression of molecules (i.e., CD16, NCRs. KIRs 
and perforin), as well as functional characteristics (i.e., the cells become able to lyse 
sensitive target cells) similar to PB CD56dim NK cells (Ferlazzo et al. 2004; Caligiuri 
2008; Moretta et al. 2008; Vivier et al. 2008). 
 
This scenario is further complicated by the fact that PB NK cells not only present 
these subsets, but they can express a different combination of activating and 
inhibitory receptors. This feature makes NK cells an extremely heterogeneous 
population able to sense different environmental stimuli and easily adapt to them 
(Mandal and Viswanathan 2015). 
 
1.10.1 Natural killer cells activation and functions 
As mentioned in the previous paragraph, the largest amount of NK cells found in the 
PB are CD56dimCD16+ NK cells and that type of cells are responsible for the cytolytic 
activities. 
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This ability consists in the polarization and release by NK cells of lytic granules 
containing cytotoxic proteins, such as perforin and granzymes, which can generate a 
pore on the plasma membrane of target cell and therefore induce cell death (Moretta 
et al. 2008). 
 
The name NK cells, derives from the observation that these cells can kill, as their 
name implies, their target without prior sensitization and without the need for target 
cell to present antigens on MHC molecules (Caligiuri 2008).  
In sharp contrast with T and B cells, to fulfill their direct cytotoxicity on a specific 
target, these lymphocytes do not express clonal antigen receptors, produced by 
somatic recombination, instead, they are equipped with a wide array of germline-
encoded activating and inhibitory receptors (Vivier et al. 2011). 
 
Although NK cells can sense a lower number of antigens compared to the T and B 
cells, the broad range of receptors expression allow these cells to respond faster to 
danger signals, in contrast with a more delayed response of adaptive immunity 
(Montaldo et al. 2013).  
The major activating receptors include the CD16 or low affinity FcγIIIA receptor, 
that is able to recognize the crystallizable fragment (Fc) region of antibodies blocked 
on cell surface. CD16 interaction with Fc leads to NK cells activation and 
degranulation, in a process defined antibody-dependent cell-mediated cytotoxicity 
(ADCC) (Vivier et al. 2008). However, NK cells can recognize target cells also in 
the absence of antibody coated cells, through many other activating receptors. 
These include NKG2D, DNAM-1, and the NKp30/NKp44/NKp46 receptors, 
collectively named natural cytotoxic receptors.  
Among the most characterized ones, NKG2D is a C-type lectin-like receptor whose 
ligands (the MHC class I polypeptide-related sequence [MIC]A and MICB) are 
normally not expressed in healthy and normal tissues, but they can be upregulated in 
virally infected cells or during malignant transformation. Similarly, Nkp30 
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recognizes the B7-H6 molecule expressed by certain tumors (Vivier et al. 2011) and 
absent on non transformed cells. Notably, while NKG2D, NKp30 and NKp46 are 
already present on unstimulated NK cells, NKp44 is upregulated only after cytokine 
stimulation and with NKp46 recognize hemagglutinins on virus infected cells 
(Mandelboim et al. 2001; Montaldo et al. 2013). 
Furthermore, DNAM-1 is a surface glycoprotein that belongs to the Ig-like family, 
which is implicated in the recognition of cancer/virally infected cells. This adhesion 
molecule, in fact, recognize CD112 and CD155, two nectin molecules upregulated 
on aberrant or stressed cells (de Andrade et al. 2014). 
 
All the receptors presented here can recognize cell surface antigens, expressed under 
pathological conditions, killing the dangerous cells. 
Despite the great cytotoxic potential of NK cells, healthy cells are generally spared 
by their activity. Besides activating receptors, in fact, NK cells are decorated with a 
broad range of inhibitory receptors. Dozens of these molecules, collectively called 
killer cell Ig-like receptors, have been identified. These include receptors that 
recognize MHC class I molecule (human leucocyte antigens [HLA]-A,-B and -C), 
and the heterodimer C-type lectin-like CD94-NKG2A, which recognize the non 
classical HLA-E molecule. Once engaged, a KIR delivers to the NK cell a signal able 
to prevent cellular activation and to overcome a low level of activating signals.  
 
Therefore, in order to fulfill their function, NK cells must encounter cells which 
present downregulation of MHC class I molecule (the missing self hypothesis), 
however, this signal alone is not sufficient to guarantee target killing, there must be 
simultaneously present also activating signals. 
As a result, NK cell activation is a complex and sophisticated process tightly 
regulated by the integration of the positive and negative signals, generated by both 
activating and inhibiting receptors, which determine whether or not they have to kill 
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a specific target (Moretta et al. 2014). These mechanisms allow the tolerance to self 
and to specifically kill only potentially dangerous cells (Fig. 7).  
 
Figure 7. Schematic representation of NK cells activation. A) balance of signals delivered 
by activating and inhibitory receptors regulates the recognition of healthy cells by NK cells. 
B) Cells that downregulate MHC class I molecules are detected as ‘missing self’ and are 
lysed by NK cells. C) Cells can overexpress induced stress ligands recognized by activating 
NK cell receptors, which override the inhibitory signals and elicit target cell lysis. D) 
antigen-specific antibodies bind to CD16 and elicit antibody-dependent NK cell-mediated 
cytotoxicity (Morvan and Lanier 2016). 
 
The use of mouse models as studies on NK cells from human PBMC, helped to 
further clarify the mechanism underlying NK cells regulation (Bryceson et al. 2006; 
Fehniger et al. 2007). In particular, it was demonstrated that although NK cells are 
already equipped with activating and inhibitory receptors, similar to T cells, they 
require “priming” in order to be fully activated. Despite priming mechanisms remain 
to be fully characterized, cytokines produced by other immune cells, including IFN, 
IL-12, IL-2, IL-15 and IL-18, are strong activators of NK cell functions. Particularly, 
IL-2 and IL-15 cytokines have been demonstrated to transform resting NK cells into 
lymphokine-activated killer cell (LAK), which develop effector cytotoxic functions 
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against cancer cells, otherwise resistant (Becknell and Caligiuri 2005; Zwirner and 
Domaica 2010). 
 
As previously stated, NK cells found in the PB are not merely effector cells, but they 
also possess the ability to release, upon activation, cytokines (such as IFN-γ, TNF-
α, GM-CSF, M-CSF) and chemokines (such as CCL2, CCL4 and CCL5) which, in 
turn, can recall and shape the activity of other immune cells. In particular, once in 
the peripheral inflamed tissues NK cells can start a cross-talk with other immune 
cells, determining, not only the initiation of the innate immune response, but also the 
polarization and amplification of the adaptive one(Caligiuri 2008; Moretta et al. 
2008; Montaldo et al. 2013; Moretta 2014). 
Through TNF and IFN-γ production, NK cells can promote DC maturation and kill 
immature DCs in order to remove myeloid cells, which are unresponsive to specific 
infectious stimuli paving the way for mature DCs. 
NK cell-mediated lysis of pathogen-infected cells might lead to the release of 
microbial products, such as LPS, that along whit IFN-γ can promote macrophage 
polarization to a pro-inflammatory phenotype. NK cells-macrophages interaction 
goes beyond M1 polarization, in fact, NK cells can preferentially kill M2 
macrophages, further sustaining a pro-inflammatory response. NK cell regulatory 
activity is not only exerted on myeloid cells, but also on T cells; in fact, as previously 
reported, NK cells can promote Th1 repose. Moreover, antigenic peptide released 
during NK cell cytotoxic activity against dangerous cells can promote the cross-
presentation by DCs to CD8+ T cells therefore specifically addressing the adaptive 
immune response (Cooper et al. 2004; Biswas and Mantovani 2010; Malhotra and 
Shanker 2011; Deauvieau et al. 2015).  
 
The presence on the same subset of NK cells of effector and cytokine producing 
functions allow a rapid and effective (around 4h) immune intervention without the 
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need for coordination with other cell subsets localized in a different anatomic 
compartment.  
The high grade of plasticity, the ability to respond directly to potentially dangerous 
cells combined with their regulatory activity on innate and adaptive immune cells 
make of NK cells a major player during the immune response.  
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2. Outline of the thesis 
 
In spite of the overall weight of evidences on the Gal-3 expression/function in human 
immune cells, data on NK cells are still very scarce and all observations are derived 
from mouse models. 
In summary, from literature data: 
 In 2002, Crider-Pirkle et al. found that during mouse pregnancy (from 
day 12) uterine NK (uNK) cells start to express Gal-3 at both mRNA and protein 
levels. uNK cells are a subset of NK lymphocytes that accumulate in large numbers 
in the decidua basalis and the metrial gland of the rodent implantation site. These 
cells influence the development of placental vasculature by production of 
proteases/matrix/biologically active factors and are less cytotoxic than peripheral 
NK cells; 
 In 2005, Kang et al. performed a serial analysis of gene expression 
(SAGE) at four different stages of NK cell differentiation, founding that Gal-3 
expression deeply changes during development; 
 In 2011, Radosavljevic et al. showed that Gal-3 null transgenic mice 
have a general reduction in the number of NK cells, which exhibit a higher cytotoxic 
activity than cells from wild type mice; 
 In 2015, Chaudhari et al. reported that Gal-3 null transgenic mice 
present a severe dysregulation in NK cell-mediated immune responses, highlighting 
the importance of Gal-3 in NK cell functions. 
 
The overall data strongly support the importance of Gal-3 in immune-mediated 
responses, but they also clearly suggest that the role of Gal-3 in NK cell functions 
has not yet been fully defined. 
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On this basis, the aim of my Ph.D. research was to: 
 examine the expression and localization of Gal-3 in human resting/activated 
NK cells; 
 analyze if changes in Gal-3 expression functionally correlate with human NK 
cell degranulation. 
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3. Materials and methods  
 
3.1 Human NK cell isolation and cell cultures  
Human NK cells were isolated from buffy coats of healthy donors (n ≥ 6), after their 
informed consensus, as previously described (Fallarini et al. 2017). After cell 
separation through negative selection (Miltenyi Biotec, Calderara di Reno, Italy), the 
percentage of CD3-CD56+ cells was routinely analyzed by FACS (S3 flow 
cytometer, Biorad, Segrate, Italy) using FITC anti-human CD56 (NCAM) Antibody 
[Clone: MEM-188 (BioLegend, San Diego, CA, USA)], PerCP anti-human CD3 
[Clone: BW264/56 (Miltenyi Biotec)] and always resulted ≥ 97%. Approximately 6 
x 106 NK cells were routinely obtained from each patient.  
Human NK cells, human erythroleukemia K562 cells (a generous gift from Prof. 
M.C. Mingari, Department of Experimental Medicine, IRCCS AOU San Martino-
IST, Genova, Italy), human monocytic leukemia THP-1 cells (ATCC TIB-202; 
American Type culture Collection, Manassas, VA, USA) and lymphoblastic 
leukemia Jurkat cells (ATCC TIB-152) were cultured (1 × 106 cells/ml) in RPMI-
1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(Carlo Erba, Cornaredo, Italy), 2mM L-glutamine, 100 µg/ml kanamycin, 1 mM 
sodium pyruvate e 1% MEM amino acid solution (Sigma-Aldrich, Milan, Italy) in a 
humidified incubator at 5% CO2 and 37°C. Recombinant human (rh) IL-2 (100 U/ml) 
and rh IL-15 (20 ng/ml) (PeproTech, London, UK) were added, if required, to the 
NK cells only at the beginning of the culture. 
 
3.2 PCR and real-time PCR 
Total RNA was isolated from 5 x 105/ml unstimulated/stimulated NK, THP-1 
(positive control) and Jurkat (negative control) cells using the RNeasy Mini Kit 
(Qiagen, Hilden, Germany), according to manufacturer's instructions, and reverse 
transcribed into cDNA (Manuelli et al. 2014). 
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For PCR amplification, 3 μl of cDNA were added to GoTaq Flexi DNA Polymerase 
(Promega, Madison, WI, USA) in 25 μl reactions, containing 0.5 μM of forward and 
reverse primers. Amplification products were visualized on 1% agarose gel, 
containing 1 μg/ml ethidium bromide (Sigma–Aldrich). For real-time PCR, cDNA 
samples were equally diluted for subsequent PCR amplification with Maxima SYBR 
Green qPCR Master Mix (Fermentas, Milan, Italy) and a final volume of 20 μL, 
which contained 1µL of template cDNA, was used. Real-time PCR analysis was 
performed in triplicate for each sample in a CFX96 Real-Time PCR system (Bio 
Rad). The level of 18S RNA was measured and used for normalization of the target 
gene abundance. The primer sequences used for PCR and real-time PCR are listed 
in Table I.  
 
Template Primers 
Galectin-3 
forward 5'-GCAGACAATTTTTCGCTCCATG-3' 
reverse 5'-CTGTTGTTCTCATTGAAGCGTG-3' 
GAPDH 
forward 5'-GGTCGGAGTCAACAACGGATTTGG-3' 
reverse 5'-ACCACCCTGTTGCTGTAGCCA-3' 
S18 
forward 5'-TGCGAGTACTCAACACCAACA-3' 
reverse 5'-CTGCTTTCCTCAACACCACA-3' 
Table I. Oligonucleotide primers used for PCR and real-time PCR 
 
3.3 Western blot  
Proteins were extracted from 1 x 106/ml human unstimulated/stimulated (24 h) NK 
cells, THP-1 (taken as positive control for Gal-3 expression), K-562 (taken as 
positive control for Gal-1 expression), and Jurkat (negative control) cells (Fallarini 
et al. 2012). 
Equal amounts of proteins (35 µg) were separated on 12% polyacrylamide gel and 
electro-blotted on nitrocellulose membrane. The membranes were blocked and then 
incubated with the following primary antibodies: rabbit anti-human Gal-3 antibody 
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[Clone: EP2275Y (Abcam, Cambridge, UK); 1:5000], mouse anti-human Gal-1 
antibody [Clone: C-8 (Santa Cruz Biotechnology, Heidelberg, Germany); 1:500], or 
mouse anti-human β-Actin antibody [Clone: AC15 (Sigma-Aldrich); 1:5000] with 
gentle shaking overnight at 4 °C or for 1 h at room temperature (RT) for β-Actin. 
The blots were, then, incubated with a specific anti-rabbit horseradish peroxidase 
(HRP) labeled secondary antibody (Ge Healthcare Life Sciences; 1:5000) or a 
specific anti-mouse HRP labeled secondary antibody (Sigma–Aldrich; 1:5000) for 1 
h at RT. 
Proteins were visualized with an enzyme linked chemiluminescence (ECL) detection 
kit, according to the manufacturer’s instructions (Ge Healthcare Life Sciences). The 
protein signals were detected using an enhanced chemiluminescence system 
(Biorad). Band intensities were quantified by the computer program Image Lab from 
Biorad. All samples were analyzed independently and the final increase in Gal-3 
protein was expressed as mean ± SEM of at least six independent experiments. 
 
3.4 Flow cytometry 
5 x 105/ml human NK cells were seeded in 24 multiwell plates and 
unstimulated/stimulated (24 h) with IL-2 (100 U/ml) and IL-15 (20 ng/ml). THP-1 
(positive control) and Jurkat (negative control) cells were always included in the 
experiments. Cells were harvested and washed with a FACS wash solution (0,5 % 
BSA-supplemented PBS and 1% FBS). For the intracellular staining, the samples 
were fixed with cold paraformaldehyde (4% PFA) for 15 min at RT and 
permeabilized with 100% cold acetone for 10 min at -20°C. All samples were, then, 
incubated with a blocking solution (1% BSA-supplemented PBS and 2% FBS) for 
30 min at RT. Afterwards, the samples were incubated for 30 min with the following 
primary antibodies: anti-human Gal-3 antibody [Clone: EPR2774 (Abcam); 1:65] or 
isotype control [Clone: EPR25A (Abcam); 1:65]. After washing, the cells were 
labeled with the Alexa 555-conjugated secondary antibody (Abcam; 1:1000). 
Samples were acquired and analyzed using a S3 flow cytometer (Biorad). All 
Materials and methods 
60 
samples were analyzed independently and the final increase in Gal-3 protein was 
expressed as mean ± SEM of at least six independent experiments. 
 
3.5 Confocal microscopy  
5 x 105/ml human NK cells, unstimulated/stimulated (24 h) with IL-2 (100 U/ml) 
and IL-15 (20 ng/ml), THP-1 (positive control), and Jurkat (negative control) cells 
were harvested, washed with PBS and fixed with cold 4% PFA for 15 min at RT. For 
intracellular staining, the cells were permeabilized with 100% cold acetone for 10 
min at -20°C; for extracellular staining, the permeabilization occurred before nuclear 
staining. Fixed cells were blocked with blocking solution for 1 h at RT, incubated 
with anti-human Gal-3 [Clone: EP2275Y (Abcam); 1:65] or isotype primary 
antibody [Clone: EPR25A (Abcam); 1:65] for 30 min at RT and subsequently with 
Alexa 555-conjugated secondary antibody (Abcam; 1:1000) for 30 min at RT. To 
localize Gal-3 in exocytic vesicles NK cells were also stained with FITC-conjugated 
anti-perforin antibody [Clone: HCD56 (BioLegend)] (positive control) for 15 min at 
RT. After washing, nuclei were counterstained with To-pro-3 iodide (Thermo Fisher 
Scientific; 1:500) for 15 min at RT and cells centrifuged onto cytospin slides at 1200 
rpm for 5 min (Shandon Cytospin 4, Thermo Fisher Scientific). Prolong Gold anti-
fade kit (Thermo Fisher Scientific) was used as mounting fluid on the cells. Images 
were collected using a Leica TCS SP2 confocal microscope with 63X oil immersion 
objective and by sequential scanning. Images were acquired at a scanning speed of 
400 Hz, 1024 x 1024 pixel resolution and a line average of 4. A 488 nm laser was 
used for IgG-FITC, 543 nm for IgG-Alexa 555 and 633 nm for To-Pro 3-iodide.  
 
3.6 NK cell degranulation assay 
NK cell degranulation was measured as previously described (Aktas et al. 2009), by 
determining the expression of CD107a, the lysosome-associated membrane protein-
1 (LAMP-1) in absence/presence of a Gal-3 inhibitor (van Hattum et al. 2013). The 
used thiodigalactoside-based inhibitor (Bis-{3-deoxy-3-[4-(phenyl)-1H-1,2,3-
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triazol-1-yl]-β-D-galactopyranosyl} sulfane) was a generous gift by Prof. Roland J. 
Pieters (Department of Medicinal Chemistry and Chemical Biology, Utrecht 
University, Netherlands). For the experiments, a stock solution in 40 % DMSO was 
prepared and diluted in RPMI-1640 before cell treatment (DMSO concentration did 
not exceed 0.1 % v/v). NK cells unstimulated/stimulated (24 h) with IL-2 (100 U/ml) 
and IL-15 (20 ng/ml), were untreated/treated with increasing concentrations (1–30 
μM) of Gal-3 inhibitor for 1 h at 37°C. To induce NK cell degranulation, the cells 
were incubated with K562 cells (target cells) at an effector/tumor cell ratio of 1:1 for 
1 h at 37 °C in presence of anti-CD107a-Phycoerythrin (PE) (Miltenyi Biotec). 
Monensin (BD GolgiStop™ reagent, BD Bioscences, Milan, Italy) was added and 
cells incubated for 3 h at 37 °C. Cells were washed, stained using FITC anti-human 
CD56 (NCAM) Antibody [Clone: MEM-188 (BioLegend)], and CD107a expression 
on CD56+ cells evaluated by FACS (Fallarini et al. 2017). To detect spontaneous NK 
cell degranulation, a negative control (NK cells without K562 target cells) was 
always included, while to measure the basal response, NK cells were stimulated only 
with IL-2 (100 U/ml) and IL-15 (20 ng/ ml) (positive controls). All control samples 
were treated with 0.1 % DMSO.  
 
3.7 Statistical analysis 
Results were expressed as means ± SEM of at least four independent experiments 
always run in triplicate. Statistical significance was evaluated by the one-way 
ANOVA followed by Student's t-test for unpaired populations (Graph Pad Software, 
Inc., San Diego, USA). Differences were considered statistically significant when P 
≤ 0.05. 
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4. Results 
 
4.1 Galectin-3 gene expression in human resting NK cells  
To determine whether human NK cells express the gene coding for Gal-3 we, first, 
performed PCR studies on resting NK cells. Human THP-1 cells were always taken 
as positive control.  
Figure 8A. clearly demonstrates that human resting NK cells express Gal-3 mRNA. 
 
4.2 Galectin-3 mRNA in human activated NK cells  
Since the expression of Gal-3 gene in a variety of immune cells can be modulated by 
cellular activations and environmental stimuli (Dietz et al. 2000; Acosta-Rodríguez 
et al. 2004; Hsu et al. 2009 [A]; Novak et al. 2012), we measured the levels of Gal-
3 mRNA in NK cells unstimulated/stimulated with IL-2 (100 U/mL) and IL-15 (20 
ng/mL) for different periods of time (1-24 h) by real-time PCR. Figure 8B shows 
that the expression of Gal-3 mRNA significantly (P ≤ 0.01) decrease (-92 ± 2% in 
comparison to resting NK cells) after 1 h of cytokine stimulation, and this decrease 
lasts for at least 6 h. Afterwards (12-24 h), the mRNA expression level progressively 
restores to the basal level.  
The overall data demonstrate that human NK cells can regulate the gene expression 
of Gal-3 following specific stimuli for an appropriate period of time. 
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Figure 8. Gal-3 mRNA is expressed in human NK cells and its expression is modulated 
by cell activation. (A) Gal-3 mRNA expression was analyzed by PCR in NK and THP-1 
(positive control) cells. The total extracted mRNA was reverse transcribed to cDNA and 
Gal-3 cDNA amplified using gene-specific primers (see Table I). PCR products were 
electrophoresed on 1% agarose gel and PCR fragments sized using a 50 -10,000 bp ladder. 
The expected fragment size for Gal-3 is 500 bp. GAPDH was amplified as a loading control 
with a fragment size of 1000 bp. (B) Time course of Gal-3 gene expression in activated NK 
cells measured by real-time PCR. Total mRNA was extracted from NK cells 
unstimulated/stimulated with IL-2 (100 U/ml) and IL-15 (20 ng/ml) for 1-24 h, converted to 
cDNA, and analyzed by real-time PCR for Gal-3 expression. The mRNA levels are 
expressed relative to 18S mRNA, and the value of the resting cells was set at 1. The results 
represent the mean ± SEM of at least six independent experiments. **P ≤ 0.01 vs. 
unstimulated NK cells. 
 
4.3 Galectin-3 protein in human activated NK cells  
Then, to determine whether the modulation of Gal-3 mRNA levels, measured in 
activated NK cells (see Results, 4.2), correlates with changes at protein levels, the 
same cells were analyzed by western blot. The estimated total Gal-3 protein levels 
were always normalized against the corresponding β-Actin level and compared to 
those measured from resting cells. 
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As shown in Figure 9, we determined resting NK cells with high (Fig. 9A) or low 
(Fig. 9B) basal level of Gal-3 protein. This variability was consistently measured in 
all experiments and seems related to the individual donor analyzed. Following 
cytokine stimulation for 24 h the Gal-3 levels resulted significantly (P ≤ 0.05) 
increased in all samples analyzed (+116 ± 32% in comparison to resting NK cells) 
(Fig. 9C).  
In THP-1 cells (positive control) Gal-3 protein was always detectable, while no 
expression was determined in Jurkat cells (negative control). 
These data indicate that upon IL-2 and IL-15 stimulation human NK cells can 
increase the level of Gal-3 protein. 
 
 
Figure 9. Gal-3 protein is expressed in human NK cells and its expression increases 
upon cell activation. Gal-3 protein expression was evaluated by western blot analysis in 
NK cells, unstimulated/stimulated (24 h) with IL-2 (100 U/ml) and IL-15 (20 ng/ml), THP-
1 (positive control) and Jurkat (negative control) cells. Total cellular proteins (35 µg) were 
resolved by 12% polyacrylamide gel and immunoblotted with a specific anti-human 
galectin-3 antibody. β-Actin was used as internal control. Left panels are representative of 
typical immunoblottings from NK cells expressing high (A) or low (B) basal levels of Gal-
Results 
66 
3. The western blot signals were densitometrically analyzed by Image Lab software and 
results expressed as fold increase of Gal-3 signal in stimulated cells compared to 
unstimulated cells set at 1 (C). The results represent the mean ± SEM of at least six 
independent experiments. **P ≤ 0.01 vs. unstimulated cells. 
 
4.4 Galectin-3 protein localization in human NK cells  
While being predominantly a cytosolic protein, Gal-3 can be detected also at the 
cellular surface (Krześlak and Lipińska 2004). To study the Gal-3 localization in 
human NK cells the Gal-3 levels were measured in resting cells by flow cytometry 
(FACS). Median fluorescence intensity (MFI) measurements confirm previous data 
from the western blot analysis (see Results, 4.3): resting NK cells express high or 
low basal levels of Gal-3 protein, as clearly shown by the distinct separation of each 
histogram from the isotype control (Fig. 10Aa and 10Ab). These data confirm that 
human NK cells can express different levels of Gal-3 depending on the individual 
donor analyzed.  
IL-2 (100 U/mL) and IL-15 (20 ng/mL) stimulation for 24 h, significantly (P ≤ 0.01) 
increased (+30 ± 9% in comparison to resting cells) (Fig. 10B) the levels of Gal-3 
expression in NK cells. 
Then, to specifically localize this lectin, NK cells were incubated with the primary 
antibody before (extracellular) or after (intracellular) the permeabilization step (see 
Methods, 3.5). In all samples analyzed, Gal-3 did not localize at the membrane cell 
surface, neither in resting nor in activated cells, indicating that human NK cells do 
not express this protein at the membrane level. In THP-1 cells, taken as positive 
control, Gal-3 was both extracellular and intracellular detectable (Fig. 10A and 11A), 
while no expression was determined in Jurkat cells (negative control).  
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Figure 10. Gal-3 is intracellularly expressed in human NK cells and its expression 
increases upon cell activation. NK cells, unstimulated/stimulated for 24 h with IL-2 (100 
U/ml) and IL-15 (20 ng/ml), THP-1 (positive control) and Jurkat (negative control) cells 
were harvested, stained with anti-human Gal-3 and analyzed by FACS. (A) Representative 
histograms of extracellular (left panels) and intracellular (right panels) Gal-3 expression in 
human NK with high (a) and low basal (b) Gal-3 expression, THP-1 and Jurkat cells. Resting 
cells are shown as blue histograms, stimulated NK cells as red, while the isotype controls as 
black histograms. (B) Mean Fluorescence Intensity (MFI) levels of Gal-3 in human NK cells 
expressed as fold increase in stimulated cells compared to unstimulated cells set at 1. The 
results represent the mean ± SEM of at least three independent experiments. **P ≤ 0.01 vs. 
unstimulated cells. 
 
Since Gal-3 differently localize depending on the immune cell type (Craig et al. 
1995; van Stijn et al. 2009; Novak et al. 2012) to investigate the subcellular 
localization of Gal-3 in human NK cells immunofluorescence staining studies were 
performed in cells, unstimulated/stimulated with IL-2 (100 U/mL) and IL-15 (20 
ng/mL) for 24h (Fig. 11A), before (extracellular) or after (intracellular) the 
permeabilization step. At the membrane level, confocal microscopy analysis 
revealed an extracellular diffuse staining in THP-1 cells (positive control: Fig. 
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11Aa), while all NK cell samples analyzed, either resting or activated (Fig. 11Ab 
and 4Ac, respectively), resulted negative. These data demonstrated that human NK 
cells do not express membrane-bound Gal-3 protein, confirming the previous results 
obtained by FACS. Conversely, all NK cell samples resulted positive for the 
intracellular staining (Fig. 11Ae-f and 11Ah-i), where Gal-3 was visualized as 
scattered dots within the cells. Interestingly, we observed positive (Fig. 11Af and h, 
close arrows) and negative (Fig. 11Af and h, open arrows) cells in both resting (Fig. 
11Ae and f) and activated (Fig. 11Ah and i) samples from the same individual. In 
positive cells, the intracellular localization of Gal-3 resulted heterogeneous, as some 
cells mainly localize the protein in cytoplasm and nucleus (Fig. 11Ba and b, open 
arrows), while others showed fluorescent dots only in cytoplasm (Fig. 11Ba and b, 
close arrows). These results were independent from the cellular activation status. 
Moreover, overlapping the perforin and Gal-3 stains, shown as yellow dots (Fig. 
11Bc), we observed that Gal-3 can occur within perforin in exocytic vesicles. Finally, 
the analysis of positive cells confirm the high variability of Gal-3 expression in NK 
cells: some samples having high levels (Fig. 11Ae and h), while others low levels of 
Gal-3 (Fig. 11Af and i). Jurkat cells, taken as negative control, resulted always 
unstained (Fig. 11Ag). 
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Figure 11. Confocal microscopy analysis of cytoplasmic and nuclear Gal-3 subcellular 
distribution in human NK cells. (A) NK cells, unstimulated/stimulated for 24 h with IL-2 
(100 U/ml) and IL-15 (20 ng/ml), THP-1 (positive control) and Jurkat (negative control) 
cells were harvested, stained with anti-human Gal-3, and analyzed by confocal microscopy. 
Representative images of Gal-3 expression in: THP-1 cells (positive control; a and d), Jurkat 
cells (negative control; g), resting NK cells (b, e and f), stimulated NK cells (c, h and i). Gal-
3 is shown as red dots, perforin as green dots. Nuclei are shown in blue. Scale bar, 10 µm. 
(B). Representative images of Gal-3 localization in the nucleus and/or in the cytoplasm (a-
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b) or co-localization of Gal-3 with perforin (c). Gal-3 is shown as red, perforin as green dots. 
Yellow dots represent co-localization of Gal-3 with perforin. Nuclei are shown in blue. Scale 
bar, 10 µm. 
 
4.5 Galectin-3 functional studies in human NK cells  
NK-cell toxicity is mediated by exocytosis of cytosolic vesicles, containing perforin, 
granzymes, and other lytic proteins (Caligiuri 2008). Since Gal-3 expression can be 
upregulated upon cytokine stimulation and accumulated within vesicles (see Results, 
4.4), to determine whether these data have functional correlations, NK cell responses 
were studied in the absence/presence of a thiodigalactoside-based Gal-3 inhibitor 
(Kd = 44 nM) (see Materials, 3.6) in a typical degranulation assay (see Methods, 
3.6). 
As shown in Figure 12Aa (representative contour plots), unstimulated NK cells 
present a small percentage of degranulating cells (dashed gate); among these cells, 
only a little percentage releases a high number of granules (solid gate). Cytokine 
stimulation (Fig. 12Ab) induced an increase in NK cell degranulation (dashed gate) 
and the number of cells expressing high levels of CD107a (solid gate) resulted larger 
than in resting cells. When cytokine-stimulated cells were treated with increasing 
concentrations (1-30 µM) of the Gal-3 inhibitor, the number of degranulating cells 
slightly increased (data not shown). The maximum increase was measured at 30 µM 
Gal-3 inhibitor (+15 ± 1% vs. inhibitor-untreated cells, Fig. 12Ac, dashed gate). Of 
note, a significant (P ≤ 0.05) concentration-dependent increase was determined (Fig. 
12B) in NK cells releasing high amount of cytotoxic granules (high level of CD107a 
expression, Fig. 12A, solid gates). 
The maximum increase was measured at 30 µM Gal-3 inhibitor (+ 36 ± 3% vs. 
inhibitor-untreated cells at 30 µM; Fig. 12B and Fig. 12Ac, solid gate). No changes 
in the CD107a levels were observed in resting NK cells incubated with K-562 cells, 
even in the presence of 30 µM of Gal-3 inhibitor (data not shown).  
Finally, since the Gal-3 inhibitor we used has binding affinity also for the Gal-1 lectin 
with similar Kd values (49 vs. 44 nM) (Delaine et al. 2016) we determined whether 
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unstimulated/stimulated NK cells express Gal-1. Results show that human NK cells 
do not express Gal-1 protein at least in our experimental conditions (Fig. 12C).  
These data demonstrate that the Gal-3 expression functionally correlates with NK 
cell degranulation.  
 
 
Figure 12. Gal-3 inhibition increases the degree of degranulation in human activated 
NK cells. A classical degranulation assay was used to measure NK cell activity (see 
Methods, 3.6). (A) The first three panels are representative contour plots of resting and 
cytokine-stimulated NK cells in the absence/presence of the 30 μM Gal-3 inhibitor (dashed 
gates represent the percentage of total CD56/CD107a positive cells, while solid gates those 
highly positive) incubated (4h) with K562 cells. The fourth panel on the right represents 
overlapped histograms of CD107a expression in resting (black histogram, 5Aa), cytokine-
stimulated (blue histogram, 5Ab), cytokine-stimulated plus Gal-3 inhibitor (red histogram, 
5Ac) NK cells incubated (4h) with K562 cells. (B) Percentage of highly positive CD107a 
cells in activated NK cells untreated/treated with increasing concentrations (1-30 μM) of the 
Gal-3 inhibitor. The percentage increases in CD107a highly positive cells are calculated vs 
the value of inhibitor-untreated cells set at 1. The results represent the mean ± SEM of at 
least four independent experiments. *P ≤ 0.05 vs. inhibitor-untreated cells. (C) 
Representative Gal-1 protein expression evaluated by western blot analysis in NK cells, 
unstimulated/stimulated (24 h) with IL-2 (100 U/ml) and IL-15 (20 ng/ml), K562 (positive 
control) and Jurkat (negative control) cells. Total cellular proteins (35 μg) were resolved by 
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12% polyacrylamide gel and immunoblotted with specific anti-human galectin-1 antibody. 
β-Actin was used as internal control. 
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5. Discussion 
 
In this study we demonstrate, for the first time, that: i) human resting NK cells 
express Gal-3 at both gene and protein levels; ii) resting NK cells can express high 
or low basal levels of Gal-3 protein, at least in our experimental conditions, 
depending on the individual donor analyzed; iii) cytokine stimulation is able to 
modulate either Gal-3 mRNA and protein levels; iv) Gal-3 localizes in both 
cytoplasm and nucleus, while it was not detected at the cell membrane surface, 
neither in resting nor stimulated cells; v) Gal-3 can occur within perforin in exocytic 
vesicles; vi) Gal-3 inhibition leads to an increase in NK cell degranulation.  
 
Several galectins can regulate the homeostasis and functions of immune cells, 
influencing both innate and adaptive immune responses (Chen et al. 2005; Liu 2005; 
Rabinovich et al. 2007). In NK cells, particularly, the expression of Gal-1 has been 
described in the third trimester of normal pregnancy (Molvarec et al. 2011), while 
that of Gal-3 remains to be investigated. Scanty literature data focus only on profiles 
of gene expression in mouse NK cells (Kang et al. 2005) and on counter-receptor 
isolation for Gal-3 from tissues of the murine utero-placental complex (Crider-Pirkle 
et al. 2002). Using Gal-3 null transgenic mice, finally, a dysregulation of NK cell 
activity has been observed (Radosavljevic et al. 2011; Chaudhari et al. 2015), when 
compared to the wild type mice. If this effect is due to the absence of Gal-3 in NK 
cells or mediated by its absence in other cells, remains to be clarified. 
To fill the research gap in this field we, here, decided to fully characterize Gal-3 in 
human NK cells.  
 
We, first, concentrate on human resting NK cells, because a downregulation of the 
transcription of genes involved in cellular quiescence and an upregulation of genes 
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associated with cell proliferation (Dybkaer et al. 2007) can occur in activated NK 
cells. 
From our results, resting NK cells express Gal-3 at both mRNA and protein levels 
with a highly variable relative expression, depending on the individual donor 
analyzed. In particular, NK cells, expressing low or high levels of Gal-3 protein, 
were identified. In our opinion, this is not a surprising result because NK cells are a 
highly heterogeneous population. These cells not only can be roughly categorized in 
two major subsets (CD56dim and CD56bright), based on different expression level of 
surface CD56 molecule (Moretta et al. 2014), but they can also exert effector 
functions through a wide array of activating or inhibitory receptors (see Introduction, 
1.10.2), which are finely controlled (Vivier et al. 2011; Thielens et al. 2012). NK 
cells can be thus considered as plastic cells, that can adapt their responsiveness and 
different receptor pattern, according to environmental stimuli, aging, and diseases 
(Vivier et al. 2011; Hazeldine and Lord 2013; Terra Junior et al. 2016). Consistently, 
Lavin et al. (2017), analyzing the distribution of NK cells in lung tumor lesions, 
showed that the specific microenvironment can shape NK cell protein expression 
leading to cells that are unique to tumors. The clinical implications of these findings 
may be of great importance, because mapping the immune cells around the tumors 
could aid successful immunotherapies.  
Collectively, our data complete those on Gal-3 expression on mammalian immune 
cells, because Gal-3 has been previously demonstrated in macrophages (Liu et al. 
1995), DCs (van Stijn et al. 2009), neutrophils (Wu et al. 2017), monocytes (Liu et 
al. 1995), eosinophils (Rao et al. 2007), mast cells and basophils (Craig et al. 1995), 
but not in human NK cells. 
 
IL-2 and IL-15 have been here used for activating cells, because these two cytokines, 
more than any others, are implicated in NK cell survival and cytotoxic function 
(Becknell and Caligiuri 2005).  
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Following cytokine stimulation, the intracellular levels of Gal-3 mRNA resulted 
significantly reduced at 1-6 h, while it returned to the basal levels after 12-24 h. A 
two fold increase in Gal-3 protein was also measured after 24 h cytokine stimulation, 
compared to unstimulated cells (see Fig. 8-9). At present, we ignore the molecular 
bases of the drastic drop in the mRNA levels that we observed after 1 h of 
stimulation. However, these results are consistent with other similar 
transcriptional/posttranscriptional gene regulation in NK cells. Resting murine cells 
are “pre-armed” with a high amount of specific mRNA that upon cell activation can 
be rapidly translated into protein, allowing the rapid production of effector proteins 
without new gene transcription and with minimal or absent change in mRNA levels 
(Fehniger et al. 2007). In addition, human NK cells, have a number of genes, 
involved in cytolytic functions, already expressed that are rapidly downregulated 
upon cytokine stimulation (Dybkaer et al. 2007; Mah and Cooper 2016). 
Of note, it was demonstrated that NK cells can transcribe and retained at nuclear 
level specific mRNA, such as IFN-γ, which upon stimulation can be transported into 
the cytoplasm, translated into the corresponding protein and rapidly degraded. Such 
type of mechanism allows a fast translation of protein involved in activated NK cell 
functions and tightly regulate the proper amount of protein inside the cell (Hodge et 
al. 2002; Kim et al. 2009). 
Despite the molecular mechanism regulating Gal-3 expression in NK cells remain to 
be fully characterized, the drastic drop in mRNA observed immediately after 
stimulation and the increase in the corresponding protein at 24 h lead us to 
hypothesize for Gal-3 a similar mechanism of regulation and experiments are in 
progress in our laboratory to clarify this point. 
 
Gal-3 cellular localization seems to be highly heterogeneous: the protein has the 
ability to space from nucleus to cytoplasm/cellular surface and to be released into 
extracellular compartments (Krześlak and Lipińska 2004). Depending on 
localization Gal-3 can modulate cellular homeostasis, organogenesis, apoptosis, 
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immune responses, cytokine secretion, cell migration, tumor invasion and metastasis 
(Dumic et al. 2006). A direct interaction of tumor-secreted Gal-3 with the NK cell 
surface activating receptor NKp30, having inhibitory activities on cytotoxicity, has 
been specifically reported by Wang et al. (2014).  
In our cells, we never detected Gal-3 at cell surface membrane, even after cytokine 
stimulation, while in THP-1, a monocytic cell line, taken as positive control, we 
found Gal-3 also bound to the plasmatic membrane. This result is in agreement with 
data from Dabelic et al. (2012) on THP-1 cells and from van Stijn et al. (2009) on 
monocytes.  
All samples analyzed were, on the contrary, positive for the intracellular localization 
of Gal-3 with different levels of protein expression, depending on the individual 
donor. Gal-3 was always detected in each sample analyzed, being found in the 
nucleus and/or in the cytoplasm in a heterogeneous manner.  
From our results, Gal-3 co-localizes with perforin in exocytic vesicles, which 
represent one of the main mechanisms underlying NK cell functions. Gal-3 could, 
thus, directly participate to NK cell degranulation. When Gal-3 function was 
inhibited by a thiodigalactoside-based Gal-3 inhibitor (van Hattum et al. 2013), 
indeed, a significant increase in the degree of granules released by NK cells was 
measured (see Fig. 12B). This result suggests that the level of intracellular Gal-3 
expression into NK cells may modulate the mobilization of secretory vesicles for 
releasing their cytotoxic contents. 
 
Previously, Chen et al. (2009) demonstrated that endogenous Gal-3 negatively 
regulates T-cell activation by TCR downregulation through the interaction with Alix. 
Alix protein, in turn, can interact with the endocytic trafficking complexes (ESCRT), 
involved in exosome biogenesis and secretion (Hurley and Odorizzi 2012), as well 
as with other intracellular regulators, involved in signal transduction (Colombo et al. 
2013). Similarly, endogenous Gal-3 might negatively regulate the release of 
cytotoxic granules from activated NK cells through the modulation of Alix (Liu et 
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al. 2012). The Gal-3 upregulation may be, consequently, a physiological mechanism 
specifically designed to protect healthy cells against toxic compounds released in the 
surrounding microenvironment. Our observations support also previous data from 
Radosavljevic et al. (2011), showing that splenic NK cells from Gal-3 null transgenic 
mice have higher cytotoxic activities than wild type animals. 
The function of intracellular Gal-3 in NK cells remains, however, to be fully 
characterized. In addition to the above mentioned hypothesis it could: i) exert anti-
apoptotic activities by binding to molecules involved in apoptosis (i.e., Bcl-2, CD95 
(APO-1/Fas), Nucling, Alix/AIP1, synexin) (Dumic et al. 2006); ii) regulate cell 
proliferation, differentiation, and survival through the modulation of specific signal 
pathways (i.e., K-Ras/MEK, PI3K/Akt and Wnt (Shalom-Feuerstein et al. 2008; 
Song et al. 2009); iii) control the dynamics of membrane domains and subsequent 
signaling events, when localized at the inner leaflet of plasma membrane (Compagno 
et al. 2014).  
Similarly, the nuclear Gal-3, associated with a ribonucleoprotein complex, could: i) 
act as a pre-mRNA splicing factor; ii) operate as a regulator of gene transcription, 
promoting the stabilization/transactivation of several transcription factors (i.e., 
CREB, Sp1, TTF-1, -catenin) (Dumic et al. 2006; Funasaka et al. 2014). 
The signal transduction cascades, initiated by IL-2/IL-5 stimulation, resulting in Gal-
3 upregulation should be investigated. The mechanism underlying Gal-3 gene 
regulation is still poorly understood (Dumic et al. 2006): Jack/STAT (Becknell and 
Caligiuri 2005), NF-kB (Hsu et al. 1996), or the Ras/MEKK1/MKK1-dependent/AP-
1 signal transduction pathway (Kim et al. 2003) may control the Gal-3 expression as 
in other cells, but this will be the topic of future research. 
 
In conclusion, the present study provides a clear demonstration of Gal-3 expression 
in human NK cells. The presence of this lectin in resting cells supports its roles in 
NK cell homeostasis, while the protein upregulation after cytokine stimulation 
sustains roles in cell function. Finally, the Gal-3 co-localization with perforin in 
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granules, as well as the increase in NK cell degranulation following Gal-3 inhibition 
suggests functional roles in NK cytotoxicity. 
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6. Conclusion and outlook 
 
The aim of the first part of my Ph.D. course was to evaluate the expression of Gal-3 
in human NK cells. The data here reported clearly demonstrate that these cells 
express Gal-3, suggesting further studies. 
In particular, we found that this protein is not equally expressed among the analyzed 
donors, ranging from individuals expressing high levels of Gal-3 to others that barely 
express this protein even after cytokine stimulation. 
Here we always analyzed NK cells from the peripheral blood of healthy patients, but 
we are planning to determine the expression of Gal-3 also in patients suffering from 
allergy, infections, or other inflammatory diseases. Moreover, we did not analyze 
Gal-3 expression in the different subpopulations of NK cells (i.e., CD56dim and 
CD56bright), but we believe that possible differences among NK cell subpopulations 
may help to clarify the role of Gal-3 in these cells. 
Furthermore, the analysis of Gal-3 localization in NK cells clearly demonstrated this 
protein into the exocytic vesicles; we did not analyze at the moment the content of 
vesicles released during cell degranulation, but in our opinion this should be 
investigated in the near future, since literature data show that this protein composes 
the cargo of secreted vesicles. At this point, it is intriguing to speculate that once in 
the extracellular compartment Gal-3 can modulate other immune cells, recalling 
them in the correct site and regulating the progression/termination of the immune 
response. 
Finally, we demonstrated that Gal-3 is implied in NK cell degranulation; in 
particular, the inhibition of this lectin led to a higher release of cytotoxic granules 
compared to controls. This finding may extend the biological application of NK cells 
in that fields in which is required an increase in NK cell activity, such as in cancer. 
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I am strongly aware that these results need to be completed and validated by “in 
vivo” studies, however I think that they can add a piece to the scientific knowledge 
on Gal-3 expression/function on innate immune cells. 
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1. Introduction  
 
1.1 Cancer and immune therapeutic strategy 
Despite considerable achievements of the scientific community in the last decades, 
cancer still represents the second leading cause of death worldwide, as reported by 
the world health organization (http://www.who.int). 
 
Recently, several immunotherapeutic strategies have been evaluated in order to 
reduce incidence and cancer progression. The rationale supporting implementation 
and clinical validation of different immunotherapeutic strategies relies on the 
theoretical ability of the immune system to eradicate cancer or to prevent its 
progression (Hanahan and Weinberg 2011). Furthermore, development of new 
immunotherapeutic approaches is also prompted by the necessity to bypass the 
limited efficacy of the present standard, chemo and radiotherapy, based anticancer 
treatments (Beatty et al. 2011; Mishra et al. 2013; Vonderheide et al. 2013; Miller et 
al. 2016; Mills et al. 2016).   
 
Our current understanding of cancer immunotherapeutic strategies largely focuses 
on the pivotal role played by T lymphocytes, in particular CD8+ T cells, in the 
elimination of cancerous cells. In this regard, pioneering studies performed in mouse 
models have clearly demonstrated the potential therapeutic activity of tumor-reactive 
CD8 positive T cells (Schumacher and Schreiber 2015; Ward et al. 2016). These 
initial observations have been also confirmed in clinical settings (Galon et al. 2006; 
Fridman et al. 2012). Indeed, it has widely been demonstrated that high percentages 
of tumor-infiltrating CD8+ T cells within the tumor masses are associated to a 
significantly increased overall and/or progression free-survival in different tumor 
types including breast, melanoma, ovarian, bladder and colorectal cancer (Figure 1) 
(Galon et al. 2006; Fridman et al. 2012; Fridman et al. 2017).   
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Figure 1. CD8+ T cells infiltration and clinical outcome of cancer patients. Bold colors 
indicate a positive (green) or a negative (red) prognostic association following analysis of 
all relevant studies; light green indicate a predominantly positive prognostic association in 
the majority of studies analyzed. White circles indicate no statistically significant correlation 
or that unclear prognostic associations were observed in a number of studies. The size of the 
circles relates to size of the cohort in clinical studies. Small circles indicate 0–100 patients, 
Medium-sized circles indicate 100–1,000 patients and Large circles indicate 1,000–10,000 
patients NSCLC: non small cell lung carcinoma (adapted from Friedman et al. 2017). 
 
Nevertheless, although these studies clearly underline the therapeutic potential of 
CD8+ T cell; cumulative results obtained in animal models and clinical studies have 
also evidenced that transformed cells are able to actively orchestrate an immune 
resistance, preventing the generation and impairing the effectiveness of tumor-
reactive CD8+ T cells (Schreiber et al. 2011; Ghirelli and Hagemann 2013). As 
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reported by Hanahan and Weinberg in 2011, in fact, a new hallmark of cancer, 
consists in its ability to evade destruction mediated by immune cells.  
In the last decade, several studies have contributed to shed light on the mechanism 
underlying the process of immune evasion. In this respect, it has been observed how 
tumor cells can prevent the generation of an effective immunological synapse with 
CD8+ T lymphocytes through their downregulation of major histocompatibility 
complex (MHC) class I molecules (Dong et al. 2002; Bubeník 2004; Ahmadzadeh 
et al. 2009). Moreover, therapeutic potential of tumor-reactive CD8+ T cells is 
impaired by the activation in cancer cells of distinct mechanisms contributing to the 
establishment of cancer immunological tolerance. In this regard, a pivotal role can 
be ascribed to PD1 : PD-L1/PD-L2 pathway.  
 
Animal studies and clinical observations have contributed to underline the relevance 
of this pathway in favoring cancer progression (Tran et al. 2008; Ahmadzadeh et al. 
2009; Topalian et al. 2012). PD1 expression on T cell surfaces has been extensively 
indicated as a physiological step following CD4 and CD8 positive lymphocytes 
activation, whose engagement lead to the silencing of T cells response. This 
mechanism, which physiologically prevents the exacerbation of adaptive immune 
responses against pathogens and the onset of autoimmune diseases, can also prevent 
T lymphocytes from killing tumor cells (Tran et al. 2008; Pardoll 2012; Topalian et 
al. 2012). 
In fact, expression of PD1 ligands (PD-L1/PD-L2) on surface of malignant cells, has 
been shown to be significantly associated with poor prognosis of cancer patients 
(Zitvogel and Kroemer 2012; Topalian et al. 2016). Remarkably, upregulation of 
PD-L1 on malignant cells appears to result from both intrinsic and adaptive immune 
resistance mechanism utilized by malignant cells (Gajewski et al. 2010; Spranger et 
al. 2013; Topalian et al. 2014). Intrinsic immune resistance is referred to the 
constitutive expression of PD-L1, as a consequence of the activation of specific 
signaling pathway during neoplastic transformation, as well as a consequence of 
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chromosomal rearrangement usually detectable in malignant cells. Most importantly, 
PD-L1 upregulation can also be detected in different solid tumor types and 
hematological malignancies as a result of an active adaptive immune resistance of 
transformed cells (Pardoll 2012; Topalian et al. 2016). Indeed, it has been reported 
that the expression of PD-L1 on cellular surface of cancer cells may be induced in 
response to interferon (IFN)-γ, produced by tumor-infiltrating immunocompetent 
cells (Kmieciak et al. 2011; Topalian et al. 2015). The latter observation 
paradoxically underlines, once again, the potential ability of the immune system to 
mediate cancer eradication and, most importantly, the ability of malignant cells to 
react and dampen immune-mediated threat.  
 
These findings have prompted the development and evaluation of therapeutic 
efficacy of different monoclonal antibodies (mAbs) targeting negative regulators of 
tumor-reactive immune responses (Sharon et al. 2014). So far, administration of 
these antibodies has proven of clinical effectiveness in around 30% of cancer patients 
enrolled in different clinical trials.  
Despite these encouraging results, it must be underlined that cancer progression 
cannot be ascribed only to the capacity of malignant cells to evade immune 
recognition through the expression of inhibitory ligands on their cellular surfaces. In 
this regard, several studies have indicated that cancer progression may mostly be 
related to the generation and promotion by malignant cells of an immunosuppressive 
microenvironment, limiting the activity of immune cell types of proven clinical 
relevance. In particular, cancer cells can evade immune recognition through the 
activation of genes encoding for enzymes, cytokines and chemokines (Cremonesi et 
al. 2017) able to restrain the antitumor activity of T cells directly or through the 
recruitment of immune suppressive cells. In this respect, a selective recruitment of 
regulatory T cells (Tregs) and myeloid-derived suppressor cells (MSDC) has been 
widely reported in different tumor types including colorectal, breast and pancreatic 
cancer (Gabrilovich and Nagaraj 2009; Facciabene et al. 2012). 
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Finally, In addition to selective recruitment of immune suppressive cell types, 
malignant cells can also steer the functional differentiation of immune cell with 
antitumor potential. In this regard, in the last years, an increased interest has been 
registered for tumor-associated macrophages (TAMs). Notably, macrophages have 
been repeatedly indicated as first line of defense against cancer (Imaizumi et al. 
1999; Buhtoiarov et al. 2005; Lum et al. 2006 [A]; Beatty et al. 2011; Kang et al. 
2011; Murray and Wynn 2011; Rakhmilevich et al. 2012). These myeloid cells are 
recruited into and infiltrate tumor mass as an early event during cancer development 
(Noy and Pollard 2014). Once in the tumor mass, macrophages have the potential to 
kill cancer cell, either through a direct activity against malignant cells or with an 
indirect activity that passes through the activation of adaptive immune system 
(Imaizumi et al. 1999; Lum et al. 2006 [A]; Biswas and Mantovani 2010; Mills et al. 
2016). Nevertheless, in most cases, the tumor microenvironment is able to re-educate 
these cells steering their activity from antitumor to tumor promoting (Mantovani et 
al. 2002; Biswas and Mantovani 2010; Mills et al. 2016). 
 
These observations, suggest that cancer immunotherapy reagents, rather than a direct 
cytotoxic activity on malignant cells, must display the capacity to sustain the 
activation of tumor infiltrating immunocompetent cells and to prevent their 
functional inactivation. Moreover, such type of reagents should ideally also be able 
to simultaneously target different immune cell types within the tumor mass in order 
to be clinically effective. In this scenario, a pivotal role is played by the CD40 
molecule, a costimulatory protein, widely expressed on immune cells, able to 
activate both, innate and adaptive immunity (Elgueta et al. 2009; Beatty et al. 2017). 
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1.2 The CD40 receptor and CD40 ligand  
The CD40 molecule or CD40 receptor (CD40R) belongs to the tumor necrosis factor 
receptor (TNFR) family (van Kooten and Banchereau 2000; Elgueta et al. 2009) and 
is encoded by a gene located on human chromosome 20q11-20q13-2. Notably, 
CD40R is an integral type I membrane glycoprotein of 45-50 kDa composed of 277 
amino acid (aa). The mature form of the molecule includes a 193 aa extracellular 
domain, a 21 aa leader sequence, a 22 aa transmembrane domain and a 62 aa 
intracellular tail (with no similarity to any other characterized molecule) 
(Banchereau et al. 1994). Of note, human and murine CD40 molecule share 62% aa 
identity for the extracellular domain whereas 78% homology has been reported for 
the intracellular domain. In addition, 32 aa composing the C-terminal of the 
intracellular domain of CD40R and 22 cysteines located in the extracellular domain, 
are fully conserved between mouse and human. These observations suggest that both 
mouse and human CD40 molecules possess similar functional domains (Banchereau 
et al. 1994; van Kooten and Banchereau 2000). 
 
CD40R was initially detected on the cellular surfaces of B lymphocytes. Later 
studies have documented the expression of CD40 on a wider range of cell types 
including myeloid immunocompetent cells (dendritic cells [DCs], monocytes and 
resident macrophages) but also endothelial cells, epithelial cells and stromal cells 
(e.g.: fibroblast and mesenchymal stromal cells) (van Kooten and Banchereau 2000; 
Elgueta et al. 2009). Remarkably, CD40 expression has been also observed in almost 
70% of solid tumors and nearly all B cell malignancies (Vonderheide 2007).  
So far, only one ligand for CD40R has been identified: CD154 also known as CD40 
ligand (CD40L). CD40L belongs to the tumor necrosis factor (TNF) superfamily and 
it is a type II transmembrane glycoprotein, with a molecular weight ranging between 
32 and 39 kDa. CD40L is encoded by a gene located on Xq26.3-Xq27.1. CD40L 
protein is composed of 261 aa. In particular, 22 aa compose the cytoplasmic domain, 
24 aa the transmembrane domain and a 215 aa are included in the extracellular 
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domain. Similarly, to its cognate receptor, comparison between human and mouse 
CD40L revealed 75% of homology for the extracellular domain, 96% for the 
transmembrane region and 81% for the cytoplasmic domain.  
In line with other members of the TNF superfamily, crystallography studies have 
indicated the ability also for CD40L molecule to form trimeric structures (van 
Kooten and Banchereau 2000; Elgueta et al. 2009). 
 
In sharp contrast with CD40R, CD40L displays a highly selective pattern of 
expression. Indeed, CD40L is primarily detected on platelets, activated T 
lymphocytes and natural killer (NK) cells (van Kooten and Banchereau 2000). Most 
importantly, in addition to the transmembrane form (mCD40L), the TNF-like 
molecule CD40L was also described to have two additional isoforms (18 and 31 
kDa), generated by proteolytic cleavage of the full-length protein. These shorter 
CD40L isoforms can be released as soluble proteins (sCD40L/s40L) by activated 
platelets and T cells (Huang et al. 2012).  
 
1.2.1 The CD40 receptor : CD40 ligand (CD154) pathway  
CD40R does not possess an intracellular domain with an intrinsic kinase activity. 
Ligation of CD40R by its cognate ligand results in the recruitment and activation of 
specific adaptor proteins termed as TNFR-associated factors (TRAFs).  
TRAFs family of adaptor proteins is composed of six different members: TRAF-1, -
2, -3, -4, -5 and TRAF-6. Members or TRAF family, except for TRAF-4, can be 
recruited to the cytoplasmic domain of CD40R, directly or through the formation of 
heterocomplexes (Bishop et al. 2007).  
Recently, some reports have contributed to the identification of another member of 
TRAFs family named TRAF-7. However, biological role and pattern of expression 
of TRAF-7 are still unclear (Bishop et al. 2007; So et al. 2015).  
CD40 triggering further tuned by specific ligand isoforms promotes the recruitment 
of different TRAF adaptor proteins resulting in the activation of complex signaling 
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cascades. These include the mitogen activated protein kinase (MAPK), c-Jun N-
terminal kinase (JNK), phosphoinositide 3-kinase (PI3K), extracellular signal-
regulated kinase (ERK) and the phospholipase Cγ (PLCγ) pathways (Elgueta et al. 
2009). The signal cascade initiated by ligation of CD40R eventually results in the 
activation of transcription factors such as the nuclear factor kappa B (NF-kB), 
activator protein (AP)-1 and the nuclear factor for interleukin-6 (NF-IL6), leading, 
in turn, to the transcription of an array of different genes involved in the regulation 
of a wide spectrum of molecular and cellular process (Figure 2) (Bishop et al. 2007; 
Elgueta et al. 2009; Elmetwali et al. 2010; Huang et al. 2012).  
 
Different studies have shed light on the critical relevance of the nature of CD40L 
stimuli in dictating different, even opposite, biological effects in targeted cells. In 
this respect, it has been shown that similarly to membrane-bound CD40L 
(mCD40L), also s40L can retain his trimeric structure resulting in the engagement 
of CD40R but culminating in a differential or reduced initiation of signaling cascade 
(Vonderheide 2007; Elmetwali et al. 2010; Huang et al. 2012; Elmetwali et al. 2016). 
In line with these observations, the s40L isoform was associated with survival 
pathway in carcinoma cells as well as increased immunosuppressive activity of 
MDSC and Tregs (Elmetwali et al. 2010; Huang et al. 2012; Jenabian et al. 2014). 
On the contrary, mCD40L isoform has been associated with apoptosis induction of 
CD40-expressing malignant cells and also to the activation of cellular and humoral 
responses (Elgueta et al. 2009).  
 
In the last decade, molecular studies from several authors have contributed to an 
increased understanding of CD40-initiated signaling pathway. Although differential 
cellular responses induced by sCD40L or mCD40L in target cells still need to be 
fully characterized, it is now widely accepted that engagement of CD40R results in 
differential receptor conformations which in turn results in a selective TRAFs 
recruitment finally leading to either short-living signals or sustained stimuli 
Introduction 
105 
(Georgopoulos et al. 2006; Elgueta et al. 2009). In this regard, Elmetwali and 
colleagues in 2010 clearly demonstrated that apoptosis induction in CD40-
expressing transformed cells, following stimulation with mCD40L, is associated 
with selective upregulation of TRAF-1 and TRAF-3 and a reduction of TRAF-6 
intracellular levels. Notably, only the TRAF-1 protein was upregulated at 
transcriptional level while no changes were observed in TRAF-3/6 mRNA. These 
observations suggested that regulation of TRAF-3 and TRAF-6 intracellular levels 
might reflect protein stabilization and turnover of TRAF-3 and TRAF-6. Alteration 
of TRAF-1, -3 and -6 protein levels leads to JNK-dependent apoptosis as results of 
cytochrome c release and activation of caspases. In line with these observations, 
further studies also demonstrated that in CD40 positive cancerous cells, apoptosis 
induced by the membrane-bound CD40L, but not soluble isoforms, is related to the 
induction of the novel Ras effector 1A (NORE1A)/Ras association domain-
containing protein 5 (RASSF5) molecule (Elmetwali et al. 2010; Elmetwali et al. 
2016).  
 
Collectively, these observations, along with CD40 broad pattern of expression, 
suggest that different TRAFs adaptor proteins are associated to the initiation of 
different intracellular signaling pathways. Therefore, it is not surprising that the 
effects of CD40R stimulation are multifaceted. In particular, CD40R ligation on 
cancer cells may lead to apoptosis or to pro-survival effects. Similarly, engagement 
of CD40R on immune cells might result in the initiation and progression of both 
humoral and cellular immune response or establishment of immune tolerance 
(Vonderheide 2007).  
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Figure 2. Multiple effects of CD40R : CD40L signaling. A cartoon summarizing TRAF-
dependent activation of intracellular pathway in response to CD40R stimulation. TRAF 
molecules are recruited to the cytoplasmic tail of CD40R where they can mediate activation 
of NF-kB, JNK, p38/ MAPK. Depending on the different microenvironment, molecular 
characteristic of the ligand, and strength of CD40R stimulation, these molecules may 
activate the transcription of different genes implied in the induction of apoptosis or 
promotion of survival (adapted from Elgueta et al. 2009). 
 
1.2.2 The CD40 receptor : CD40 ligand (CD154) in the immune system  
A pivotal role for CD40R : CD40L pathway in the regulation of immune system has 
been extensively reported (Banchereau et al. 1994; Bishop et al. 2007; Vonderheide 
2007; Elgueta et al. 2009; Vonderheide et al. 2013; Loskog et al. 2016). Indeed, 
ligation of CD40R expressed on the surface of immunocompetent cells has been 
associated to upregulation of a broad range of costimulatory/inhibitory 
receptors/ligands, production of antibodies and release of cytokines in the 
extracellular environment (Banchereau et al. 1994; Vonderheide 2007; Elgueta et al 
2009; Vonderheide et al. 2013).  
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CD40 was initially described and functionally characterized as a key receptor 
expressed on cellular surfaces of B cells (van Kooten and Banchereau 2000). 
Stimulation of CD40R on surfaces of B cells, by CD40L-expressing CD4+ T cells, 
has been shown to play a pivotal role in the initiation and maintenance of effective 
humoral responses. Indeed, triggering of CD40R, results in B cells 
proliferation/expansion, inhibition of apoptosis and, most importantly, in their 
maturation as indicated by antibody isotype switching and differentiation into long-
living plasma cells. Furthermore, CD40R-stimulated B cells display an increased 
expression of molecules mediating intracellular adhesion and co-stimulation of T 
cell (CD23 [FcεRII], CD80 [B7.1] and CD86 [B7.2], MHC class I/II molecule) as 
well as of cytokine production (IL-6, IL-10, TNF-α) (van Kooten and Banchereau 
2000; Elgueta et al 2009).  
Remarkably, mutations in the CD40L gene have been associated to hyper 
Immunoglobulin (Ig)M syndrome characterized by elevated levels of IgM, low 
levels of IgE, IgG and IgA, absence of germinal centers and inability to generate a 
protective humoral response (Grewal and Flavell 1998).  
 
The identification of an increasing number of different immunocompetent cells 
expressing CD40 has expanded considerably the implication of this pathway in the 
control of immune responses. In particular, pioneering studies (Bennett et al. 1998; 
Ridge et al. 1998; Schoenberger et al. 1998) on DCs have underlined the critical 
relevance of CD40R : CD40L pathway not only in the generation of a humoral 
response but also in the generation of CD8-mediate immune responses.  
Naïve CD8+ T lymphocytes require a full activation to produce antiviral and 
antitumor cytokines and to develop the capacity to eliminate target cells 
(Lanzavecchia 1998; Laidlaw et al. 2016). It is nowadays widely accepted that 
activation and generation of protective viruses/tumor-specific CD8+ T cells are 
achieved by the integration of three different signals. In particular, full activation of 
naïve CD8+ T cells requires, along to the recognition by the T cell receptor of the 
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MHC class I-peptide complex on the surface of DCs (Signal-1), also the delivery of 
additional signals such as costimulatory ligands (Signal-2) and exposure to pro-
inflammatory cytokines (Signal-3) (Curtsinger et al. 2003; Obar and Lefrançois 
2010). In this scenario, several studies have repeatedly reported a critical role for 
CD4+ T cells help in the generation of an efficient CD8+ T cell immune response 
(Keene and Forman 1982; Mitchison and O'Malley 1987; Cassell and Forman 1988; 
Husmann and Bevan 1988; Guerder and Matzinger 1992). 
 
The initial interpretation of the “help” provided by CD4+ T cells was focused on the 
production of high amounts of IL-2 after the simultaneous recognition on the same 
antigen presenting cell (APC), of the cognate antigen (Mitchison and O'Malley 1987; 
Cassell and Forman 1988; Keene and Forman 1992). However, CD8+ T cells 
response could be also generated in IL-2 independent manner (Steiger et al. 1995). 
In addition, a potential limitation of this model was represented by the simultaneous 
interaction of two rare antigen-specific cells on the same APC (Lanzavecchia 1998).  
 
Our current understanding of the interplay between DCs, CD8 and CD4 positive T 
cells largely relies on the APC-licensing model proposed by Matzinger (Matzinger 
1994). According to this model, CD4+ T cells following antigen recognition on DCs 
can deliver a signal able to activate the APC to a state in which they can 
autonomously and properly prime CD8+ T cells (Matzinger 1994; Ridge et al. 1998). 
Thus, rather than being simple scaffold with the mere function to bring CD4+ and 
CD8+ T cells together, the DC play a pivotal role in the generation of the CD8+ T 
cell immune response (Ridge et al. 1998; Behrens et al. 2004).  
The molecular basis accounting for CD4+ T cell-mediated activation of DCs were 
identified in the CD40R : CD40L interaction and currently, stimulation of CD40R-
expressing DCs by CD40L+ CD4+ T cells is referred as antigen presenting cells 
licensing (APCs-licensing) (Lanzavecchia 1998).  
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Notably, APCs-licensing has been extensively indicated in animal studies and 
clinical studies as a critical step in the generation of protective CD8-mediated 
cellular responses (Di Rosa and Matzinger 1996; Vonderheide 2007). T-helper cells, 
through the expression on their cell surfaces of CD40L, promote the activation of 
CD8+ T cells by increasing the ability of CD40-licensed DCs to deliver the three 
activating signals to specific CD8+ T cells (Di Rosa and Matzinger 1996; 
Lanzavecchia 1998, Vonderheide 2007). Indeed, upon recognition of the cognate 
antigen in the context of MHC class II molecules, specific CD4+ T cells rapidly 
express on their cellular surfaces CD40L, which in turn results in an increased 
antigen presentation capacity of DCs to T cells as confirmed by upregulation of MHC 
class I/II molecules. Moreover, CD40L-stimulated DCs express high levels of 
molecules implicated in the formation of the immunological synapse such as the 
adhesion and costimulatory molecules CD58 (LFA-3), CD54 (ICAM-1), CD80 
(B7.1) and CD86 (B7.2) (van Kooten and Banchereau 2000; Quezada et al 2004; 
Elgueta et al. 2009; Ma and Clark 2009; Kawabe et al. 2011).   
Finally, CD40R-stimulated DCs release high amount of pro-inflammatory cytokines, 
most importantly, IL-12. This cytokine plays a crucial role in the initiation and 
maintenance of protective T helper (Th)1-responses (Hsieh et al. 1993; Hirohata 
1999; Athie-Morales et al. 2004). Moreover, IL-12 is a strong amplifier of CD8+ 
response and was demonstrated to act as a third signal in CD8 priming (Curtsinger 
et al. 2003; Behrens et al. 2004). 
 
This model has been further confirmed by later studies demonstrating that the crucial 
nature of CD4+ T cell help relies on the CD40-dependent licensing of APC (Bennett 
et al. 1998; Ridge et al. 1998; Schoenberger et al. 1998; Fransen et al. 2011). Indeed, 
neutralization of CD40L resulted in the abrogation of CD8+ T cell priming 
(Schoenberger et al. 1998). Most importantly, these studies demonstrated that 
specific agonistic monoclonal antibodies targeting CD40R can replace CD4+ T cells 
during CD8+ T cells priming.  
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1.2.3 Targeting CD40 receptor to harness the immune system against 
cancer 
Generation of an effective CD8+ T cells response plays a pivotal role in protective 
antitumor immunity (Vonderheide 2007; Vonderheide and Glennie 2013). Several 
studies have shown that activation status of APCs (e.g.: DCs) represents a critical 
determinant for the induction of tumor-reactive CD8+ T cells. In this regard, ligation 
of CD40R on cellular surfaces of DCs leads to their activation. Indeed, CD40R-
stimulated DCs display a high expression of MHC class I/II, co-stimulatory 
molecules and cytokines able to optimally prime tumor-reactive naïve CD8+ T cells. 
Based on the critical role of DCs in regulating antitumor CD8-mediated immune 
responses, initial therapeutic strategies were designed in order to promote, in a 
CD40-dependent manner, APC activation (Vonderheide 2007; Elgueta et al. 2009). 
Different reagents including agonistic CD40R antibodies, small molecules and viral 
vectors have been tested in animal models and also evaluated in cancer patients 
(Vonderheide 2007; Ullenhag and Loskog 2012). 
 
In particular, animal studies have documented the antitumor efficacy of anti-CD40R 
agonistic antibodies. Intratumoral or intravenous administration of these type of 
antibodies resulted in the rapid generation, in a CD4+ T cell independent manner, of 
cytotoxic CD8+ T cells targeting syngeneic lymphoma (French et al. 1999). 
Furthermore, administration of anti-CD40R agonistic antibodies resulted in an 
increased induction of specific CD8+ T cells following peptide-based antitumor 
vaccination protocols (Diehl et al. 1999; French et al. 1999; Sotomayor et al. 1999).  
Most importantly, pre-clinical studies underlined therapeutic activity of CD40R 
mAbs for treatment of both solid and hematological cancers regardless the CD40 
status of malignant cells (Todryk et al. 2001; Tutt et al. 2002). The latter observation 
prompted the development and clinical validation of similar reagents due to the broad 
range of tumors potentially treatable with anti-CD40R mAbs (Todryk et al. 2001; 
Tutt et al. 2002; van Mierlo et al. 2002; Vonderheide 2007). 
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Different anti-CD40R mAbs with activities ranging from antagonist to agonist have 
been used for clinical treatment of lymphoma and solid tumors. Results obtained in 
phase I/II clinical trials are consistent with disease stabilization in 20 to 60% of 
treated patients. Most importantly, clinical efficacy of CD40R mAbs based treatment 
has been correlated to activation of antitumor immune responses (Vonderheide 2007; 
Vonderheide and Glennie 2013; Remer et al. 2015). In particular, targeting CD40R 
with CP-870,893, a fully human IgG2 anti-CD40R agonistic mAb, resulted in 
objective tumor response against melanoma and pancreatic cancer. Patients receiving 
this mAb displayed activation of B cells, as antigen presenting cells, as evidenced by 
upregulation of CD86 costimulatory marker, MHC class I/II and CD54 adhesion 
molecule. To a similar extent, also ChiLob 7/4 mAb has been demonstrated to induce 
host APCs activation. This latter antibody is a chimeric IgG1 mAb that was tested in 
phase I clinical study with lymphoma and melanoma patients (Vonderheide 2013; 
Remer et al. 2015). Subjects enrolled in the study displayed DCs activation as 
indicated by CD83 expression and production of Th1 cytokines (Vonderheide 2007; 
Carpenter et al. 2009; Vonderheide and Glennie 2013; Remer et al. 2015).  
 
The development of cancer immunotherapies targeting CD40R was prompted by the 
necessity to achieve a full activation of host APCs (especially DCs) in order to 
generate a powerful antitumor T cells response.  
Nevertheless, targeting CD40R : CD40L pathway might also result in the activation 
of other immune mechanisms, which are not mutually exclusive, and can contribute 
to the elimination of cancerous cells (Vonderheide 2013). Indeed, engagement of 
CD40R on tumor endothelium can participate in the recruitment of immune effector 
cells in the tumor mass. Stimulation of CD40(+) endothelial cells, in fact, has been 
associated to the production of pro-inflammatory cytokines, such as the granulocyte-
macrophage colony-stimulating factor (GM-CSF), IL-6 and with the upregulation 
adhesion molecules. The latter include vascular cell adhesion molecule (VCAM)-1, 
intracellular cell adhesion molecule (ICAM)-1 and E-selectin important for the 
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recruitment and adhesion of leucocyte in the inflamed area (Déchanet et al. 1997; 
Kotowicz et al. 2000; Ullenhag and Loskog 2012). However, once in the tumor mass, 
effector cells can then be impaired in their function by cells with immunosuppressive 
activity. The tumor microenvironment, in fact, is usually highly infiltrated by 
immunosuppressive cells belonging to the lymphocytic or myeloid lineage (Fridman 
et al. 2011; Fridman et al. 2012; Fridman et al. 2013; Fridman et al. 2017). These 
cells may impair antigen-presenting capacity of DCs through direct contact or by 
cytokine release, blocking the generation of tumor-specific effector clones and 
therefore establishing tumor tolerance (Ullenhag and Loskog 2012). In this scenario, 
CD40R engagement has been demonstrated to be associated with the reduction of 
immunosuppressive mechanism and elimination of immunosuppressive cell 
populations thereby concurring in overcoming the immune tolerance detectable in 
tumor microenvironment. Finally, CD40R-stimulation of cancerous cells might 
result in the upregulation of adhesion (CD54), costimulatory (CD80 and CD86) and 
MHC (class I/II) molecule on their cell membrane, promoting the formation of a 
productive immunological synapse between CD8+ T lymphocytes and malignant 
cells (de Charette et al. 2016).  
 
In addition to these immune-mediated effects, CD40R engagement with agonistic 
mAbs can also have a direct effect on cancer cells, potentially resulting in their 
apoptosis (Vonderheide 2007; Loskog and Eliopoulos 2009; Ullenhag and Loskog 
2012). 
Interestingly, cell death induction in cancer cells has been associated with the 
intensity of CD40R stimulation and therefore with the specific TRAF molecule and 
signal transduction chain expressed by tumor cells. The most profound effect in 
carcinoma cells has been found to be induced by mCD40L rather than sCD40L 
(Elmetwali et al. 2010; Vonderheide 2007). Moreover, antibodies recognizing cancer 
cell markers also induce elimination of targeted cells through other, T cell 
independent, mechanisms, which include antibody-dependent cell-mediated 
Introduction 
113 
cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) (Vonderheide 
et al. 2013).  
 
Based on the latter considerations, different mAbs have been developed in order to 
mediate direct cancer cell death, as consequence of direct CD40R engagement on 
target cell. In this regard, Dacetuzumab, a humanized IgG1 agonist was 
demonstrated to induce cancer cell death through various mechanism, including 
ADCC, CDC and direct apoptotic signaling. Similarly, Lucatumumab a fully 
humanized IgG1 blocking CD40L ligation was demonstrated to augment ADCC 
(Vonderheide et al. 2013; Suresh et al. 2014; Remer et al. 2015). Despite the 
remarkable antitumor activity of anti-CD40R mAbs, the use of this strategy in 
patients with cancer is associated with several side effects. In particular, the systemic 
administration of antibody targeting CD40R might result in activation of immune 
and normal cells leading to adverse reactions. Concerns are principally related to 
possible induction of cytokine release syndromes, thromboembolic syndrome, due 
to CD40 expression on platelets and endothelial cells and autoimmune reactions. 
Some of these effects were observed in patients after antibody treatment. In 
Particular, CP-870.893 and SGN-40 administration resulted in the development of 
cytokine release syndrome with serum increase of cytokines such as IL-6, TNF-α, 
IL-10, IL-1β, fever and chills. Moreover, transaminase elevation, a symptom of liver 
stress, was also observed immediately after antibody administration (Vonderheide 
and Glennie 2013; Remer et al. 2015; Beatty et al. 2017).  
Importantly, although CD8+ T cells and DCs play key role in tumor cell eradication, 
data obtained from clinical studies as well as evidence from animal models suggest 
that tumor regression may also be obtained through T cell independent mechanisms. 
In this regard, a principal role has been described for myeloid cells. In particular, 
CD40R-stimulated macrophages were reported to display an efficient tumoricidal 
activity possibly based on the secretion of reactive nitrogen (RNI)/oxygen (ROI) 
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intermediates and/or effector cytokines such as TNF-α (Beatty et al. 2011; Ullenhag 
and Loskog 2012; Vonderheide et al. 2013).  
 
1.3 Macrophages  
Macrophages have been widely described as critical players of innate immune 
responses against cancer and pathogens (Murray and Wynn 2011). Traditionally, 
circulating CD14+ monocytes were indicated as precursors of tissue resident 
macrophages. This initial interpretation has recently been challenged. Indeed, origin 
of macrophages has been associated to specific tissue precursors seeded, in different 
anatomical district, during embryonic development (Geissmann et al. 2010; Ginhoux 
et al. 2016; Mantovani et al. 2017).  
 
A peculiar feature of macrophages is represented by their high plasticity. Indeed, 
cells belonging to macrophage lineage display an enhanced ability to integrate 
different stimuli from the extracellular environment and to respond to them by 
acquiring specific phenotypic and functional profiles. In this regard, it was reported 
that IFN-γ and/or microbial products might promote the differentiation of classically 
activated (M1) CD14-derived macrophages with pro-inflammatory functional 
attributes. In contrast, Th-2 cytokines (IL-4/IL-13) promote the generation of 
alternatively activated (M2) CD14-derived macrophages defined by an 
immunosuppressive functional profile (Stein et al. 1992; Mantovani et al. 2002; 
Biswas and Mantovani 2010; Sica and Mantovani 2012; Martinez and Gordon 2014) 
 
M1 macrophages are characterized by high expression of CD16 receptor and reduced 
expression of CD163 and CD204 on their cell surfaces (Nebiker et al. 2014). In 
addition, activated CD14-derived M1 macrophages display high levels of MHC class 
I/II and costimulatory molecules (CD80/CD86). Activation of M1 macrophages 
results also in the de-novo production of pro-inflammatory cytokines including IL-
12, IL-23, TNF-α and RNI/ROI (Gordon and Taylor 2005; Mantovani et al. 2008; 
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Sica and Mantovani 2012; Mills 2015). Based on this functional profile, CD14-
derived M1 macrophages have been indicated as sentinels of innate immune 
responses against cancer, viruses and bacterial infections (Mosser and Edwards 
2008). In addition to their direct activity against target cells, CD14-derived M1 
macrophages have been shown to have a critical role in regulating adaptive immune 
responses. In this regard, release of C-X-C motif chemokine ligand (CXCL)9 and 
CXCL10, efficient antigen presentation capacity and production of high amount of 
pro-inflammatory cytokines, including IL-12, have been described as crucial 
elements dictating the ability of M1 macrophages to recruit and promote the 
activation of Th1-mediated immune responses (Martinez et al. 2006; Mantovani et 
al. 2008; Biswas and Mantovani 2010). 
 
In contrast, M2 macrophages display reduced expression on their cell surfaces of 
CD16 and high levels of CD163 and CD204 (Nebiker et al. 2014). Several studies 
support a critical role of CD14-derived M2 macrophages in the elimination of 
parasites and in tissue remodeling. Moreover, a pro-tumoral activity in different 
types of malignancies has also been described for M2 macrophages. These roles have 
been directly associated to the impaired ability of CD14-derived M2 macrophages to 
produce pro-inflammatory cytokines including IL-12 (Mantovani et al. 2002; 
Gordon and Taylor 2005; Mantovani et al. 2008; Sica and Mantovani 2012; Mills 
2015). In addition, activation of M2 macrophages results in the secretion of C-C 
motif chemokine ligand (CCL) 17, CCL22 and CCL24 promoting the recruitment of 
Th2 lymphocytes (Martinez et al. 2006; Mantovani et al. 2008).  
These two different forms of macrophage polarization are tightly regulated at the 
intracellular levels by specific transcription factors. In this regard, high levels of 
signal transducer and activator of transcription (STAT)1, NF-kB and interferon 
regulatory factor (IRF)5 have been associated to an M1-like functional profile as 
suggested by the increased expression of genes encoding pro-inflammatory 
cytokines such as IL-12, IL-23 and TNF-α. On the other hand, stimuli resulting in 
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increased levels of IRF4, STAT3/6 and cMyc have been associated to the skewing 
of CD14 monocytes toward the M2 profile (Sica and Mantovani 2012; Mantovani 
and Allavena 2015).  
 
Notably, these M1 and M2 activation status of macrophages mirror the Th1/Th2 
polarization of CD4+ T cells. Nevertheless, in contrast with T-helper cells 
differentiation, M1 and M2 macrophages have been extensively indicated as two 
extremes of a continuum of differentiation states (Mantovani et al. 2002; Mosser and 
Edwards 2008). Indeed, it has been observed that in different pathological or 
physiological contexts macrophages can assume a phenotype that does not overlap 
with M1 or M2 profiles but present features of both polarization states (Chan et al. 
2008; Shaul et al. 2010). Moreover, due to their intrinsic plasticity, macrophage 
polarization can also be modified during the course of different disease such as 
cancer and obesity (Lumeng et al. 2007; Biswas et al. 2008). 
Chemokines, including CCL2 and CXCL4, soluble factors such as macrophage 
colony-stimulating factor (M-CSF), IL-10, and transforming growth factor (TGF)-β 
have been indicated as critical mediators in the establishment of an M2 favorable 
immunosuppressive microenvironment. These molecules, in fact, can cooperate in 
recruitment and induction of macrophage polarization toward phenotype sharing 
distinct features with IL-4/IL-13 activated macrophages (M2) and often observed in 
TAMs (Roca et al. 2009; Biswas and Mantovani 2010; Gleissner et al. 2010) 
 
1.3.1 Macrophages and cancer   
Macrophages represent a significant fraction of tumor-infiltrating immunocompetent 
cells (Noy and Pollard 2014). Abundance of macrophages has been extensively 
reported in several solid tumor types, in both tumor center and invasive margins 
(Fridman et al. 2017). Most importantly, several studies have contributed to define 
the relationship occurring between “quantity” and “quality” of macrophages 
infiltration and clinical outcome in cancer patients (Figure 3). 
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In this regard, high infiltration of M1 macrophages defined using, among others, the 
human leukocyte antigen-antigen D related (HLA-DR) or the inducible nitric oxide 
synthase (iNOS) markers, has been correlated with a favorable prognosis in non-
small-cell lung cancer (NSCLC) (Ohri et al. 2009; Ma et al. 2010; Ohri et al. 2011) 
(patient n=140), hepatocellular carcinoma (HCC) (Dong et al. 2016) (n=253), 
ovarian cancer (OC) (Zhang et al. 2014) (n=112) and gastric cancer (Pantano et al. 
2013; Zhang et al. 2015) (n=232). In contrast, high infiltration by M2-like 
macrophages, as defined using, among others, CD163 and CD204 expression as 
marker, has been associated with poor prognosis in breast (Medrek et al. 2012) (n= 
144), bladder (Ichimura et al. 2014) (n=171), ovarian (Lan et al. 2013) (n=110), renal 
cell carcinoma (RCC) (Dannenmann et al. 2013; Xu et al. 2014) (n=239), gastric 
(Kawahara et al. 2010; Zhang et al. 2015) (n=434) and in melanoma (Jensen et al. 
2009) (n=227) (Fridman et al. 2017). 
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Figure 3. M1 or M2 macrophages (M) infiltration and clinical outcome in cancer 
patients. Bold colors indicate a positive (green) or a negative (red) prognostic association 
following analysis of all relevant studies; orange color indicates a predominantly negative 
prognostic association in the majority of studies analyzed. White circles indicate no 
statistically significant correlation, or that unclear prognostic associations were observed in 
a similar number of studies. The size of the circles relates to the size of the cohort in clinical 
studies. Small circles indicate 0–100 patients, Medium-sized circles indicate 100–1,000 
patients and Large circles indicate 1,000–10,000 patients (adapted from Fridman et al. 
2017). 
 
Our current understanding regarding the impact of macrophages infiltration and 
clinical outcome of cancer patients is based on the M1/M2 differentiation model. In 
this respect, classically activated M1 macrophages were shown, in animal models 
and clinical studies, to possess a potent antitumor activity (Mills et al. 2016; Fridman 
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et al. 2017). In particular, the enhanced ability of M1 macrophages to inhibit tumor 
progression has been correlated mostly to their capacity to release high amount of 
TNF-α (Sica and Mantovani 2012; Fridman et al. 2017). Furthermore, CD14-derived 
M1 macrophages can selectively eliminate pre-malignant cells preventing tumor 
progression, at least in the animal model (Kang et al. 2011). In addition to these latter 
observations, the antitumor role of CD14-derived M1 macrophages is also based on 
their ability to orchestrate generation of innate and adaptive immune responses 
against cancer. Accordingly, it has been shown that IFN-γ production by NK cells, 
Th1 and CD8+ T lymphocytes might sustain M1 polarization of myeloid cells, which 
in turn release IL-12 and CXCL9, CXCL10 chemokines resulting in a sustained 
antitumor immune response (Biswas and Mantovani 2010). In vitro and in vivo 
studies have repeatedly shown a protective role for CD14-derived M1 macrophages 
(Grabstein et al. 1986; Mills et al. 2016). 
 
However, a significant infiltration of pro-tumor M2 macrophages, particularly at the 
late stages of malignancy, has also been observed (Biswas et al. 2013; Noy and 
Pollard 2014).  
In this regard, an increased attention has been focused, in the last years, regarding on 
the ability of chronically inflamed tissues, including many tumor types(Mantovani 
and Sica 2010), to promote preferential recruitment and polarization of TAMs 
toward an M2-like profile (Fridman et al. 2012; Sica and Mantovani 2012; Mills et 
al. 2016; Fridman et al. 2017). In this type of microenvironment, macrophages are 
exposed to cytokines and chemokines (such as M-CSF, IL-10, TGF-β, CCL2) 
produced by the malignant and tumor-associated stromal and inflammatory cells 
educating macrophages to become pro-tumoral cells with an M2-like phenotype 
(Biswas et al. 2013; Noy and Pollard 2014). These macrophages display a low 
production of IL-12 and high production of IL-10. Furthermore, they show low 
antigen presentation and tumoricidal activity, impaired production of RNI but large 
production of the tumor growth molecule ornithine as well as molecules involve in 
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tissue remodeling and angiogenesis (vascular endothelial growth factor [VEGF], 
epidermal growth factor [EGF], CXCL8) (Mills 2012; Biswas et al. 2013; Noy and 
Pollard 2014). Most importantly, when cancers become invasive, the tumor 
microenvironment appears to be dominated by cytokines that promote T cells 
skewing from a Th1 to a Th2 immune response. IL-4 and IL-13 cytokines, derived 
from Th2 cells, further sustain macrophages polarization to an M2 phenotype, which 
in turn express a set of chemokines (CCL17, CCL22, CCL24) resulting in the 
recruitment of other inflammatory cells (Treg, Th2, eosinophils, basophils) 
expressing cognate receptors CCR3 and CCR4. Once in the tumor 
microenvironment, these cells produce cytokines (IL-10, IL-4, IL-13) that further 
promote macrophage polarization through an M2/M2-like phenotype in a self-
sustaining cycle promoting cancer progression (Biswas and Mantovani 2010; Noy 
and Pollard 2014) (Figure 4). 
 
 
Figure 4. Macrophage’s activation and polarization orchestrate by immune cells. M1-
polarized macrophages and their crosstalk with Th1 and NK cells. M2 polarization of 
macrophages driven by Th2 cells and basophils, through their secretion of IL-4 or IL-13. 
M2-like macrophages polarized by interaction with Treg. In green M1 or in red M2/M2-like 
polarized macrophages (adapted from Biswas and Mantovani 2010). 
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Due to the pivotal role played by macrophages in either cancer progression or cancer 
eradication, a number of potential macrophage-centered therapeutic approaches are 
being explored. (Mantovani et al. 2017; Zheng et al. 2017). In particular, since it has 
been demonstrated that macrophage polarization can be reverted to some extent 
(Guiducci et al. 2005; Saccani et al. 2006) potentially leading to the elicitation of M1 
direct anticancer activity, an appealing strategy appears to be the functional re-
education of TAMs to an M1-like functional phenotype. 
 
1.3.2 Targeting the CD40 pathway to enhance antitumor macrophage 
activity 
Current understanding of successful cancer immunotherapeutic strategies largely 
focuses on the ability of tumor-reactive CD8+ T cells to mediate the elimination of 
transformed cells.  
However, in the last years, the role of myeloid cells in tumor eradication has been 
revised. In particular, a potential protective role against cancer has been underlined 
for macrophages. Several studies have shown that these myeloid cells might mediate 
cancer cells clearance and tumor regression through mechanisms not requiring the 
activation of CD8+ T cells immunity (Beatty et al. 2011; Rakhmilevich et al. 2012; 
Mills et al. 2016). In particular, studies performed in animal models indicate that 
tumor infiltration by M1 macrophages results in decreased tumor progression as 
compared to M2-infiltrated tumors (Evans et al. 1977; Fidler and Poste 1982; Mills 
2015; Mills et al. 2016). In addition, skewing M2 toward M1 phenotype might favor 
tumor regression (Mills et al. 1992; Beatty et al. 2011; O'Sullivan 2012). Notably, 
antitumor activity of myeloid cells of monocyte and macrophage lineage can be 
finely tuned by the CD40R : CD40L pathway (Rakhmilevich et al. 2012). Indeed, 
several in vitro, ex vivo and in vivo studies have demonstrated that myeloid cells once 
stimulated through CD40R develop an M1 pro-inflammatory phenotype that can 
rapidly lead to tumor cells elimination (Buhtoiarov et al. 2005; Lum et al. 2006).  
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The first evidence on the antitumor potential of myeloid cells was reported by 
Alderson and colleagues. This study showed that CD40L transfected cells were able 
to activate the tumoricidal activity of human monocytes against melanoma cells 
(Alderson et al. 1993). This initial observation was later confirmed by in vitro, ex 
vivo and in vivo studies aimed at clarifying the antitumor potential of macrophages 
with similar results. Taken together, these studies have revealed that following 
CD40R stimulation, murine macrophages are able to secrete effector cytokines and 
soluble cytotoxic molecules, most notably nitric oxide (NO), IL-12 and TNF-α, 
resulting in a significant cytostatic/cytotoxic activity against different types of 
transformed cells (Imaizumi et al. 1999; Buhtoiarov et al. 2005; Lum et al. 2006 [A]; 
Rakhmilevich et al. 2012).  
IL-12 production by CD40R-stimulated macrophages plays a pivotal role in the 
elicitation of their antitumor activity. Indeed, it has been reported that IL-12 
produced in response to CD40R triggering induces the production of IFN-γ, which 
in turn results in the activation and stimulation of macrophages antitumor effect 
(Buhtoiarov et al. 2005). Moreover, INF-γ was demonstrated to be responsible for 
CD40 upregulation on macrophages cell surface and, in combination with CD40R 
stimulation, to increase NO and TNF-α production by these myeloid cells (Imaizumi 
et al. 1999) 
 
These initial findings were confirmed and further extended in vivo, by demonstrating 
that a CD40R specific agonist mAb stimulated murine macrophages to maturate into 
an M1 pro-inflammatory phenotype able to inhibit tumor growth in a T/B/NK 
independent manner (Lum et al. 2006; Rakhmilevich et al. 2012). In particular, 
CD40R stimulation of these cells led to their rapid activation, as indicated by 
upregulation of costimulatory (CD80, CD86, CD40, toll like receptor [TLR] 4) and 
MHC class II molecules. Most importantly, after CD40 stimulation, they produce 
pro-inflammatory Th1 cytokines (IFN-γ, IL-12; TNF-α) and display an increased 
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cytostatic activity against neuroblastoma and melanoma cancer cells (Lum et al. 
2006).  
 
In line with these findings underlining the critical role of macrophages in cancer 
eradication, important results were also obtained in pre-clinical and clinical studies 
performed on pancreatic ductal adenocarcinoma (PDA) (Beatty et al. 2011; Beatty 
et al. 2013). 
PDA is a highly aggressive cancer, poorly responsive to standard therapies such as 
chemotherapy, which offer only minimal benefit in patients not eligible for surgery 
(Beatty et al. 2011; Vonderheide et al. 2013). New drugs approved for treatment of 
PDA (erlotinib) extend patients survival by only a couple of weeks compared to 
classical therapies. In contrast, the combination of standard care treatment 
(gemcitabine) with systemic administration of CD40R agonist (CP-870,893) for 
advanced/surgically incurable PDA, chemotherapy naïve patients gave encouraging 
results (Vonderheide et al. 2013). Although gemcitabine alone results only in 
approximately 5% partial response, the addition of a CD40R agonist resulted in 4/21 
patients in partial response and 11/21 in disease stabilization with a median 
progression free survival of 5.6 months, while gemcitabine alone only achieves 2.3 
months (Beatty et al. 2011; Beatty et al. 2013; Vonderheide et al. 2013). Histological 
analysis of surgically resected tumor lesions from patients with partial response 
revealed an immune infiltrate, which was enriched in macrophages, but not in T 
lymphocytes as expected. In particular, animal studies have contributed to clarify the 
antitumor activity of CP-870,893. Indeed, administration of a rat anti-mouse CD40R 
agonist mAb FGK45 (homolog of human CP-870,893) following gemcitabine 
treatment resulted in a similar antitumor activity as observed in cancer patients 
(Beatty et al. 2011). Most importantly, systemic administration of FGK45 resulted, 
similarly to CP-870,893, in a high infiltration of myeloid cells but not T lymphocytes 
into the neoplastic lesion (Beatty et al. 2011; Beatty 2013). Analysis of tumor-
associated immune cells after FGK45 treatment provides evidence that macrophages 
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were activated as indicated by upregulation of MHC class II and CD86 molecule. 
These CD40R-activated macrophages acquired tumoricidal properties and the 
capacity to secrete high levels of IL-12 and TNF-α. Most importantly these cells shift 
their phenotype from stroma supporting to stroma degrading cells and mediate 
disruption of Type I collagen (a major component of extracellular matrix) (Beatty et 
al. 2011; Beatty et al. 2013).  
 
These findings reinforce the idea that immunotherapeutic strategy aimed at targeting 
CD40R can drive both T cell dependent and independent mechanisms. In regard to 
the latter, triggering of the CD40 pathway has been demonstrated to efficiently 
restore tumor immune surveillance by targeting tumor-infiltrating macrophages 
(Vonderheide et al. 2013). Notably, these results also imply that the final antitumor 
activity may pass through a re-education of tumor promoting macrophages and 
stromal destruction (Vonderheide et al. 2013). 
 
1.4 Vaccinia virus and cancer immunotherapy 
Therapeutic efficacy of engineered CD40L-expressing recombinant viral vectors has 
been extensively evaluated in animal models and clinical studies (Ullenhag and 
Loskog 2012; Parviainen et al. 2014). Interestingly, several phase I/II clinical trials 
have addressed the clinical efficacy of CD40L-expressing recombinant adenovirus 
(AdCD40L) alone or in combination with IL-2 in patients with solid cancer and 
hematological malignancies (Wierda et al. 2000; Biagi et al. 2005; Rousseau et al. 
2006; Malmström et al. 2010). Remarkably, following treatment, a significant 
increase in tumor-reactive T cells along with shrinkage of tumor masses was 
observed in cancer patients enrolled in clinical studies (Biagi et al. 2005; Rousseau 
et al. 2006) Most importantly, immune activation promoted by AdCD40L resulted 
in 5-year overall survival of 90% of treated patients with acute leukemia (Rousseau 
et al. 2006).  
Introduction 
125 
Among different viral vectors evaluated for cancer therapeutic purposes, 
recombinant vaccinia viruses (rVVs) have been extensively explored. Several studies 
in pre-clinical and clinical settings have addressed the antitumor potential of rVVs 
encoding together with tumor-associated antigens, costimulatory molecules of 
immunological relevance (Zajac et al. 1998; Adamina et al. 2010; Parviainen et al. 
2014).  
 
Vaccinia Virus (VV) belongs to the Poxviridae family. VV is a double-strand DNA 
virus (Shen and Nemunaitis 2005). The length of virus backbone is approximately 
of 190kbp and contains 250 genes (Larocca and Schlom 2011). The effectiveness of 
VV as preventive vaccine has been proven by the eradication of variola virus, 
officially achieved in 1980 (Moss 1991). Due to its historical role, VV biology has 
been extensively studied in laboratory resulting in its use as an effective vehicle for 
gene delivery in immunotherapy. 
A peculiar feature of VV is represented by its ability to infect a broad range of 
mammalian cells. Notably, host cell infection by VV does not require any defined 
cell surface receptor, but it is due to its fusion with plasma membrane of mammalian 
cells. In this regard, it must be underlined that other viruses, including adenovirus, 
have a more restricted host cell range due to the requirement for specific surface 
receptors during the infection process.  
VV genome can be easily engineered leading to the accommodation to up to 25 kb 
of foreign genetic material. Finally, VV displays an enhanced tumor tropism due to 
cancer cell dysregulation in cell cycle, immune evasion and uncontrolled replication. 
Importantly, the use of vaccinia virus is safe, since replication of the virus takes place 
in cytoplasmic structures defined “viral factories” and the virus does not integrate 
into the host genome (Shen and Nemunaitis 2005; Kirn and Thorne 2009; Kim and 
Gulley 2012). 
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The use of vaccinia virus (Copenhagen strain) in preclinical studies has been 
extensively explored at the University of Basel. In previous studies, the efficacy of 
rVV in the generation and the expansion of tumor-reactive CD8+ T cells was tested. 
Remarkably, the use of a rVV encoding tumor-associated antigens and costimulatory 
molecules has shown an enhanced ability to promote the expansion of CD8+ tumor-
reactive T cells. This was observed with cells from peripheral blood of healthy donor 
and tumor-infiltrating lymphocytes, obtained from clinical specimens (Zajac et al. 
1997; Zajac et al. 1998; Groeper et al. 2007). 
Interestingly, rVV displayed also therapeutic efficacy in phase I/II clinical studies in 
stage III/IV melanoma patients. This viral vector was engineered to express three 
HLA-A0201 restricted epitopes from melanoma differentiation antigens (gp100280-
288; - Melan-A/MART-127-35; - tyrosinase1-9) and CD80, CD86 costimulatory 
molecules.  
The treatment administered to the patients enrolled in the study consisted in the 
intradermal administration or the recombinant virus, followed by re-call boosts with 
the antigenic soluble peptides together with GM-CSF injected intradermally.  
Clinical observations indicate that 7/10 treated patients developed a CD8+ T cells 
response against at least one of the antigens and showed stable disease. Moreover, 
3/7 responsive patients displayed single metastasis regression (Adamina et al. 2010). 
Thus, clinical benefit correlated with the generation of CD8+ T cells targeting at least 
one tumor-associated peptide, indicating that the administration of rVV is safe and 
induces the generation of tumor-specific T cells. In this regards Trella et al., more 
recently (2016), demonstrated that the use of a recombinant vaccinia virus encoding 
for CD40L (rVV40L) promotes the rapid “in vitro” differentiation of naïve CD8+ T 
cells into CD8+ T central memory cells reactive against human tumor-associated 
antigens. This work underlines once again the ability of such type of vector to fine 
tune CD8+ T cell-mediated immune response. 
However, tumor regression is also associated to T cell independent mechanisms (see 
paragraph 1.3.2). In this respect, CD40 pathway targeting has been demonstrated to 
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efficiently restore tumor immune surveillance through re-education of tumor-
infiltrating macrophages. Therefore, rVV40L could theoretically be able not only to 
promote the generation and expansion the CD8+ T cells responses, but also to 
generate antitumor activity through the modulation of functional profiles of tumor-
infiltrating myeloid cells.   
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2. Outline of the thesis 
 
In the present study, I have analyzed CD40 expression on malignant and tumor-
infiltrating immune cells in a large (n>800) cohort of human cancers and identified 
malignancies potentially representing important clinical targets. This information 
was then used to perform tailored “in vitro” and “in vivo” experiments using CD40(-
) and (+) cell lines of defined histological origin. In particular, I evaluated the ability 
of rVV40L to directly induce apoptosis on CD40(+) tumor cells. In addition to the 
direct effect on cancerous cells, I also investigated the ability of rVV40L to modulate 
the functional profile of differentially polarized macrophages potentially leading to 
in vivo inhibition of tumor progression.   
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3. Materials and methods  
 
3.1 Immunohistochemistry 
Tumor characteristics and peritumoral immune cell infiltration were evaluated by 
using the original hematoxylin and eosin (H&E) slides of resection specimens 
corresponding to microarray punches. Tissue microarray (TMA) slides were 
incubated with CD40 specific primary antibodies (Clone58612; Abcam). 
Percentages of CD40 positive cells were evaluated by experienced pathologists 
blinded to any prior information. In particular, percentages of positive malignant and 
tumor-infiltrating immune cells were evaluated in total tumor and peritumoral areas 
in each punch. Intensity of staining on malignant cells was also analyzed and samples 
were classified as negative (0), weakly positive (1), moderately positive (2) and 
strongly positive (3). Tumor cells were scored positive if they displayed at least 
intensity 2 staining. Positivity cut-off for tumor-infiltrating immune cells was 20% 
regardless of staining intensity.  
 
3.2 CD40 ligand-expressing recombinant Vaccinia Virus (rVV40L) 
rVV40L was generated as previously described (Feder-Mengus et al. 2015). In order 
to avoid the cytopathic/lytic effect of replicating virus and focus on the effect of the 
transgene expression, viral replication was inactivated by DNA cross-linking by 
using psoralen (1 μg/ml) and long-wave UV (365nm) irradiation (Feder-Mengus et 
al. 2015).  
 
3.3 Established tumor cell lines 
Established melanoma (A375), hepatocellular carcinoma (PLC, HepG2 and HuH-7), 
colorectal (HCT116, LS180 and HT29) and breast (MDA-231 and BT-474) cancer 
cell lines were purchased from European Collection of Cell Cultures (ECACC). Na-
8 melanoma cell line was a gift from Dr.Jotereau (Nantes, France). Breast and 
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colorectal cancer cell lines were cultured in RPMI-1640 CM supplemented with 1% 
GlutaMAX-I, 1% non-essential amino acids (NEAA), 1% sodium pyruvate, HEPES, 
1% Kanamycin Sulfate (Gibco-Life Technologies), thereafter referred to as complete 
medium (CM) and 10% FBS. Melanoma and hepatocellular carcinoma, HepG2 and 
HuH-7 cells, were cultured in D-MEM CM 10% FBS. PLC cells were cultured in 
ALPHA-MEM supplemented with 10% FBS. When specific established tumor cell 
lines were required for indicated experiments, early passage cells were thawed and 
maintained in culture forless than 2 months. 
 
3.4 In vitro generation of CD14+ derived macrophages 
CD14+ monocytes were isolated from peripheral blood mononuclear cells (PBMCs) 
from healthy donors to a > 95% purity by using anti-CD14 magnetic beads (Miltenyi 
Biotech). Magnetically isolated cells were cultured in RPMI-CM and 10% FBS in 
presence of 12,5 ng/ml GM-CSF (R&D System) to generate M1 macrophages or 
MCSF (R&D System) for M2 macrophages. On day 6, cells were collected and 
stained with anti-CD16, anti-CD163, anti-CD204 and anti-CD40R receptor specific, 
fluorochrome-conjugated mAbs. 
 
3.5 CD40 triggering on tumor cells 
Tumor cell lines were left untreated, infected with rVV40L or with vaccinia virus 
wild type (VV WT) at 10 multiplicity of infection (MOI). Furthermore, established 
tumor cell lines were also treated with soluble CD40L (s40L; 0,5 μg/ml; Enzo 
Lifescience) recombinant protein alone or following VV WT infection (WT+s40L). 
After 4 days, tumor cells from different culture conditions were collected and their 
viability was assessed by Annexin V apoptosis detection kit (Becton Dickson) 
according to the manufacturer's instructions. In brief, the cells were washed twice 
with cold PBS and then resuspended in the binding buffer at 1 x 106 cell/ml 
concentration. 100 µl of this solution (1 x 105 cells) were stained with 5 µl of 
Annexin V antibody plus 5 µl PI (ready-to-use solutions), then incubated for 15 min 
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at room temperature in the dark. Finally, the cells were diluted with 400 µl of the 
binding buffer and analyzed by flow cytometry. 
 
3.6 Activation of CD14+ monocytes and macrophages differentiation 
CD14+ monocytes obtained from peripheral blood of healthy donors were left 
untreated or infected in 500 µl RPMI-1640 CM 10% FBS for 1 hour at 37°C with 
rVV40L or with VV WT at MOI of 5. In addition, CD14+ monocytes were also 
treated with s40L (0,5 μg/ml) alone or following VV WT infection (WT+s40L). 
CD14+ monocytes were then cultured in RPMI-1640 CM 10% FBS in presence of 
either GM-CSF or M-CSF (see above). At indicated time points, supernatants from 
different culture conditions were collected and cytokine release was assessed by 
ELISA. 
 
3.7 Co-culture of M1 and M2 macrophages with established tumor cell 
lines 
LS180 and HuH-7 established tumor cell lines were left untreated or infected with 
rVV40L or with VV WT at 10 MOI. After 24 hours, 3000 untreated and VV WT or 
rVV40L-infected tumor cells were cultured alone or in presence of M1 or M2 
macrophages at different effector: target ratios in 96 well-plates. On day 4, cytokines 
and chemokine released in supernatants from different culture conditions were 
evaluated by ELISA. Cytostatic activity of M1 and M2 macrophages on tumor cells 
was evaluated by adding 1µCi of 3H-thymidine for the last 18 hours of culture. Cells 
were then harvested and tracer incorporation was measured by scintillation counting. 
TNF-α neutralization was achieved by adding to cultures anti-human TNF-α mAb 
(BioLegend) at 10 μg/ml final concentration. 
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3.8 Cross-presentation assays 
Generation of MelanA/Mart-127-35 specific HLA-A0201 restricted CD8+ T cell 
clones was described previously (Mariotti and Nisini 2009). 3000 cells from CD40 
(-) HLA-A0201(-) HT29 cell line were left untreated or infected with VV WT or 
rVV40L and co-infected with a recombinant vaccinia virus encoding MART-1 full 
gene, inducing the production of the entire protein in infected cells at MOI of 10. 
After 24 hours, differentially infected HT29 cells were cultured alone or in presence 
of HLA-A0201 (+) M1 or M2 macrophages at 1:1 ratio. Two days later, 30.000 cells 
of a MelanA/Mart-127-35 specific, HLA-A0201 restricted, CD8+ T cell clone were 
added to the different culture conditions. After 48 hours, the release of IFN-γ in the 
supernatants was assessed by ELISA. 
 
3.9 Migration assay 
Migration of CD8+ T cells towards supernatants from co-cultures of M1 
macrophages and tumor cells was assessed in 96 well trans-well plates (5μm pore 
size; Corning Costars) upon 60 min culture at 37°C. When indicated, anti-CXCL10 
antibody (10 μg/ml; R&D System) was also added to culture supernatants. Cell 
migration was quantified by flow-cytometry. 
 
3. 10 In vivo experiments 
In vivo experiments were approved by Basel Cantonal Veterinary Office (License 
Number 2266). NSG mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) from Charles 
River Laboratories, were bred and maintained under specific pathogen-free 
conditions in the animal facility of Department of Biomedicine, University of Basel. 
Eight-ten week old mice were injected subcutaneously (s.c.) in the flank with tumor 
cells (105 cells/mouse), resuspended in 1:1 growth factor reduced Matrigel (BD 
Biosciences) / PBS solution. Tumor formation was monitored twice weekly by 
palpation and caliper measurements. Once tumor masses reached an approximate 
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diameter of 5 mm (1 x 106 tumor cells), 20μl of virus solution (107 eq. pfu of VV 
WT or rVV40L) or PBS were injected in the tumor tissues. After 48 hours PBS or 5 
x 105 M1 or M2 macrophages were also injected intratumorally. Tumor size changes 
were followed every day by caliper measurements. One week after, all mice were 
sacrificed and tumors were harvested. Tumor volumes (in mm3) were determined 
according to the formula (length x width2)/2. Samples from all tissues were 
harvested for subsequent histological examination. 
 
3.11 Gene expression analysis 
Total cellular RNA was extracted by using the RNeasyVR Mini Kit (Qiagen) and 
reverse transcribed according to the manufacturer’s instructions (Invitrogen-Life 
Technologies). Human TRAF-1 and NORE1A (RASSF5) gene expression were 
evaluated by quantitative RT-PCR (qRT-PCR) using specific primer sets (TaqMan® 
Assays, Applied Biosystems-Life Technologies) and normalized to human 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping gene 
expression. Expression of genes displaying a delta to reference gene >13Ct were 
considered. 
 
3.12 Flow cytometry 
Fluorochrome-labeled monoclonal antibodies (mAbs) recognizing CD163, CD204, 
CD154 (CD40L), CD3, CD4, CD8, CD45RO, CD62L, CD183 (CXCR3) and HLA-
A0201 were obtained from Becton Dickinson. A mAb recognizing CD16 was 
obtained from BioLegend whereas a mAb recognizing CD40 receptor (Clone 5C3) 
was obtained from eBioscience. Viability of tumor cells was measured by Annexin 
V apoptosis detection kit (Becton Dickson). Signals derived from mAbs and 
fluorochrome-conjugated annexin by exposure of phosphatidylserine and 
incorporation of propidium iodide (PI) were evaluated by flow cytometry 
(FACScalibur; Becton Dickinson). Data were analyzed by FlowJo software (Tree 
Star). 
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3.14 ELISA 
Interleukin-10 (IL-10), interleukin-12 (IL-12p70) and interferon-γ (IFN-γ) release in 
culture supernatants was measured by using ELISA kits (Becton Dickinson). Tumor 
Necrosis Factor-α (TNF-α) release was measured by using an ELISA kit from 
BioLegend, whereas C-X-C motif chemokine 10 (CXCL10, IP-10) release was 
evaluated by using a kit from R&D System.  
 
3.15 Histological evaluation 
Cryo-sections embedded in OCT compound (Leica) were cut (10μm) from each 
tumor and fixed in formalin. Sections were either stained for Hematoxylin and Eosin 
using a Continuous Linear Stainer COT 20 (Medite) or incubated with rabbit anti-
cleaved caspase 3 (Cell Signalling), followed by secondary species-specific Alexa 
Fluor 488-conjugated antibody (Invitrogen) and DAPI for nuclei counterstaining. 
Sections were examined with a Nikon TI fluorescence microscope (Nikon 
Switzerland) and images captured with 20x magnification using a digital camera and 
NIS-Elements software. 
 
3.16 Statistical analysis 
Statistical analysis software SPSS (Version 14.0, SPSS Inc) was used for statistical 
analyses. Skewness, Kurtosis distribution parameters and respective standard errors 
were used to test normality of the concerned populations. Mann-Whitney was used 
for non-parametric tests, with non-Gaussian distribution of the test population. All 
reported P-values were considered to be statistically significant at P ≤ 0.05. 
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4. Results 
 
4.1 CD40 receptor expression in clinical tumor specimens 
CD40R has been reported to be expressed in nearly all B cell malignancies and 
approximately 70% of solid tumors (Vonderheide 2007). Triggering of CD40R 
expressed on surfaces of transformed cells has been associated to pro-survival effects 
or to inhibition of proliferation and/or apoptosis induction (Banchereau et al 1994; 
Elgueta et al. 2009). We initially evaluated CD40 expression in a TMA including 
836 tumor specimens of 27 different histological origins, focusing on both malignant 
and tumor-infiltrating immune cells. Representative examples of CD40-specific 
staining are reported in Figure 5A. 
CD40 expression was detectable in >15% of cases in breast and lung cancers 
subtypes, hepatocellular carcinoma (HCC) and esophageal cancers. Lower 
percentages of positive cases were observed in ovarian cancers, mesothelioma, 
gastrointestinal (GI) tract malignancies and head and neck cancers. In contrast, CD40 
expression was virtually undetectable in prostate and pancreatic cancers (Figure 5B). 
Differential analysis in clinical specimens revealed that CD40 expression, in ≥ 5% 
malignant cells, was only observed in limited numbers of cancer types including 
medullary breast carcinoma (20%) and subtypes of ovarian and lung cancers (5-10%) 
(Figure 5C). In contrast, in a wide range of malignant tissues, CD40 expression was 
usually detectable in significantly higher percentages of infiltrating immune cells, 
except in endometroid ovarian carcinoma. 
Taken together, TMA data underline that CD40R might serve as therapeutic target 
for different cell types present in the tumor microenvironment, and predominantly in 
tumor-infiltrating immune cells in sizeable percentages of cancers of high 
epidemiological relevance. 
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Figure 5. Evaluation of CD40R expression in clinical specimens. (A) Representative 
examples of CD40R-specific positive and negative staining. (B) Cumulative results of 
CD40R expression in tumor specimens included in the TMA. (C) CD40R expression on 
tumor and infiltrating immune cells was differentially analyzed in clinical samples derived 
from breast, ovarian and lung cancers. 
 
4.2 rVV40L infection induces apoptosis of CD40(+) tumor cell lines 
TMA data prompted us to first evaluate the biological responses induced by 
replication incompetent rVV40L infection in a panel of CD40(+) and CD40(-) 
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established tumor cell lines. In particular, CD40(+) Na8 melanoma, HCT116 
colorectal cancer, MDA-231 breast cancer, PLC and HepG2 (CD40DIM) 
hepatocellular carcinoma cell lines were tested. We also investigated cell lines of the 
same histological origin (A375, BT-474, LS180 and HuH-7) with undetectable 
expression of CD40R at mRNA and protein level (Figure 6A, B). 
 
 
Figure 6. Characterization of established tumor cell lines. (A) Expression of CD40R 
(shaded histograms), as compared to isotype control reagents (open histograms) was 
evaluated on indicated cell lines by flow cytometry analysis. (B) CD40R expression was 
also evaluated by qRT-PCR and normalized in comparison to GAPDH in all established 
tumor cell lines. (C) Tumor cells from different cell lines were left untreated or infected with 
rVV40L or VV WT at MOI 10. Different cell lines were also treated with soluble CD40L 
recombinant protein (s40L; 0.5 μg/ml) alone or following VV WT infection (WT+s40L). 
After 24h of culture, untreated and differentially treated cells were collected and stained with 
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anti-CD154 (CD40L) fluorochrome-labeled mAbs. Data are reported as mean + SEM (n:5). 
*p<0.05, **p<0.01; Mann-Whitney nonparametric test. 
 
Expectably, rVV40L infection of tumor cells, regardless of their histological origin 
and CD40R status, resulted in significant expression of CD40L on cell surfaces 
(Figure 6C). 
Importantly, rVV40L infection of CD40(+) Na8 melanoma (Figure 7A), MDA-231 
breast (Figure 7B) and PLC hepatocellular carcinoma cell line (Figure 7D) resulted 
in significant increases of percentages of apoptotic cells, as compared to control 
cultures. In contrast, s40L-stimulation of the same tumor cell lines was totally 
ineffective (Fig. 7A, B, D). Surprisingly however, ligation of CD40R expressed on 
cellular surfaces of HCT116 colorectal cancer cells did not impact on their survival 
(Fig. 7C). As expected, both rVV40L infection and s40L-treatment failed to induce 
apoptosis in CD40(-) cell lines. 
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Figure 7. CD40L-expressing recombinant vaccinia virus but not s40L treatment 
induces cytotoxic effects on CD40(+) tumor cells in ‘vitro’. Established tumor cell lines 
from (A) melanoma (Na8 and A375), (B) breast cancer (MDA-231 and BT-474), (C) 
colorectal cancer (HCT116 and LS180) and (D) hepatocellular carcinoma (PLC, HepG2 and 
HuH-7) were left untreated or infected with CD40L-expressing recombinant vaccinia virus 
(rVV40L) or vaccinia virus wild type (VV WT) at MOI of 10. Tumor cells were also treated 
with soluble CD40L recombinant protein (s40L; 0.5 μg/ml) alone or following VV WT 
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infection (VV WT). At day 4, cells were collected and stained with annexin V and propidium 
iodide (PI). (A, B, C and D) Data are referred to a representative experiment for each 
established tumor cell line (upper panels) and report collective results (mean +/- SEM) from 
five different experiments (lower panels). *p<0.05, **p<0.01; Mann-Whitney 
nonparametric test. 
 
4.3 Impaired CD40 signaling pathway is associated with tumor cell 
resistance to rVV40L induced apoptosis 
CD40R ligation has been shown to result in receptor clustering, inducing in turn 
recruitment to its cytoplasmic domain of TNF receptor-associated factors (TRAFs), 
mediating intracellular signaling (Banchereau et al 1994). However, only TRAF-1 is 
regulated at transcription level in response to CD40R ligation and initiates signaling 
cascades leading to cell death (Elmetwali et al. 2010). Furthermore, cytotoxic effects 
on tumor cells elicited by CD40R ligation have been recently reported to result in 
upregulation of NORE1A protein mediating proapoptotic JNK pathway and caspase 
activation inducing apoptosis of target cells (Elmetwali et al. 2016). 
Thus, we investigated CD40R signaling in HCT116 cells using TRAF-1 and 
NORE1A expression as downstream markers. 
As expected, in apoptosis-responsive CD40(+) Na8 and MDA-231 cells, a 
significant upregulation of TRAF-1 gene expression was observed upon rVV40L 
infection whereas s40L, alone or in combination with VV WT, was ineffective 
(Figure 8A, B, D). A similar trend (p=0.0671) was also observed in PLC CD40(+) 
hepatocellular carcinoma cells. In sharp contrast, triggering of CD40R expressed on 
cellular surfaces of HCT116 did not result in upregulation of TRAF-1 gene 
expression levels (Figure 8C). 
Similarly, gene expression level of NORE1A was clearly increased following 
rVV40L infection but not s40L or WT+s40L treatment, only in ‘sensitive’ CD40(+) 
PLC but not in ‘insensitive’ CD40(+) HCT116 cells (Figure 8E). 
These data underline that rVV40L, but not s40L treatment, might induce apoptosis 
upon infection. However, our results indicate that CD40 expression is not ‘per se’ 
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predictive of sensitivity to rVV40L cytotoxic effects and induction of functional 
adapter proteins is required for apoptosis induction (Elmetwali et al. 2010; Elmetwali 
et al. 2016). 
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Figure 8. Impaired CD40 signaling pathway is associated with a reduced tumor cell 
cytotoxicity following rVV40L infection. Established melanoma (Na8 and A375) (A), 
breast cancer (MDA-231 and BT-474) (B), colorectal cancer (HCT116 and LS180) (C) and 
hepatocellular carcinoma (PLC, HepG2 and HuH-7) (D) cell lines were treated as indicated. 
After 4 days, TRAF-1 gene expression was evaluated by qRT-PCR. HCT116 (CD40+) 
colorectal cancer and PLC (CD40+) hepatocellular carcinoma cell lines were treated as 
described and NORE1A gene expression was assessed by qRT-PCR (E). Data are expressed 
as fold increase, as compared to untreated tumor cells. (n=5 A, B, C, D and n=3 E). *p<0.05, 
**p<0.01; Mann-Whitney nonparametric test. 
 
4.4 Modulation of M1/M2 functional profiles by rVV40L infection 
TMA data underline the relevant expression of CD40 in tumor-infiltrating immune 
cells. A potential role of tumor-associated macrophages in the control of tumor 
progression has been repeatedly reported. A key feature of macrophages is 
represented by their high plasticity. Indeed, M1/M2 macrophages may represent 
extremes of a continuum of differentiation states, characterized by specific 
functional attributes (Mantovani et al. 2002; Sica and Mantovani 2012). Therefore, 
we addressed the possibility that targeting CD40 might condition in vitro 
differentiation of CD14+ monocytes towards M1/M2 functional profiles. 
We generated M1 and M2 CD14-derived macrophages by culturing CD14+ 
monocytes in presence of GM-CSF (M1) or M-CSF (M2) (Nebiker et al. 2014). 
Phenotypic characterization of M1 and M2 CD14-derived macrophages confirmed a 
significantly higher expression of CD16 and reduced level of CD163 and CD204 on 
M1 as compared to M2 macrophages (Nebiker et al. 2014, Ruffell and Coussens 
2015) (Figure 9A, B).  
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Figure 9. Phenotypic profile of in vitro generated GM-CSF (M1) and M-CSF (M2), 
CD14+ monocyte-derived macrophages. CD14+ monocytes magnetically isolated from 
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peripheral blood of healthy donors were cultured in presence of GM-CSF (12,5 ng/ml) or 
M-CSF (12,5 ng/ml). At day 6, cells were harvested and phenotypic profiles and cytokine 
gene expression patterns were evaluated by flow cytometry analysis and qRT-PCR, 
respectively. (A+B) Expression of CD16 (% and MFI), CD163 (MFI) and CD204 (MFI) 
surfaces antigens on GM-CSF (M1) and M-CSF (M2) CD14-derived macrophages. (C) In 
addition, expression level of IL-6 and IL-10 genes was also evaluated on GM-CSF (M1) and 
M-CSF (M2) conditioned macrophages Data are referred to representative (A) experiments 
and display cumulative results from eight independent experiments (B+C). *p<0.05, 
**p<0.01; Mann-Whitney nonparametric test. 
 
Accordingly, analysis of cytokine gene pattern profiles revealed a significant IL-6 
gene expression in M1 macrophages whereas IL-10 gene expression was higher in 
M2 macrophages (Figure 9C). Notably, we also observed a significantly higher 
expression of CD40R in M1, as compared to M2, CD14-derived macrophages 
(Figure 10A). 
At difference with sCD40L treatment alone or in combination with WT infection, 
rVV40L infection promoted a significant IL-12 production by CD14+ monocytes 
cultured in presence of GM-CSF. Moreover, unexpectedly, rVV40L infection also 
induced detectable IL-12p70 release by M2 macrophages. On the other hand, IL-10 
production was induced in M2 by sCD40L treatment alone or in combination with 
WT infection, but not by rVV40L (Figure 10B). 
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Figure 10. rVV40L modulates functional profile of M1/M2 CD14-derived 
macrophages. (A) Expression of CD40, on surfaces of CD14+ cell-derived M1 or M2 
macrophages, was evaluated by flow cytometry. (B) M1/M2 cells were infected with VV 
WT or rVV40L (MOI 5) or cultured in presence s40L alone or following VV WT infection 
(WT+s40L). On day 2, 4 and 6 of culture supernatants were collected and IL-12p70 and IL-
10 release was evaluated by ELISA. (C) M1 and M2 macrophages were co-cultured (1:1 
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ratio) with LS180 CRC cells infected with VV WT or rVV40L (MOI 10). After 4 days, 
supernatants were collected and TNF-α, IL-12p70, IL-6 and IL-10 release was evaluated by 
ELISA. (D) M1 (GM-CSF) and M2 (M-CSF) macrophages were co-cultured with LS180 
CRC cells, treated as described above, at the indicated ratios. On day 4, proliferation of 
LS180 CRC cells was evaluated by 3H-thymidine incorporation and expressed as percentage 
of proliferation as compared to untreated tumor cells. (E) Proliferative capacity of LS180 
CRC cells, treated as described in C+D, co-cultured with M1 and M2 macrophages, as 
evaluated by 3H-thymidine incorporation in presence of anti-TNF-α at 10 μg/ml 
concentration. Data are referred to cumulative results from eight (A) or four (B, C, D, E) 
independent experiments. *p<0.05, **p<0.01; Mann-Whitney nonparametric test. 
 
These data prompted us to further evaluate the relevance of CD40R ligation in the 
modulation of effector functions of fully in vitro differentiated M1 or M2 
macrophages. We analyzed cytokine production pattern of polarized macrophages 
upon co-culture with untreated, VV WT or rVV40L-infected CD40(-) HuH-7 HCC 
and LS180 CRC cells. In these conditions, TNF-α production was only detectable 
following CD40R ligation in M1 differentiated macrophages. CD40R ligation also 
induced IL-12p70 and IL-6 production in M1 cells. Interestingly, IL-12p70 and IL-
6 release by M2 cells, albeit to lower extents, was detected following CD40R 
ligation. Induction of IL-10 production was observed in M2 macrophages only upon 
co-culture with rVV40L-infected HuH-7 (Figure 11A), but not LS180 cells (Figure 
10C). These data indicate that CD40R is functional in both M1 and M2 macrophages 
and suggest that its ligation might partially steer M2 cells towards M1-like functional 
profile. 
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Figure 11. rVV40L-infected HuH7 HCC promote the activation of M1/M2 
macrophages. (A) M1 and M2 CD14+ monocyte-derived macrophages were co-cultured at 
1:1 ratio with Huh7 hepatocellular carcinoma (HCC) cells left untreated or infected with VV 
WT or rVV40L at MOI of 10. After 4 days, supernatants from different culture conditions 
were collected and TNF-α, IL-12p70, IL-6 and IL-10 release was evaluated by ELISA (B) 
M1 (GM-CSF) and M2 (M-CSF) CD14+ monocyte-derived macrophages were co-cultured 
with LS180 CRC cells, treated as described above, at indicated ratios in flat bottom 96 well 
plates in quadruplicates. On day 4, Huh7 HCC cell proliferation was evaluated by 3H-
thymidine incorporation and expressed as percentage of proliferation, as compared to tumor 
cells cultured alone. (C) Proliferative capacity of Huh7 cells, treated as described in C+D, 
and co-cultured with M1 and M2 macrophages was also evaluated by 3H-thymidine 
incorporation in the presence of anti-TNF-α antibodies at 10 μg/ml concentration. Data refer 
to cumulative results from four independent experiments. *p<0.05, **p<0.01; Mann-
Whitney nonparametric test. 
 
Consistently with their TNF-α production, M1, but not M2, macrophages displayed 
significant cytostatic activity on rVV40L-infected LS180 CRC (Figure 10D) and 
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HuH-7 HCC established tumor cell lines (Figure 11B). Although macrophages could 
generate a variety of cytotoxic/cytostatic mediators, the pivotal role of TNF-α was 
confirmed by its neutralization resulting in significant inhibition of antiproliferative 
effects of CD40R-stimulated M1 cells on rVV40L-infected tumor cells (Figure 10E 
and Figure 11C). 
 
4.5 CD40 receptor-stimulated M1 and M2 macrophages promote the 
recruitment of CD8+ T cells 
In a variety of solid tumors, high infiltration by CD8+ T cells is associated with 
favorable prognosis. Thus, their recruitment may represent a critical step in the 
elicitation of antitumor immune responses (Fridman et al. 2011; Fridman et al. 2012; 
Fridman et al. 2013; Fridman et al. 2017). 
CXCR3 chemokine receptor is expressed in CD8+ lymphocytes, and, preferentially 
in “central memory” T cells, characterized by strong antitumor potential (Klebanoff 
et al. 2006; Trella et al. 2016) (Figure 12A). CXCR3 ligands include CXCL9, 
CXCL10 and CXCL11. A main role in CD8+ T cells recruitment has been attributed 
to CXCL10 (Yue et al. 2015). 
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Figure 12. CXCR3 expression on immune cells and M1/M2 cross-presentation of 
cellular antigens. (A) CXCR3 expression on naïve and memory CD8+ T lymphocytes 
subsets, as according to CD45RO and CD62L surface marker expression. (B) Phenotypes 
characterization of the HLA-A0201 restricted, MelanA/MART-127-35-specific CD8+ T cell 
clone (left) and HLA-A0201- CD40(-) HT29 CRC cell lines were used (right ) used in cross-
presentation assay. (C) IFN-γ release in the supernatant from the indicated control conditions 
of the cross-presentation assay. 
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We tested CXCL10 release in supernatants of co-cultures of M1 or M2 macrophages 
and LS180 CRC and HuH-7 HCC cell lines. As depicted in Figure 13A, rVV40L but 
not VV WT infection of tumor cells, resulted in significant increases of CXCL10 
production by both M1 and M2 macrophages. 
Migration assays were performed to formally prove the ability of CD40R-stimulated 
M1 and M2 macrophages to promote CXCL10-mediated CD8+ T cell recruitment. 
Supernatants from macrophages, CD40L-stimulated as described above, induced the 
migration of CD8+ T cells to significantly higher extents, as compared to control 
supernatants. Importantly, antibody-mediated CXCL10 depletion from these 
supernatants, abrogates CD8+ T cells migration (Figure 13B), confirming its crucial 
significance in lymphocyte recruitment. 
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Figure 13. rVV40L induces CXCL10-mediated recruitment of CD8+ T cells and 
promotes cross-presentation of tumor-associated antigens by M1 macrophages. 
(A) M1 or M2 macrophages were co-cultured at 1:1 ratio with LS180 CRC (upper 
panel) or HuH-7 HCC (lower panel) cell lines untreated or infected with VV WT or 
rVV40L at MOI 10. After 4 days, supernatants were collected and CXCL10 release 
was evaluated by ELISA. (B) CD8+ T cell migration, induced by supernatants from 
co-cultures of M1/M2 macrophages with differentially infected tumor cells, as 
evaluated by flow cytometry. (C) Cross-presentation of MelanA/Mart-127-35 epitope 
from HLAA0201(-) CD40(-) HT29 CRC cell lines co-infected with VV WT or 
Results 
 
154 
rVV40L and with a rVV encoding MelanA/MART-1 full gene (rVVMART1 FG). 
After 24h, HT29 were co-cultured, at 1:1 ratio, with HLA-A0201+ M1 or M2 
macrophages. After 48 additional hours, 20.000 HLA-A0201 restricted CD8+ T cells 
were added to the cultures and concentration of IFN-γ release was evaluated by 
ELISA two days later. *p<0.05; Mann-Whitney nonparametric test. 
 
4.6 rVV40L promotes M1-mediated cross-presentation of tumor-
associated antigens (TAAs) to CD8+ T cells 
Macrophages have been shown to be able to cross-present antigens derived from 
apoptotic cells to specific T cells (Heath and Carbone 2001). Cross-presentation-
based vaccination strategies have shown promising results for cancer treatment 
(Zwaveling et al. 2002; Melief 2008). Therefore, we evaluated the capacity of 
rVV40L-stimulated macrophages to promote the activation of tumor-reactive CD8+ 
T cells through cross-presentation of cellular antigens. 
HLA-A0201(-) CD40(-) HT29 CRC cells (Figure 12B) were co-infected with 
rVV40L and a recombinant vaccinia virus expressing MelanA/MART-1 full gene 
(rVVMART-1 FG). HT29 CRC cells were then co-cultured with HLA-0201(+) M1 
or M2 macrophages and, after 4 days, the ability of macrophages to cross-present 
MART-127-35 HLA-A0201 restricted epitope was evaluated by measuring IFN-γ 
release by a specific CD8+ T cell clone (Figure 12B). The clone efficiently 
responded to presentation of the target peptide by M1, but not M2 antigen presenting 
cells, or to antibody-mediated CD3 triggering (Figure 12C left panel). Most 
importantly, our data clearly indicate that priming of HLA-A0201(+) M1 
macrophages by rVV40L-infected HLA-A0201- tumor cells resulted in significantly 
enhanced activation of MART-127-35-reactive CD8+ T cells, as compared to control 
culture conditions (Figure 13C). On the other hand, as expectable, HLA-A0201(-) 
tumor cells infected by the reagents under investigation, were unable “per se” to 
induce IFN-γ production in macrophages alone or in CTL alone (Figure 13C right 
panel). 
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4.7 rVV40L promotes in vivo tumor regression through macrophage 
activation 
To address antitumor efficacy of rVV40L in vivo, NSG immunodeficient mice were 
subcutaneously inoculated with LS180 CRC and HuH-7 HCC cells. Upon 
development, tumors were first injected with replication incompetent VV WT or 
rVV40L followed, after 48 hours, by human M1 or M2 macrophages. 
Control and VV WT-infected tumors rapidly and similarly progressed in the 
presence or absence of M1 or M2 cells (Figure 14A-F). In sharp contrast, consistently 
with in vitro observations, rVV40L infection of HuH-7 HCC and LS180 CRC 
resulted in a complete inhibition of tumor progression upon intratumor injection of 
M1 cells (Figure 14B and E). Similar effects were also observed upon injection of 
the positive control LPS-stimulated M1 cells (data not shown). Injection of M2 also 
resulted in a modest nonsignificant inhibition of LS180 CRC tumor progression 
(Figure 14F). 
Remarkably, histological analysis of excised tumors clearly revealed that rVV40L-
mediated activation of M1 macrophages resulted in a significant disruption of tumor 
tissues, comparably to LPS-stimulated M1 macrophages (Figure 14G-H). 
Consistently, immunofluorescence studies provided evidence of significant caspase 
3 cleavages in these tumors (Figure 14G-H). 
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Figure 14. rVV40L promotes antitumor activity of M1 macrophages in vivo. 105 LS180 
CRC or HuH-7 HCC cells were inoculated subcutaneously (s.c.) into the flanks of NSG 
mice. Established tumors were then injected with PBS or 107 pfu of replication incompetent 
VV WT or rVV40L. 48 hours later, 5*105 M1 or M2 macrophages were injected in the tumor 
masses. Tumor volume of LS180 (A-C) and Huh7 (B-F) is expressed as fold increases, as 
compared to tumor volumes measured at the time of macrophage inoculation. Data refer to 
two independent experiments with 3 mice in each condition. On day 8, mice were sacrificed 
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and histology (H&E) and cleaved Caspase 3 expression (green) were evaluated in LS180 
(G) and HuH-7 (H) tumors. Data are referred to representative stainings out of two tumors 
per condition displaying similar results (Magnification 20x; scale bar 100μm). 
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5. Discussion 
 
Due to a peculiar expression pattern and multifunctional potential, CD40 represents 
an important target for the development of innovative cancer immunotherapy 
protocols (Vonderheide 2007; Loskog et al. 2016). 
Administration of agonistic anti-CD40R mAbs and CD154 (CD40L)-expressing 
recombinant adenovirus has been shown to result in tumor regression in 
experimental models (Ullenhag and Loskog 2012; Vonderheide et al. 2013). These 
effects have initially been largely attributed to CD40-mediated-APC licensing and 
activation of T cell-mediated antitumor immune responses (Ridge et al. 1998). 
However, data from clinical studies in human pancreatic cancers, typically lacking 
T cell infiltration, suggest that elicitation of antitumor effects of therapeutic anti-
CD40R agonistic mAbs might rather rely on macrophage activation (Beatty et al. 
2011; Beatty et al. 2013; Vonderheide et al. 2013). 
Notably however, effectiveness of CD40R-targeting strategies developed so far 
appears to be limited. In particular, CD40 expression by tumor-infiltrating immune 
cells does not effectively predict responsiveness to agonistic anti-CD40R mAbs 
(Beatty et al. 2011; Beatty et al. 2013). 
Furthermore, epitope specificity and isotype might critically affect the activity of 
therapeutic reagents (Vonderheide and Glennie 2013; Richman and Vonderheide 
2014). 
 
Regarding CD40L recombinant adenovirus, while safety has been reported, 
convincing evidence of clinical efficacy is still missing (Malmström et al. 2010; 
Hangalapura et al. 2012; Loskog et al. 2016). Potential limitations of adenovirus-
mediated gene transfer approach might be associated to the requirement of specific 
cell entry pathways and of the administration of high viral titers (Malmström et al. 
2010; Hangalapura et al. 2012; Loskog et al. 2016). 
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In order to develop a multipotent anticancer biological, we generated a replication 
incompetent CD40L-expressing recombinant vaccinia virus (rVV40L) targeting 
multiple functional aspects of tumor-immune system interaction and tested its 
antitumor effects in vitro and in vivo. In particular, we addressed the ability of 
rVV40L to promote direct CD40(+) tumor cell apoptosis, to modulate functional 
profiles of differentially polarized macrophages, to recruit immune cell populations 
of proven anticancer relevance, and to inhibit tumor progression in vivo. 
Evaluation of CD40 expression in a large cohort of clinical specimens (n: 836) 
derived from different tumor types (n: 27) indicates that, with some exceptions, 
CD40 is expressed on cellular surface of transformed cells in limited percentages of 
tumors included in a TMA. Instead, CD40 expression was often detectable in 
infiltrating immune cells in a majority of malignant tissues analyzed. This 
observation, further underlines that the effectiveness of CD40-based therapeutic 
strategies should focus on immune infiltrating cells in addition to direct 
cytostatic/cytotoxic effects on CD40(+) malignant cells. 
rVV40L infection but not soluble CD40L recombinant protein treatment (s40L), 
resulted in cytotoxic effects on CD40(+) melanoma, hepatocellular carcinoma and 
breast cancer tumor cell lines. In line with previous reports (Elmetwali et al. 2010; 
Elmetwali et al. 2016), our data underline the different biological properties of 
membrane-bound CD40L as compared to its soluble counterparts. Additional 
limitations of therapeutic strategies targeting CD40R on cancer cell surfaces should 
also be considered (Elmetwali et al. 2010; Ullenhag and Loskog 2012; Vonderheide 
and Glennie 2013; Elmetwali et al. 2016). Indeed, CD40 expression cannot be 
considered a sufficient signature predicting the effectiveness of “direct” strategies, 
since lack of cytotoxic effects, following receptor ligation on malignant cells, may 
correlate with impaired intracellular signaling. Thus, TRAFs adapter molecules 
alterations and defective activation of effector proteins may result in defective 
triggering of apoptosis induced by CD40 binding (Elmetwali et al. 2010; Elmetwali 
et al. 2016). 
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Tumor microenvironment (TME) includes, in addition to malignant cells, a variety 
of different non-transformed cell types exerting a major impact on clinical course 
(Fridman et al. 2011; Fridman et al. 2012; Fridman et al. 2013). 
Initial evidence suggested antitumor activity of macrophages based on their capacity 
to mediate elimination of transformed cells and to promote in situ adaptive tumor-
reactive immune responses (Fidler and Poste 1982). This interpretation has 
subsequently been largely challenged since different pro-tumorigenic functions, such 
as supporting tumor-associated angiogenesis, proliferation of malignant cells and 
suppression of antitumor T cell responses have been convincingly demonstrated in 
experimental models (Bingle et al. 2002; Pollard 2004; Biswas et al. 2006; 
Mantovani and Sica 2010; Qian and Pollard 2010; Biswas et al. 2013; Noy and 
Pollard 2014). 
Furthermore, clinical evidence underlines that in a majority of human tumors, high 
macrophage infiltration is frequently associated with severe prognosis (Bingle et al. 
2002; Pollard 2004; Biswas et al. 2006; Mantovani and Sica 2010; Qian and Pollard 
2010; Biswas et al. 2013; Noy and Pollard 2014). 
Thus, macrophage infiltrate emerges as a critical target of antitumor therapeutic 
strategies and the clinical potential of mAbs neutralizing CCL2 (Sandhu et al. 2013) 
and M-CSF (Cassier et al. 2015) receptor is currently being evaluated in specific 
clinical trials. These strategies point to the prevention of recruitment and 
differentiation of macrophages (Qian and Pollard 2010; Sandhu et al. 2013; Cassier 
et al. 2015). Alternative approaches focus on re-conditioning of tumor-infiltrating 
macrophages through the modulation of their functional activity (Beatty et al. 2011; 
Beatty et al. 2013; Vonderheide et al. 2013) by exogenous signals enhancing their 
antitumor activity (Beatty 2013; Ruffell and Coussens 2015; Mills et al. 2016). 
 
Therefore, we evaluated the ability of rVV40L to steer, upon infection of tumor cells, 
functional profiles of M1 and M2 polarized macrophages into antitumor properties. 
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In vitro, co-culture with rVV40L-infected tumor cells resulted in a significant 
production of TNF-α by M1 but not M2 macrophages. More importantly, TNF-α 
production appears to represent a critical mediator of cytostatic/cytotoxic activity 
exerted by CD40-activated M1 macrophages on malignant cells. 
 
Macrophages have been also shown to be able to orchestrate anticancer adaptive 
immune responses “in situ” (Mills et al. 2016). Several studies have underlined their 
capacity to mediate, through chemokines production, selective recruitment of 
defined immune cell subsets, such as CD8+ T cells, with a critical antitumor activity 
(Fridman et al. 2011; Fridman et al. 2012; Fridman et al. 2013) in malignant tissues 
(Qian and Pollard 2010; Panni et al. 2013). CXCL10 is a main mediator of CD8+ T 
lymphocyte recruitment (Yue et al. 2015) and, in our study, rVV40L driven CD40R-
stimulation resulted in a significant release of CXCL10 by both M1 and M2 polarized 
macrophages leading to effective migration of CD8+ T cells. 
The elicitation of CD8+ T cell immune responses is conditioned by cytokines 
produced by APC (Ridge et al. 1998; Mescher et al. 2006; Trella et al. 2016). 
Production of IL-12 or IL-10 has been associated to the ability of tumor-associated 
macrophages to promote or, respectively, inhibit adaptive anticancer T cell- 
mediated immune response (Mantovani and Sica 2010; Mills et al. 2016). Ligation 
of CD40R expressed on cellular surface of M1 macrophages significantly modulated 
their cytokine pattern profile. Interestingly, similar functional effects were also 
elicited in M2 macrophages, despite a significantly lower CD40 expression. 
In particular, triggering of CD40R resulted in robust production of IL-12 by M1 
macrophages and, more surprisingly, although to a lower extent, also by M2 
macrophages. Notably, CD40R-stimulated M2 macrophages did not show increased 
production of immunosuppressive IL-10 (Panni et al. 2013; Mills et al. 2016). Most 
importantly, our data underline that infection of tumor cells by rVV40L enhances 
M1-mediated cross-presentation of tumor-associated antigens to CD8+ T cells. 
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In vivo studies nicely reinforce our in vitro results. Indeed, we observed a significant 
inhibition in the progression of CD40(-) tumors upon rVV40L infection. In 
particular, exogenous administration of human M1 macrophages, induced massive 
destruction of tumor tissue mediated by cleaved-caspase 3 activation. Intriguingly, 
detectable, albeit not significant, effects were elicited by M2 macrophages. 
Considering the absence of overt toxic effects of macrophage administration in 
animals bearing rVV40L-infected tumors, and the replication incompetent nature of 
our reagent, these data may also suggest innovative adoptive cancer immunotherapy 
protocols, based on re-infusion of differentiated, patient-derived macrophages. 
 
Taken together, our data underline the major antitumor potential of a CD40L-
expressing recombinant vaccinia virus. Indeed, rVV40L infection might lead to 
direct inhibitory effects on CD40(+) malignant cells. In addition, inhibition of tumor 
progression could also result from the marked ability of rVV40L to promote M1 
activation and possibly from a partial re-education of M2 macrophages. Most 
importantly, CD40-activated macrophages are able to induce direct TNF-α-mediated 
antitumor cytotoxic activity, lymphocyte recruitment and cross-presentation of 
cellular antigens to CD8+ T cells. 
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6. Conclusion and outlook 
 
Collectively, the data presented in this study pave the way for additional research. 
1) First, we have demonstrated that CD40R stimulation of monocytes, cultured in 
presence of GM-CSF, efficiently promotes their activation. Most importantly, 
ligation of CD40R on monocyte cultured in the presence of M-CSF, e.g. M2 induces 
functional features which resemble the M1-like, as indicated by a detailed analysis 
of their cytokine expression pattern. This latter observation is particularly important 
and of potential clinical relevance. In particular, it is tempting to speculate that 
through the use of this CD40L-expressing vaccinia virus, monocytes recruited within 
the tumor mass during cancer progression, might partially overcome their 
polarization to an M2-like phenotype and educate to exert M1-like functions, even 
in an immunosuppressive environment.  
2) Second, our data clearly indicate that stimulation of CD40(+) tumor might result 
in the elimination of cancerous cells. Nevertheless, CD40 expression on transformed 
cells appears to be limited to a minor fraction of tumor cells and, most importantly, 
CD40 expression per se is not predictive of apoptosis induction following rVV40L 
infection or CD40R stimulation. However, in this scenario, expression of CD40L on 
surfaces of infected tumor cells might result in the elicitation of cytotoxic activity by 
tumor-infiltrating M1 macrophages resulting in disruption of malignant tissues. Of 
note, partial effects of M2 (M-CSF) macrophages on tumor growth are also 
detectable. Therefore, the use of such type of viral vector in the context of clinical 
trials could potentially have a major antitumor impact. 
3) Most importantly, the data here presented extended beyond the direct effect of 
rVV40L/macrophages on tumor cells. Tissue disruption observed after CD40R 
stimulation of M1 (GM-CSF) macrophages and their ability to cross-present antigen 
to CD8+ T cells suggest another intriguing possibility to be verified in the context of 
clinical studies. In particular, tumor-associated antigens released during cancer cells 
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lysis could be potentially presented to CD8+ T cells, actively recalled in the tumor 
microenvironment by CD40R-stimulated macrophages, therefore promoting a 
specific CD8+ T cells-mediated antitumor response.  
A potential limitation preventing the use of vaccinia virus as viral vector for gene 
delivery is represented by its high immunogenicity. On one hand, administered 
recombinant vaccinia virus might be rapidly eliminated particularly vaccinated 
cancer patients. On the other hand, this potential caveat restraining the use of 
rVV40L as a potential tool for cancer immunotherapy might also support its clinical 
validation. Indeed, intratumoral injection of the virus, which displays preferential 
tropism for cancer cells, could induce the activation of CD8+ T cells toward tumor-
associated antigens, but also the re-activation of memory CD8+ T cells specific for 
viral antigens expressed on cellular surfaces of rVV40L-infected tumor cells. 
Last but not least, our study demonstrates that rVV40L presents many promising 
features that make this type of approach highly promising specially in the context of 
tumor highly infiltrated with macrophages. In conclusion, such type of research 
might also contribute to a better understanding of the pivotal role played by 
macrophages in the tumor microenvironment and in the orchestration of innate and 
adaptive immune responses.    
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